A novel conjugate molecule targeting CD39 and TGFβ
Patent Information
- Application Number
- JP2023532306
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-23
- Filing Date
- 2021-11-25
- Publication Date
- 2024-11-21
AI Technical Summary
Current immune checkpoint inhibitors are limited by the tumor microenvironment rich in adenosine and TGFβ, which suppresses immune cell activation and tumor response.
Development of conjugate molecules that simultaneously target CD39 and TGFβ, disrupting their interactions to normalize the tumor microenvironment and enhance immune cell function.
The conjugate molecules demonstrate synergistic antitumor effects by restoring T cell function and suppressing Tregs, leading to improved tumor control beyond single-target therapies.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001]
[0001] This disclosure generally relates to novel conjugate molecules that target CD39 and TGFβ. [Background technology]
[0002]
[0002] CD39, also known as ecto-nucleoside triphophosphate diphosphohydrolase 1 (ENTPDase 1), is an intrinsic membrane protein that converts ATP or ADP to AMP, and then CD73 dephosphorylates AMP to convert it to adenosine. Adenosine is a potent immunosuppressant, and CD4 + CD8 + Adenosine binds to adenosine receptors (e.g., A2A receptors) on the surface of T cells and natural killer (NK) cells, inhibiting T cell and NK cell responses and thereby suppressing the immune system. Adenosine also binds to A2A and A2B receptors on macrophages and dendritic cells, inhibiting phagocytosis and antigen presentation and increasing the secretion of tumorigenic factors such as VEGF, TGFβ, and IL-6. The enzymatic activity of CD39 and CD73 plays a crucial role in regulating the duration, magnitude, and chemistry of purinergic signals delivered to immune cells through the conversion of ADP and ATP to AMP, and the conversion of AMP to adenosine, respectively (Luca Antonioli et al., Trends Mol Med. 2013 Jun;19(6):355-367). Increased adenosine levels mediated by CD39 and CD73 create an immunosuppressive environment, thereby promoting cancer development and progression.
[0003]
[0003] Transforming growth factor beta (TGFβ) is a multifaceted cytokine that is highly expressed in terminal primary and metastatic tumors and activates both antiproliferative and tumor-promoting signaling cascades. TGFβ is produced at high levels in tumor stromal cells and in many types of tumors, including breast, colorectal, lung, pancreatic, prostate, and hematological malignancies. In addition to promoting epithelial-mesenchymal transition (EMT), invasion, and metastasis of tumor cells, TGFβ also suppresses interferon-γ (IFN-γ) expression, inhibits Th1 cell differentiation, and CD8 + Tumors evade immune surveillance through mechanisms such as the reduction of effector cell function. Most importantly, TGFβ induces the differentiation of regulatory T cells (Tregs). Tregs further suppress inflammation by producing immunosuppressive cytokines (IL-10, TGFβ, IL-35), expressing inhibitory molecules (CTLA-4), and hydrolyzing ATP to adenosine via CD39. [Overview of the project] [Problems that the invention aims to solve]
[0004]
[0004] Given that CD39 and TGFβ play a role in regulating the immune response to tumors, there is still a need for therapeutic agents that antagonize CD39 activity, or the activity of both CD39 and TGFβ, for the treatment of diseases such as cancer. [Means for solving the problem]
[0005]
[0005] Throughout this disclosure, the articles “a,” “an,” and “the” are used herein to mean one or more (i.e., at least one) of the grammatical objects of the article. For example, “antibody” means one antibody or two or more antibodies.
[0006]
[0006] In one aspect, the present disclosure provides a conjugate molecule comprising a CD39 inhibitory moiety that can interfere with the interaction between CD39 and its substrate, and a TGFβ inhibitory moiety that can interfere with the interaction between TGFβ and its receptor.
[0007]
[0007] In certain embodiments, the CD39 inhibitory portion can interfere with the interaction between CD39 and ATP / ADP, and / or the TGFβ inhibitory portion can interfere with the interaction between TGFβ and the TGFβ receptor. In certain embodiments, the CD39 inhibitory portion is a CD39 antagonist selected from the group consisting of CD39 conjugates, RNAi targeting the coding sequence of CD39, antisense nucleotides targeting the coding sequence of CD39, and drugs that compete with CD39 to bind to its substrate. In certain embodiments, the TGFβ inhibitory portion is a TGFβ antagonist selected from the group consisting of TGFβ conjugates, RNAi targeting the coding sequence of TGFβ, antisense nucleotides targeting the coding sequence of TGFβ, and drugs that compete with TGFβ to bind to its receptor. In certain embodiments, the CD39 conjugate is selected from the group consisting of an antibody or antigen-binding fragment thereof that specifically recognizes CD39, and a small molecule compound that binds to CD39, and / or the TGFβ conjugate is selected from the group consisting of an antibody or antigen-binding fragment thereof that specifically recognizes TGFβ, and a small molecule compound that binds to TGFβ.
[0008]
[0008] In certain embodiments, the conjugate molecule is a fusion protein comprising a CD39-binding domain linked to a TGFβ-binding domain. In certain embodiments, the TGFβ-binding domain binds to human and / or mouse TGFβ. In certain embodiments, the TGFβ-binding domain binds to human TGFβ1, human TGFβ2, and / or human TGFβ3. In certain embodiments, the TGFβ-binding domain comprises the extracellular domain (ECD) of the TGFβ receptor. In certain embodiments, the TGFβ receptor is TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), or TGFβ receptor III (TGFβRIII). In certain embodiments, the ECD comprises the amino acid sequence of SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, or an amino acid sequence having at least 85% sequence identity thereto and retaining binding specificity to TGFβ. In certain embodiments, the TGFβ-binding domain comprises two or more ECDs of the TGFβ receptor. In certain embodiments, two or more ECDs are derived from the same TGFβ receptor or from at least two different TGFβ receptors. In certain embodiments, two or more ECDs include a first ECD derived from TGFβRI and a second ECD derived from TGFβRII. In certain embodiments, two or more ECDs are linked in a sequentially operable manner. In certain embodiments, two or more ECDs are linked via a first linker. In certain embodiments, the TGFβ-binding domain includes an amino acid sequence selected from the group consisting of SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, or any combination thereof.
[0009]
[0009] In certain embodiments, the CD39-binding domain binds to human CD39. In certain embodiments, the TGFβ-binding domain is linked to the CD39-binding domain via a second linker. In certain embodiments, the CD39-binding domain includes an anti-CD39 antibody moiety. In certain embodiments, the anti-CD39 antibody moiety includes a heavy chain variable region and a light chain variable region. In certain embodiments, the anti-CD39 antibody moiety further includes a heavy chain constant domain attached to the carboxyl terminus of the heavy chain variable region. In certain embodiments, the anti-CD39 antibody moiety further includes a light chain constant domain attached to the carboxyl terminus of the light chain variable region. In certain embodiments, the TGFβ-binding domain is linked to the anti-CD39 antibody moiety at a position selected from the group consisting of 1) the amino terminus of the heavy chain variable region, 2) the amino terminus of the light chain variable region, 3) the carboxyl terminus of the heavy chain variable region, 4) the carboxyl terminus of the light chain variable region, 5) the carboxyl terminus of the heavy chain constant region, and 6) the carboxyl terminus of the light chain constant region.
[0010]
[0010] In certain embodiments, the fusion protein includes two or more TGFβ-binding domains that are (i) entirely linked to the heavy chain variable region of the anti-CD39 antibody moiety, or (ii) entirely linked to the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the fusion protein includes two or more TGFβ-binding domains that are, respectively, linked to the heavy chain and light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the fusion protein includes two or more TGFβ-binding domains that are entirely linked to the heavy chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the fusion protein includes two or more TGFβ-binding domains that are entirely linked to the light chain constant region of the anti-CD39 antibody moiety. The fusion protein includes two or more TGFβ-binding domains that are, respectively, linked to the heavy chain and light chain constant region of the anti-CD39 antibody moiety.
[0011]
[0011] In certain embodiments, the fusion protein comprises two, three, four, five, six or more TGFβ-binding domains. In certain embodiments, the first and / or second linker is selected from the group consisting of cleavable linkers, non-cleavable linkers, peptide linkers, flexible linkers, rigid linkers, helix linkers, and non-helix linkers. In certain embodiments, the first and / or second linker comprises a peptide linker. In certain embodiments, the peptide linker comprises a GS linker. In certain embodiments, the GS linker comprises one or more repeats of SEQ ID NO: 177 (GGGS) or SEQ ID NO: 173 (GGGGS). In certain embodiments, the peptide linker comprises the amino acid sequence GGGGSGGGGSGGGGSG (SEQ ID NO: 182).
[0012]
[0012] In another aspect, the Disclosure provides a pharmaceutical composition comprising the conjugate molecule of the Disclosure and one or more pharmaceutically acceptable carriers. In another aspect, the Disclosure provides an isolated polynucleotide encoding the conjugate molecule of the Disclosure. In another aspect, the Disclosure provides a vector comprising the isolated polynucleotide of the Disclosure. In another aspect, the Disclosure provides a host cell comprising the vector of the Disclosure. In another aspect, the Disclosure provides a kit comprising the conjugate molecule of the Disclosure and / or the pharmaceutical composition of the Disclosure, as well as a second therapeutic agent.
[0013]
[0013] In another aspect, the Disclosure provides a method for expressing the conjugate molecule of the Disclosure, comprising the step of culturing host cells of the Disclosure under conditions in which the vector of the Disclosure is expressed. In another aspect, the Disclosure provides a method for treating, preventing or mitigating a CD39-related and / or TGFβ-related disease, disorder, or condition in a subject, comprising the step of administering a therapeutically effective amount of the conjugate molecule of the Disclosure and / or a pharmaceutical composition of the Disclosure to the subject. In another aspect, the Disclosure provides a method for treating, preventing, or mitigating a disease treatable by reducing the ATPase activity of CD39 in a subject, comprising the step of administering a therapeutically effective amount of the conjugate molecule of the Disclosure and / or a pharmaceutical composition of the Disclosure to the subject. In another aspect, the Disclosure provides a method for treating, preventing, or mitigating a disease associated with adenosine-mediated inhibition of the activity of T, monocytes, macrophages, DCs, APCs, NKs and / or B cells in a subject, comprising the step of administering a therapeutically effective amount of the conjugate molecule of the Disclosure and / or a pharmaceutical composition of the Disclosure to the subject. In another aspect, the Disclosure provides a method for modulating the activity of CD39 in CD39-positive cells, comprising the step of exposing CD39-positive cells to the conjugate molecules and / or pharmaceutical compositions of the Disclosure.
[0014]
[0014] In another aspect, the Disclosure provides a method for treating, preventing, or mitigating a disease associated with elevated levels and / or activity of TGFβ in a subject, comprising the step of administering a therapeutically effective amount of the conjugate molecules and / or pharmaceutical compositions of the Disclosure to the subject. In another aspect, the Disclosure provides the use of the conjugate molecules and / or pharmaceutical compositions of the Disclosure in the manufacture of a medicament for treating, preventing, or mitigating a CD39-related or TGFβ-related disease, disorder, or condition in a subject. [Brief explanation of the drawing]
[0015] [Figure 1]
[0015] Figure 1 shows the blockade of ATP-mediated suppression of T cell proliferation by anti-CD39 monoclonal antibodies mAb21 and mAb23. mIgG2a was used as the isotype control antibody. [Figure 2]
[0016] Figure 2 shows the blockade of ATP-mediated suppression of T cell proliferation by anti-CD39 chimeric antibodies c14, c19, c21, and c23. hIgG4 refers to the human IgG4 isotype control antibody. [Figure 3]
[0017] Figure 3 shows the expression levels of CD39 on dendritic cells (DCs). [Figure 4-1]
[0018] Figures 4A-4C show ATP-mediated DC activation by anti-CD39 chimeric antibodies c14, c19, c21, and c23, as measured by FACS expression of CD86 (Figure 4A), CD83 (Figure 4B), and HLA-DR (Figure 4C). [Figure 4-2] Same as above. [Figure 5]
[0019] Figure 5 shows tumor growth in mice inoculated with MOLP-8 cells (human multiple myeloma cell line) after treatment with anti-CD39 chimeric antibodies c23-hIgG4 and c23-hIgG1. [Figure 6]
[0020] Figure 6A shows the binding properties of the humanized antibody hu23.H5L5 to the ENTPD1 (i.e., CD39), ENTPD2 (i.e., CD39L1), ENTPD3 (i.e., CD39L3), ENTPD5 (i.e., CD39L4), and ENTPD6 (i.e., CD39L2) proteins, respectively. Figure 6B shows the binding of the negative control hIgG4 to the ENTPD1 (i.e., CD39), ENTPD2 (i.e., CD39L1), ENTPD3 (i.e., CD39L3), ENTPD5 (i.e., CD39L4), and ENTPD6 (i.e., CD39L2) proteins, respectively. [Figure 7]
[0021] Figures 7A and 7B show the binding activity of the c23 humanized antibody to MOLP-8 cells as measured by FACS. [Figure 8]
[0022] Figure 8 shows the binding activity of the c23 humanized antibody (obtained by yeast display) to MOLP-8 cells. [Figure 9]
[0023] Figures 9A and 9B show FACS-mediated inhibition of ATPase by c23 humanized antibodies in SK-MEL-28 cells. [Figure 10-1]
[0024] Figures 10A-10C show the binding activity of c14 humanized antibodies to MOLP-8 cells as determined by FACS. [Figure 10-2] Same as above. [Figure 11-1]
[0025] Figures 11A-11D show ATP-mediated T cell activation in PMBC by the humanized antibody hu23.H5L5, as measured by IL-2 (Figure 11A), IFN-γ (Figure 11B), CD4+ T cell proliferation (Figure 11C), and CD8+ T cell proliferation (Figure 11D). [Figure 11-2] Same as above. [Figure 12-1]
[0026] Figures 12A-12E show the binding activity of humanized antibodies hu23.H5L5 and hu14.H1L1 to SK-MEL-5 cells (Figure 12A), SK-MEL-28 cells (Figure 12B), MOLP-8 cells (Figure 12C), CHOK1-cynoCD39 cells (Figure 12D), and CHOK1-mCD39 cells (Figure 12E) as determined by FACS. [Figure 12-2] Same as above. [Figure 12-3] Same as above. [Figure 13]
[0027] Figure 13A shows the ATPase inhibitory activity of humanized antibodies hu23.H5L5 and hu14.H1L1 in SK-MEL-5 cells. Figure 13B shows the ATPase inhibitory activity of humanized antibodies hu23.H5L5 and hu14.H1L1 in MOLP-8 cells. [Figure 14-1]
[0028] Figures 14A-14C show ATP-mediated monocyte activation by the anti-CD39 humanized antibody hu23.H5L5, as measured by the expression of CD80 (Figure 14A), CD86 (Figure 14B), and CD40 (Figure 14C). [Figure 14-2] Same as above. [Figure 15-1]
[0029] Figure 15 shows that the humanized antibody hu23.H5L5 increases ATP-mediated DC activation, as measured by CD83 expression (Figure 15A), enhanced T cell proliferation (Figure 15B), and T cell activation (Figure 15C). [Figure 15-2] Same as above. [Figure 15-3] Same as above. [Figure 16]
[0030] Figure 16 shows the inhibition of tumor growth by humanized antibodies hu23.H5L5 and hu14.H1L1 in MOLP-8 xenograft mice. [Figure 17]
[0031] Figure 17 shows the inhibition of tumor growth by the anti-CD39 humanized antibody hu23.H5L5 in MOLP-8 xenograft mice with depleted NK cells. [Figure 18]
[0032] Figure 18 shows the inhibition of tumor growth by the anti-CD39 humanized antibody hu23.H5L5 in MOLP-8 xenograft mice with macrophage depletion. [Figure 19-1]
[0033] Figure 19A shows the results of epitope binning between the humanized antibodies hu23.H5L5 and hu14.H1L1 and the reference antibody. Figure 19B shows the epitope classification of the tested antibodies. [Figure 19-2] Same as above. [Figure 20]
[0034] Figure 20 shows the effect of the anti-CD39 humanized antibody hu23.H5L5 on IL1β release from human macrophages induced by LPS stimulation. [Figure 21]
[0035] Figure 21 shows the inhibition of tumor growth by humanized antibody hu23.H5L5 at different doses (0.03 mg / kg, 0.3 mg / kg, 3 mg / kg, 10 mg / kg, 30 mg / kg) in PBMC adoptive mice. [Figure 22]
[0036] Figure 22 shows the epitope mapping results for the humanized antibody hu23.H5L5, the chimeric antibodies c34 and c35, and the reference antibodies T895, I394, and 9-8B. [Figure 23-1]
[0037] Figures 23A-23C show the proliferation of extracellular ATP-inhibited CD8+ T cells inverted by the humanized antibody hu23.H5L5, as measured by T cell proliferation (Figure 23A), CD25+ cells (Figure 23B), and a live cell population (Figure 23C). [Figure 23-2] Same as above. [Figure 24-1]
[0038] Figures 24A–24G show schematic diagrams of exemplary anti-CD39 / TGFβ trap molecules of this disclosure. [Figure 24-2] Same as above. [Figure 24-3] Same as above. [Figure 24-4] Same as above. [Figure 24-5] Same as above. [Figure 24-6] Same as above. [Figure 24-7] Same as above. [Figure 25-1]
[0039] Figures 25A-25D show the binding properties of exemplary anti-CD39 / TGFβ trap molecules to human TGFβ1 (Figure 25A), human TGFβ2 (Figure 25B), human TGFβ3 (Figure 25C), and mouse TGFβ1 (Figure 25D), respectively. [Figure 25-2] Same as above. [Figure 26]
[0040] Figure 26 shows the results of an exemplary blocking assay of an anti-CD39 / TGFβ trap molecule against human TGFβ1 and TGFβRII. [Figure 27]
[0041] Figures 27A and 27B show the binding activity of exemplary anti-CD39 / TGFβ trap molecules to human CD39, as measured by FACS, using MOLP-8 cells (Figure 27A) and CHOK1 cells (Figure 27B), respectively. [Figure 28]
[0042] Figures 28A and 28B show the co-binding activity of exemplary anti-CD39 / TGFβ trap molecules to human CD39 and TGFβ1, respectively, as determined by ELISA (Figure 28A) and FACS (Figure 28B). [Figure 29]
[0043] Figure 29A shows the results of a TGFβ reporter assay of exemplary anti-CD39 / TGFβ trap molecules in transfected HEK293 cells. Figure 29B shows the TGFβ neutralizing activity of exemplary anti-CD39 / TGFβ trap molecules when pre-incubated with different CD39 protein:anti-CD39 / TGFβ trap molecule ratios. [Figure 30-1]
[0044] Figures 30A-30C show the ATPase inhibitory activity of exemplary anti-CD39 / TGFβ trap molecules in MOLP-8 cells (Figures 30A and 30B) and CHO cells (Figure 30C), respectively. [Figure 30-2] Same as above. [Figure 31-1]
[0045] Figure 31A shows that the addition of Tregs to autologous T cells primed by allogeneic DCs suppresses IFN-γ secretion by T cells. Figures 31B-31D show the effects of exemplary anti-CD39 / TGFβ trap molecules on Treg-mediated suppression of human T cells, as measured by changes in CD4+ T cell proliferation (Figure 31B), CD8+ T cell proliferation (Figure 31C), and IFN-γ secretion (Figure 31D). [Figure 31-2] Same as above. [Figure 32]
[0046] Figure 32 provides graphs illustrating the percentage of apoptosis inhibition in human T cells treated with the same molar amounts of anti-CD39 / TGFβ Trap molecules ES014-1 and ES014-2, anti-CD39 antibody ES014_v2, TGF-beta Trap ES014_v1, and control antibody ES014_v3, as shown. Figure 32A shows the percentage of early apoptosis in all T cells, with the X axis showing the antibody and concentration and the Y axis showing the percentage of early T cell apoptosis (%) (Annexin V+PI-). Figure 32B shows the percentage of late apoptosis in all T cells, with the X axis showing the antibody and concentration and the Y axis showing the percentage of late T cell apoptosis (%) (Annexin V+PI+). [Figure 33]
[0047] Figure 33 provides graphs illustrating the function of T cells treated with the same molar amounts of anti-CD39 / TGFβ Trap molecules ES014-1 and ES014-2, anti-CD39 antibody ES014_v2, TGF-beta Trap ES014_v1, and control antibody ES014_v3, as shown. Figure 33A shows FACS plots for cell viability and cell activation, and Figure 33B shows the production of IL-2 and IFN-γ in the supernatant. [Figure 34]
[0048] Figure 34 provides graphs illustrating Foxp3 expression in T cells treated with anti-CD39 / TGFβ Trap molecules ES014-1 and ES014-2, anti-CD39 antibody ES014_v2, TGF-beta Trap ES014_v1, and control antibody ES014_v3, as shown. Figure 34A shows the percentage of Foxp3 expression in CD4+ T cells, and Figure 34B shows the percentage of Foxp3 expression in CD8+ T cells. [Figure 35]
[0049] Figure 35 provides graphs illustrating the percentage of total T cells cleaved after treatment with anti-CD39 / TGFβ Trap molecules ES014-1 and ES014-2, anti-CD39 antibody ES014_v2, TGF-beta Trap ES014_v1, and control antibody ES014_v3, as shown. Figure 35A shows the percentage of CD4+ T cells cleaved, and Figure 35B shows the percentage of CD8+ T cells cleaved. [Modes for carrying out the invention]
[0016]
[0050] The following descriptions of this disclosure are intended solely to illustrate various embodiments of this disclosure. Therefore, any specific modifications discussed should not be construed as limiting the scope of this disclosure. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the scope of this disclosure, and it will be understood that such equivalent embodiments should be included herein. All references cited herein, including publications, patents, and patent applications, are incorporated herein by reference as a whole.
[0017] definition
[0051] As used herein, the term “antibody” includes any immunoglobulin, monoclonal antibody, polyclonal antibody, multivalent antibody, bivalent antibody, monovalent antibody, multispecific antibody, or bispecific antibody that binds to a specific antigen. Naturally intact antibodies consist of two heavy (H) chains and two light (L) chains. Mammalian heavy chains are classified as alpha, delta, epsilon, gamma, and mu, each consisting of a variable region (VH) and first, second, third, and optionally fourth constant regions (CH1, CH2, CH3, CH4, respectively). Mammalian light chains are classified as λ or κ, each consisting of a variable region (VL) and a constant region. Antibodies have a “Y” shape, where the Y axis consists of the second and third constant regions of two heavy chains linked to each other via disulfide bonds. Each arm of the Y contains the variable region and first constant region of one heavy chain, which is linked to the variable and constant regions of one light chain. The variable regions of the light and heavy chains are involved in antigen binding. The variable regions of both chains generally contain three highly variable loops called complementarity-determining regions (CDRs) (light chain CDRs including LCDR1, LCDR2, and LCDR3, and heavy chain CDRs including HCDR1, HCDR2, and HCDR3).The CDR boundaries of the antibodies and antigen-binding fragments disclosed herein may be defined or identified by the rules of Kabat, IMGT, Chothia, or Al-Lazikani (Al-Lazikani, B., Chothia, C., Lesk, AM, J. Mol. Biol., 273(4), 927 (1997); Chothia, C. et al., J Mol Biol. Dec 5; 186(3): 651-63 (1985); Chothia, C. and Lesk, AM, J. Mol. Biol., 196, 901 (1987); Chothia, C. et al., Nature. Dec 21-28; 342(6252): 877-83 (1989); Kabat EA et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991); Marie-Paule Lefranc et al., Developmental and Comparative Immunology, 27:55-77 (2003); Marie-Paule Lefranc et al., Immunome Research, 1(3), (2005); Marie-Paule Lefranc, Molecular Biology of B cells (second edition), chapter 26, 481-514, (2015). The three CDRs are inserted between adjacent segments known as framework regions (FRs) (light chain FRs including LFR1, LFR2, LFR3, and LFR4, and heavy chain FRs including HFR1, HFR2, HFR3, and HFR4) which form a scaffold supporting a highly conserved and highly variable loop than the CDRs. The constant regions of the heavy and light chains do not participate in antigen binding but exhibit various effector functions. Antibodies are assigned to classes based on the amino acid sequence of the constant region of their heavy chain.The five main classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of alpha, delta, epsilon, gamma, and muon heavy chains, respectively. Some of the main antibody classes are divided into subclasses such as IgG1 (gamma single-chain), IgG2 (gamma double-chain), IgG3 (gamma triple-chain), IgG4 (gamma quadruple-chain), IgA1 (alpha single-chain), or IgA2 (alpha double-chain).
[0018]
[0052] In certain embodiments, the antibodies provided herein encompass any antigen-binding fragment. As used herein, “antigen-binding fragment” means an antibody fragment formed from a portion of an antibody containing one or more CDRs, or any other antibody fragment that binds to an antigen but does not contain an intact, native antibody structure. Examples of antigen-binding fragments include, but are not limited to, diabodies, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (dsdiabodies), single-chain antibody molecules (scFv), scFv dimers (bivalent diabodies), bispecific antibodies, multispecific antibodies, camelized single-chain domain antibodies, nanobodies, domain antibodies, or bivalent domain antibodies. Antigen-binding fragments can bind to the same antigen to which the parent antibody binds.
[0019]
[0053] In the context of antibodies, "Fab" refers to the portion of the antibody consisting of a single light chain (both variable and constant regions) attached to a single heavy chain by disulfide bonds.
[0020]
[0054] "Fab'" refers to a Fab fragment that includes part of the hinge region.
[0055] "F(ab')2" means the dimer of Fab'.
[0056] "Fc" refers to the antibody portion (e.g., IgG, IgA, or IgD isotype) consisting of the second and third constant domains of the first heavy chain, which are bound to the second and third constant domains of the second heavy chain via disulfide bonds. For IgM and IgE isotype antibodies, Fc further includes a fourth constant domain. The Fc portion of an antibody is involved in various effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), but does not function in antigen binding.
[0021]
[0057] "Fv" in the context of antibodies refers to the smallest fragment of an antibody that is responsible for the complete antigen-binding site. The Fv fragment consists of a single variable region of a light chain bound to a variable region of a single heavy chain.
[0058] "Single-chain Fv antibody" or "scFv" refers to an engineered antibody consisting of a light-chain variable region and a heavy-chain variable region linked together directly or via a peptide linker sequence (Huston JS et al. Proc Natl Acad Sci USA, 85:5879 (1988)).
[0022]
[0059] "Single-chain Fv-Fc antibody" or "scFv-Fc" refers to an engineered antibody consisting of scFv ligated to the Fc region of the antibody.
[0060] "Camel-type single-chain domain antibody," "heavy-chain antibody," or "HCAb" is a type of antibody containing two V HAn antibody that contains a domain and does not contain a light chain (Riechmann L. and Muyldermans S., J Immunol Methods. Dec 10;231(1-2):25-38(1999); Muyldermans S., J Biotechnol. Jun;74(4):277-302(2001); WO94 / 04678; WO94 / 25591; US Patent No. 6,005,079). Heavy chain antibodies originally come from Camelidae (camels, dromedaries, and llamas). Camelized antibodies do not have a light chain but have true antigen-binding ability (Hamers-Casterman C. et al., Nature. Jun 3;363(6428):446-8(1993); Nguyen VK. et al. Immunogenetics. Apr;54(1):39-47(2002); Nguyen VK. et al. Immunology. May;109(1):93-101(2003)). The variable domain (VHH domain) of the heavy chain antibody represents the smallest known antigen-binding unit generated by the adaptive immune response (Koch-Nolte F. et al., FASEB J. Nov;21(13):3490-8. Epub 2007 Jun 15(2007)).
[0023]
[0061] "Nanobody" means an antibody fragment consisting of the VHH domain of a heavy chain antibody and two constant domains, CH2 and CH3.
[0062] "Diabody" or "dAb" includes a small antibody fragment with two antigen-binding sites, and the fragment contains a V L domain linked to a V H domain (V H -V L or V L -V H(See, for example, Holliger P. et al., Proc Natl Acad Sci USA. Jul 15;90(14):6444-8(1993);EP404097;WO93 / 11161). By using a linker that is too short to allow pairing between two domains on the same chain, the domains are forced to pair with a complementary domain on another chain, thereby creating two antigen-binding sites. The antigen-binding sites can target the same or different antigens (or epitopes). In certain embodiments, a “dual-specific ds diabody” is a diabody that targets two different antigens (or epitopes).
[0024]
[0063] A "domain antibody" refers to an antibody fragment that contains only the variable region of the heavy chain or only the variable region of the light chain. In some cases, two or more V H The domains are covalently joined to the peptide linker to create bivalent or polyvalent domain antibodies. The two Vs of a bivalent domain antibody H Domains can target the same or different antigens.
[0025]
[0064] As used herein, the term "valency" refers to the presence of a specific number of antigen-binding sites in a given molecule. The term "monovalent" refers to an antibody or antigen-binding fragment having only one single antigen-binding site, and the term "polyvalent" refers to an antibody or antigen-binding fragment having multiple antigen-binding sites. Therefore, the terms "divalent," "tetravalent," and "hexavalent" indicate the presence of two, four, and six binding sites, respectively, in an antigen-binding molecule. In some embodiments, the antibody or its antigen-binding fragment is divalent. In some embodiments, the antibody or its antigen-binding fragment is tetravalent.
[0026]
[0065] As used herein, a “bispecific” antibody means an artificial antibody having fragments derived from two different monoclonal antibodies, or fragments derived from one antibody and another protein (e.g., the TGFβ receptor), and capable of binding to two different epitopes. The two epitopes may be located on the same antigen or on two different antigens.
[0027]
[0066] In a particular embodiment, the "scFv dimer" is another V H -V L Partially dimerized (dimerized by peptide linker) V H -V L It is a bivalent diabody or bispecific scFv(BsFv) containing one part of V H V in other parts L In coordination with this, it forms two binding sites that can target the same antigen (or epitope) or different antigens (or epitopes). In other embodiments, the "scFv dimer" is V (linked by a peptide linker). L1 -V H2 V associated with (which was also linked by a peptide linker) H1 -V L2 It is a dual specific diabody that includes V H1 and V L1 They cooperated, V H2 and V L2 These coordinated pairs possess different antigen specificities.
[0028]
[0067] "dsFv" refers to a disulfide-stabilized Fv fragment in which the linkage between the variable region of a single light chain and the variable region of a single heavy chain is a disulfide bond. In some embodiments, "(dsFv)2" or "(dsFv-dsFv')" is three peptide chains, i.e., linked by a peptide linker (e.g., a long flexible linker), each with two V chains via disulfide bridges. L Two V's joined together in the part HThis includes a portion. In some embodiments, dsFv-dsFv' is bispecific, with each heavy and light chain paired by a disulfide having different antigen specificities.
[0029]
[0068] As used herein, the term “chimera” means an antibody or antigen-binding fragment having a portion of the heavy chain and / or light chain from one species and the remainder of the heavy chain and / or light chain from a different species. In descriptive examples, a chimeric antibody may include a constant region derived from a human and a variable region derived from a non-human animal such as a mouse. In some embodiments, the non-human animal is a mammal, such as a mouse, rat, rabbit, goat, sheep, guinea pig, or hamster.
[0030]
[0069] As used herein, the term "humanization" means that the antibody or antigen-binding fragment includes a CDR derived from a non-human animal, a FR region derived from a human, and, where applicable, a constant region derived from a human.
[0031]
[0070] As used herein, the term "affinity" refers to the strength of the non-covalent interaction between an immunoglobulin molecule (i.e., an antibody) or a fragment thereof and an antigen.
[0071] As used herein, the terms "specific binding" or "specifically binding" refer to a non-random binding reaction between two molecules, such as an antibody and an antigen. Specific binding is defined as the K2 binding reaction that occurs when the binding between an antigen and an antigen-binding molecule reaches equilibrium. D The value, i.e., the ratio of the dissociation rate to the association rate (k off / k on It can be characterized by its binding affinity, which is represented by K. D This may be determined using any conventional method known in the art, including, but not limited to, surface plasmon resonance, Octet method, microscale thermophoresis, HPLC-MS, and FACS assay. 10 -6 M or less (for example, 5 x 10) -7 M or less, 2×10 -7 M or less, 10 -7 M or less, 5×10 -8M or less, 2×10 -8 M or less, 10 -8 M or less, 5×10 -9 M or less, 4×10 -9 M or less, 3×10 -9 M or less, 2×10 -9 M or less, or 10 -9 K (M or below) D The value may indicate specific binding between the antibody or its antigen-binding fragment and CD39 (e.g., human CD39).
[0032]
[0072] As used herein, the ability to “compete for binding to human CD39” means the ability of the first antibody or antigen-binding fragment to inhibit the binding interaction between human CD39 and the second anti-CD39 antibody to some detectable degree. In certain embodiments, the antibody or antigen-binding fragment competing for binding to human CD39 inhibits the binding interaction between human CD39 and the second anti-human CD39 antibody by at least 85%, or at least 90%. In certain embodiments, this inhibition may be greater than 95%, or greater than 99%.
[0033]
[0073] As used herein, the term “epitope” refers to a specific group of atoms or amino acids on an antigen to which an antibody binds. If two antibodies exhibit competitive binding to an antigen, they may bind to the same or closely related epitopes in the antigen. Epitopes may be linear or conformal (i.e., containing separated amino acid residues). For example, if an antibody or antigen-binding fragment blocks the binding of a reference antibody to an antigen by at least 85%, or at least 90%, or at least 95%, then that antibody or antigen-binding fragment may be considered to bind to the same / closely related epitope as the reference antibody.
[0034]
[0074] As used herein, the term "amino acid" refers to an organic compound containing an amine (-NH2) and a carboxyl (-COOH) functional group, along with a side chain specific to each amino acid. In this disclosure, amino acid names may also be represented by standard one- or three-letter codes, which are summarized below.
[0035] [Table 1]
[0036]
[0075] The terms “polypeptide,” “peptide,” and “protein” are interchangeable herein and refer to polymers of amino acid residues. This term also applies to amino acid polymers, in which one or more amino acid residues are artificial chemical mimics of corresponding naturally occurring amino acids, as well as to naturally occurring and unnaturally occurring amino acid polymers.
[0037]
[0076] A "conservative substitution" in an amino acid sequence means replacing an amino acid residue with a different amino acid residue that has a side chain with similar physicochemical properties. For example, conservative substitutions can be made between amino acid residues with hydrophobic side chains (e.g., Met, Ala, Val, Leu, and Ile), between amino acid residues with neutral hydrophilic side chains (e.g., Cys, Ser, Thr, Asn, and Gln), between amino acid residues with acidic side chains (e.g., Asp, Glu), between amino acid residues with basic side chains (e.g., His, Lys, and Arg), or between amino acid residues with aromatic side chains (e.g., Trp, Tyr, and Phe). As is known in the art, conservative substitutions usually do not result in significant changes to the conformational structure of a protein and can therefore preserve the biological activity of the protein.
[0038]
[0077] As used herein, the term “homology” means a nucleic acid sequence (or its complementary strand) or amino acid sequence that, when optimally aligned, has at least 60% sequence identity with another sequence (for example, at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%).
[0039]
[0078] The "sequence identity percentage (%)" for an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to those in a reference sequence, after the sequences have been aligned and gaps have been introduced where necessary to maximize the number of identical amino acids (or nucleic acids). In other words, the sequence identity percentage (%) for an amino acid sequence (or nucleic acid sequence) can be calculated by dividing the number of identical amino acid residues (or bases) with respect to the reference sequence being compared by the total number of amino acid residues (or bases) in the shorter of the candidate sequence or the reference sequence. Conservative substitutions of amino acid residues may or may not be considered identical residues. Alignment for calculating the sequence identity percentage of amino acids (or nucleic acids) can be achieved using publicly available tools such as BLASTN, BLASTp (available from the US National Center for Biotechnology Information (NCBI) website; see also Altschul SF et al., J.Mol.Biol., 215:403-410 (1990); Stephen F. et al., Nucleic Acids Res., 25:3389-3402 (1997)), ClustalW2 (available from the European Bioinformatics Institute website; see also Higgins DGet al., Methods in Enzymology, 266:383-402 (1996); Larkin MA et al., Bioinformatics (Oxford, England), 23(21):2947-8 (2007)), and ALIGN or Megalign (DNASTAR) software. Those skilled in the art may use the default parameters provided by the tool, or they may customize the parameters to suit the alignment, for example, by selecting a suitable algorithm.
[0040]
[0079] As used herein, "effector function" refers to the biological activity attributable to the binding of the antibody's Fc region to its effectors, such as the C1 complex and Fc receptor. Exemplary effector functions include complement-dependent cytotoxicity (CDC) mediated by the interaction between the antibody and C1q on the C1 complex, antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by the binding of the antibody's Fc region to the Fc receptor on effector cells, and phagocytosis. Effector functions can be evaluated using various assays, such as Fc receptor binding assays, C1q binding assays, and cell lysis assays.
[0041]
[0080] A “isolated” substance has been modified by human intervention from its natural state. If an “isolated” composition or substance occurs naturally, it has been altered or removed from its original environment, or both. For example, a polynucleotide or polypeptide that is naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide is “isolated” if it is sufficiently separated from the substances that coexist in its natural state and exists in a substantially pure state. “Isolated nucleic acid sequence” means a sequence of an isolated nucleic acid molecule. In certain embodiments, “isolated antibody or antigen-binding fragment thereof” means an antibody or antigen-binding fragment thereof having a purity of at least 60%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, as determined by electrophoresis (SDS-PAGE, isoelectric focusing, capillary electrophoresis, etc.) or chromatography (ion-exchange chromatography or reverse-phase HPLC).
[0042]
[0081] As used herein, the term “vector” means a vehicle into which a genetic element is operably inserted, resulting in the expression of that genetic element, thereby producing a protein, RNA, or DNA encoded by that genetic element, or replicating that genetic element. A vector may be used to transform, transduce, or transfect a host cell to produce the expression of a genetic element it carries within the host cell. Examples of vectors include plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs), bacteriophages such as lambda phages or M13 phages, and animal viruses. A vector may contain various elements for controlling expression, such as promoter sequences, transcription start sequences, enhancer sequences, selectable elements, and reporter genes. Furthermore, a vector may contain a replication origin. A vector may contain substances that assist in the entry of the vector into the cell, including but not limited to viral particles, liposomes, or protein coatings. A vector may be an expression vector or a cloning vector. This disclosure provides a vector (e.g., an expression vector) comprising a nucleic acid sequence provided herein that encodes an antibody or an antigen-binding fragment thereof, at least one promoter operably ligated to the nucleic acid sequence (e.g., SV40, CMV, EF-1α), and at least one select marker.
[0043]
[0082] As used herein, the term "host cell" means a cell into which foreign polynucleotides and / or vectors can be introduced, or into which such foreign polynucleotides and / or vectors have been introduced.
[0083] The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, such as mammals and non-human primates, mice, rats, cats, rabbits, sheep, dogs, cows, chickens, amphibians, and reptiles, among other non-mammalian species. Unless otherwise noted, the terms "patient" and "subject" are used interchangeably herein.
[0044]
[0084] The term “antitumor activity” refers to a reduction in the proliferation, viability, or metastatic activity of tumor cells. For example, antitumor activity can be demonstrated by a decrease in the rate of abnormal cell proliferation that occurs during treatment, or by stability or reduction in tumor size, or by long-term survival with treatment, compared to an untreated control. Such activity can be evaluated using acceptable in vitro or in vivo tumor models, including but not limited to xenograft models, allograft models, mouse mammary tumor virus (MMTV) models, and other models known in the art for examining antitumor activity.
[0045]
[0085] As used herein, “treating” a disease, disorder, or condition, or “treating” such a disease, disorder, or condition, includes preventing or mitigating the disease, disorder, or condition; slowing the onset or rate of occurrence of the disease, disorder, or condition; reducing the risk of developing the disease, disorder, or condition; preventing or delaying the onset of symptoms associated with the disease, disorder, or condition; reducing or terminating symptoms associated with the disease, disorder, or condition; achieving complete or partial remission of the disease, disorder, or condition; curing the disease, disorder, or condition; or any combination thereof.
[0046]
[0086] The terms “diagnosis,” “to diagnose,” or “to diagnose” mean the identification of a pathological condition, disease, or state, such as the identification of a CD39-related disease, or the identification of a subject who may benefit from a particular treatment regimen. In some embodiments, diagnosis includes the identification of an abnormal amount or activity of CD39. In some embodiments, diagnosis means the identification of cancer or autoimmune disease in a subject.
[0047]
[0087] As used herein, the terms “biological sample” or “sample” mean a biological composition comprising cells and / or other molecular entities obtained from or derived from the subject of interest and characterized and / or identified, for example, on the basis of physical, biochemical, chemical and / or physiological characteristics. A biological sample includes, but is not limited to, cells, tissues, organs and / or biological fluids of the subject obtained by any method known to those skilled in the art. In some embodiments, the biological sample is a fluid sample. In some embodiments, the fluid sample is whole blood, plasma, serum, mucus (including rhinorrhea and sputum), ascites, pleural fluid, pleural fluid, saliva, urine, synovial fluid, cerebrospinal fluid (CSF), thoracentesis fluid, abdominal fluid, ascites, or pericardial fluid. In some embodiments, the biological sample is tissue or cells obtained from the heart, liver, spleen, lungs, kidneys, skin, or blood vessels of the subject.
[0048]
[0088] The term “operatably linked” or “operatably linked” means that two or more biological sequences of interest, with or without spacers or linkers, are juxtaposed in such a way that they enable them to function in the manner intended. When used in relation to polypeptides, it is intended to mean that polypeptide sequences are linked in such a way that the linked product has the intended biological function. For example, an antibody variable region may be operatably linked to a constant region to provide a stable product with antigen-binding activity. This term may also be used in relation to polynucleotides. As an example, when a polynucleotide encoding a polypeptide is operatably linked to a regulatory sequence (e.g., a promoter, enhancer, silencer sequence, etc.), it is intended to mean that the polynucleotide sequences are linked in such a way that they enable the regulated expression of the polypeptide from the polynucleotide.
[0049]
[0089] When used in relation to amino acid sequences (e.g., peptides, polypeptides, or proteins), the terms “fusion” or “fused” mean the joining of two or more amino acid sequences to a single amino acid sequence that does not exist in nature, for example, by chemical bonding or recombinant means. A fused amino acid sequence may be produced by genetic recombination of two coding polynucleotide sequences and can be expressed by introducing a construct containing the recombinant polynucleotide into a host cell.
[0050]
[0090] As used herein, “CD39” refers to the endogenous membrane protein that converts ATP to AMP, also known as ENTPD1 or ENTPDase 1. Structurally, it is characterized by two transmembrane domains, a small cytoplasmic domain, and a large extracellular hydrophobic domain. In certain embodiments, CD39 is human CD39. As used herein, CD39 may be from mouse and other animal species, particularly cynomolgus monkeys. An exemplary sequence of the human CD39 protein is disclosed in NCBI Ref Seq No. NP_001767.3. An exemplary sequence of the Mus musculus (mouse) CD39 protein is disclosed in NCBI Ref Seq No. NP_033978.1. An exemplary sequence of the cynomolgus monkey (monkey) CD39 protein is disclosed in NCBI Ref Seq No. XP_015311945.1.
[0051]
[0091] In addition to CD39, the ENTPDase family also includes several other members, including ENTPDases 2, 3, 4, 5, 6, 7, and 8 (also known as ENTPD2, 3, 4, 5, 6, 7, and 8, and used interchangeably in this disclosure). Four of the ENTPDases are typical cell surface-localized enzymes (ENTPDases 1, 2, 3, and 8) with catalytic sites facing the extracellular space. ENTPDases 5 and 6 exhibit intracellular localization and are secreted after non-homologous expression. ENTPDases 4 and 7 are fully intracellularly localized and face the lumen of cytoplasmic organelles. In some embodiments, the antibodies or antigen-binding fragments provided herein bind specifically to CD39 (i.e., ENTPDase 1) but not to other family members, such as ENTPDases 2, 3, 5, or 6.
[0052]
[0092] The term "anti-CD39 antibody moiety" refers to an antibody (including its antigen-binding fragment) that can specifically bind to CD39 (e.g., human or monkey CD39) and forms part of a conjugate molecule that targets both CD39 and TGFβ. The term "anti-human CD39 antibody moiety" refers to an antibody (including its antigen-binding fragment) that can specifically bind to human CD39 and forms part of a conjugate molecule that targets both human CD39 and TGFβ.
[0053]
[0093] As used herein, “CD39-related” disease, disorder, or condition means any disease or condition caused, aggravated, or otherwise related to increased or decreased expression or activity of CD39. In some embodiments, the CD39-related disease, disorder, or condition is an immune-related disorder, such as an autoimmune disease. In some embodiments, the CD39-related disease, disorder, or condition is a disorder related to excessive cell proliferation, such as cancer. In certain embodiments, the CD39-related disease or condition is characterized by the expression or overexpression of CD39 and / or CD39-related genes, such as the ENTPD1, 2, 3, 4, 5, 6, 7, or 8 gene.
[0054]
[0094] As used herein, the terms “transforming growth factor beta” and “TGFβ” mean any full-length TGFβ of any TGFβ of a subject (e.g., human), any TGFβ family protein having a native amino acid sequence, including latent forms, and associated or unassociated complexes of precursors and mature TGFβ (“latent TGFβ”). Such references to TGFβ herein refer to any of the currently identified forms, including TGFβ1, TGFβ2, TGFβ3 isoforms and their latent forms, as well as any human TGFβ species to be identified in the future, and are understood to include polypeptides derived from any known TGFβ sequence that are at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, and even more preferably at least about 95% homologous to the sequence. The specific terms “TGFβ1,” “TGFβ2,” and “TGFβ3” refer to TGF-beta as defined in the following literature, for example: Derynck et al., Nature, Cancer Res., 47:707 (1987); Seyedin et al., J. Biol. Chem., 261:5693-5695 (1986); deMartin et al., EMBO J., 6:3673 (1987); and Kuppner et al., Int. J. Cancer, 42:562 (1988). The terms “Transforming Growth Factor Beta,” “TGFβ,” “TGFbeta,” “TGF-β,” “TGF-beta,” “TGFb,” “TGF-b,” “TGFB,” and “TGF-B” are interchangeable in this disclosure.
[0055]
[0095] As used herein, the term "human TGFβ1" means the TGFβ1 protein encoded by the human TGFB1 gene (e.g., the wild-type human TGFB1 gene). An example of wild-type human TGFβ1 protein is provided by GenBank acceptance number NP_000651.3. As used herein, the term "human TGFβ2" means the TGFβ2 protein encoded by the human TGFB2 gene (e.g., the wild-type human TGFB2 gene). An example of wild-type human TGFβ2 protein is provided by GenBank acceptance numbers NP_001129071.1 and NP_003229.1. As used herein, the term "human TGFβ3" means the TGFβ3 protein encoded by the human TGFB3 gene (e.g., the wild-type human TGFB3 gene). Exemplary wild-type human TGFβ3 proteins are provided by GenBank acceptance numbers NP_003230.1, NP_001316868.1, and NP_001316867.1.
[0056]
[0096] As used herein, the terms “mouse TGFβ1,” “mouse TGFβ2,” and “mouse TGFβ3” mean the TGFβ1, TGFβ2, and TGFβ3 proteins encoded by the mouse TGFB1 gene (e.g., the wild-type mouse TGFB1 gene), the mouse TGFB2 gene (e.g., the wild-type mouse TGFB2 gene), and the mouse TGFB3 gene (e.g., the wild-type mouse TGFB3 gene), respectively. Exemplary wild-type mouse (Mus musculus) TGFβ1 protein is provided by GenBank acceptance numbers NP_035707.1 and CAA08900.1. Exemplary wild-type mouse TGFβ2 protein is provided by GenBank acceptance number NP_033393.2. Exemplary wild-type mouse TGFβ3 protein is provided by GenBank acceptance number AAA40422.1.
[0057]
[0097] As used herein, the term "TGFβ receptor" means any receptor that binds at least one TGFβ isoform. Generally, TGFβ receptors are TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), or TGFβ receptor III (TGFβRIII).
[0058]
[0098] In humans, the terms “TGFβ receptor I” or “TGFβRI” mean a polypeptide having the wild-type human TGFβ receptor type 1 sequence (e.g., the amino acid sequence of GenBank acceptance number ABD46753.1) or a sequence substantially identical to the amino acid sequence of GenBank acceptance number ABD46753.1. A TGFβRI may retain at least 0.1%, at least 0.5%, at least 1%, at least 5%, at least 10%, at least 25%, at least 35%, at least 50%, at least 75%, at least 90%, at least 95%, or at least 99% of the TGFβ-binding activity of the wild-type sequence. The polypeptide of an expressed TGFβRI lacks a signal sequence.
[0059]
[0099] With respect to humans, the term "TGFβ receptor II" or "TGFβRII" means a polypeptide having the wild-type human TGFβ receptor type 2 isoform A sequence (e.g., the amino acid sequence of GenBank acceptance number NP_001020018.1), or having the wild-type human TGFβ receptor type 2 isoform B sequence (e.g., the amino acid sequence of GenBank acceptance number NP_003233.4), or having a sequence with at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the amino acid sequence of GenBank acceptance number NP_001020018.1 or GenBank acceptance number NP_003233.4. TGFβRII may retain at least 0.1%, at least 0.5%, at least 1%, at least 5%, at least 10%, at least 25%, at least 35%, at least 50%, at least 75%, at least 90%, at least 95%, or at least 99% of the TGFβ-binding activity of the wild-type sequence. The polypeptide of expressed TGFβRII lacks a signal sequence.
[0060]
[0100] With respect to humans, the term "TGFβ receptor III" or "TGFβRIII" means a polypeptide having the wild-type human TGFβ receptor type 3 isoform A sequence (e.g., the amino acid sequence of GenBank acceptance number NP_003234.2), or having the wild-type human TGFβ receptor type 3 isoform B sequence (e.g., the amino acid sequence of GenBank acceptance number NP_001182612.1), or having a sequence with at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99% sequence identity with the amino acid sequences of GenBank acceptance numbers NP_003234.2 and NP_001182612.1. TGFβRIII may retain at least 0.1%, at least 0.5%, at least 1%, at least 5%, at least 10%, at least 25%, at least 35%, at least 50%, at least 75%, at least 90%, at least 95%, or at least 99% of the TGFβ-binding activity of the wild-type sequence. The polypeptide of the expressed TGFβRIII lacks a signal sequence.
[0061]
[0101] As used herein, the term “TGFβ-related” disease, disorder, or condition means any disease or condition caused, aggravated, or otherwise related to increased or decreased expression or activity of TGFβ. In some embodiments, the TGFβ-related disease, disorder, or condition is an immune-related disorder, such as an autoimmune disease. In some embodiments, the TGFβ-related disease, disorder, or condition is a disorder related to excessive cell proliferation, such as cancer. In certain embodiments, the TGFβ-related disease or condition is characterized by the expression or overexpression of TGFβ and / or TGFβ-related genes, such as the TGFB1, TGFB2, TGFB3 genes.
[0062]
[0102] The term "anti-TGFβ antibody moiety" refers to an antibody that can specifically bind to TGFβ (e.g., TGFβ1, TGFβ2, TGFβ3) and forms part of a protein that targets both CD39 and TGFβ. The term "anti-human TGFβ antibody moiety" refers to an antibody that can specifically bind to human TGFβ and forms part of a protein that targets both CD39 and human TGFβ.
[0063]
[0103] The term "pharmaceutically acceptable" indicates that a specified carrier, vehicle, diluent, excipient, and / or salt is generally chemically and / or physically compatible with the other components of the formulation and physiologically compatible with its recipient.
[0064]
[0104] As used herein, the term "CD39-positive cell" refers to a cell that expresses CD39 on its surface (for example, a phagocytic cell).
[0105] As used herein, the term "pathway" refers to a group of biochemical reactions that can sequentially convert one compound into another in a stepwise process. The product of the first step of a pathway may be the substrate of the second step, the product of the second step may be the substrate of the third step, and so on. The components of a pathway include all substrates, cofactors, by-products, intermediates, end products, and any enzymes of the pathway. Thus, as used herein, the term "adenosine pathway" refers to a collection of biochemical pathways, any one of which includes the production of adenosine, e.g., adenosine, or the conversion of adenosine to another substance. As used herein, the term "TGFβ signaling pathway" refers to a collection of biochemical pathways, any one of which includes the production of TGFβ, e.g., TGFβ, or the conversion of TGFβ to another substance.
[0065]
[0106] As used herein, the term “antagonist” means a molecule that inhibits the expression level or activity of a protein, polypeptide, or peptide, thereby reducing the quantity, formation, function, and / or downstream signaling of that protein, polypeptide, or peptide. For example, “CD39 antagonist” as used herein means a molecule that inhibits the expression level or activity of CD39, thereby reducing the quantity, formation, function, and / or downstream signaling of CD39. As another example, “TGFβ antagonist” as used herein means a molecule that inhibits the expression level or activity of TGFβ, thereby reducing the quantity, formation, function, and / or downstream signaling of TGFβ.
[0066]
[0107] As used herein, the terms “encoded” or “encode” mean that they are transcribed into mRNA and / or translated into peptides or proteins. The terms “coding sequence” or “gene” mean a polynucleotide sequence that codes for a peptide or protein. These two terms may be used interchangeably in this disclosure. In some embodiments, the coding sequence is a complementary DNA (cDNA) sequence that is reverse transcribed from messenger RNA (mRNA). In some embodiments, the coding sequence is mRNA.
[0067]
[0108] As used herein, the term "antisense nucleotide" refers to an oligomeric compound that can hybridize to a target nucleic acid via hydrogen bonding. For example, "antisense nucleotide targeting the coding sequence of CD39" refers to a nucleotide that can hybridize to the coding sequence of CD39 or a portion thereof.
[0068] Conjugate molecules targeting CD39 and TGFβ
[0109] A potential limitation of current immune checkpoint inhibitors (e.g., PD1 and CTLA-4) is the adenosine and TGFβ-rich tumor microenvironment ("TME"). Adenosine and TGFβ signaling in the localization microenvironment of tumor-infiltrating T cells has been able to bias them towards Tregs and attenuate the activation of immune effector cells. We unexpectedly discovered that by simultaneously targeting CD39 and TGFβ with a novel conjugate molecule, we can achieve a more immunonormalized TME and synergistic antitumor effects by simultaneously blocking the adenosine pathway (by inhibiting CD39) and the TGFβ signaling pathway (via TGFβ traps). In fact, we have demonstrated that the CD39 and TGFβ-targeting conjugate molecule of this disclosure exhibits synergistic antitumor effects that surpass those observed with monotherapy using TGFβ receptors or anti-CD39 antibodies, particularly in terms of T cell survival, cytokine production, and Treg suppression.
[0069]
[0110] In one embodiment, the disclosure provides a conjugate molecule comprising a CD39 inhibitory moiety capable of interfering with the interaction between CD39 and its substrate, and a TGFβ inhibitory moiety capable of interfering with the interaction between TGFβ and its receptor. The conjugate molecule may be a small molecule, a compound (natural or synthetic), a peptide, a polypeptide, a protein, an interfering RNA, a messenger RNA, etc. In certain embodiments, the conjugate molecule is not a mixture of two or more different substances (i.e., two or more different substances are simply placed together and not chemically bonded). In certain embodiments, the conjugate molecule is a bifunctional molecule capable of interfering with the interaction between CD39 and its substrate, and capable of interfering with the interaction between TGFβ and its receptor.
[0070]
[0111] The adenosine pathway is involved in the formation of an immune-tolerant tumor microenvironment by regulating the function of immune and inflammatory cells such as macrophages, dendritic cells, myeloid suppressor cells, T cells, and natural killer (NK) cells. The adenosine pathway also controls cancer growth and metastasis by interfering with cancer cell proliferation, apoptosis, and angiogenesis via adenosine receptors expressed on cancer cells and endothelial cells, respectively. Solid tumors express high levels of CD39 and CD73, as well as low levels of the nucleoside transporter (NT), ectoadenosine deaminase, and its cofactor CD26. This results in increased adenosine signaling in the cancer environment. In certain embodiments, the CD39 inhibitory portion of this disclosure can interfere with the interaction between CD39 and ATP / ADP. In certain embodiments, the CD39 inhibitory portion of a conjugate molecule is particularly useful for treating, preventing, or mitigating cancer.
[0071]
[0112] In a particular embodiment, the CD39 inhibitory portion of the conjugate molecule is a CD39 antagonist selected from the group consisting of CD39 conjugates, RNAi targeting the CD39 coding sequence, antisense nucleotides targeting the CD39 coding sequence, and drugs that compete with CD39 for binding to its substrate.
[0072]
[0113] A molecule is considered to inhibit the expression level or activity of CD39 if it significantly reduces the expression level (either transcriptional or translational) or activity of CD39. Similarly, a molecule is considered to inhibit the binding between CD39 and its substrate (e.g., ATP or ADP) if it significantly reduces the binding between CD39 and its substrate. This significantly reduces downstream signaling and function mediated by CD39. The reduction is considered significant if, for example, the reduction is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
[0073]
[0114] CD39 conjugates (antagonists) can act in two ways. In some embodiments, the CD39 conjugates of this disclosure can compete with CD39 to bind to its substrate, thereby interfering, blocking, or otherwise preventing CD39 from binding to that substrate. This type of antagonist, which binds to the substrate but does not induce the expected signaling, is also known as a “competitive antagonist.” In other embodiments, the CD39 conjugates of this disclosure can bind to and sequester CD39 with sufficient affinity and specificity to substantially interfering, blocking, or otherwise preventing CD39 from binding to its substrate. This type of antagonist is also known as a “neutralizing antagonist” and may include, for example, an antibody or aptamer directed to CD39 that specifically binds to CD39.
[0074]
[0115] In certain embodiments, the CD39 conjugate is selected from the group consisting of an antibody that specifically recognizes CD39 or its antigen-binding fragment, and a small molecule compound that binds to CD39.
[0075]
[0116] As used herein, the term “low molecular weight compound” means a low molecular weight compound that can function as an enzyme substrate or a regulator of a biological process. Generally, a “low molecular weight compound” is a molecule with a size of less than about 5 kilodaltons (kD). In some embodiments, the low molecular weight is less than about 4 kD, less than 3 kD, less than about 2 kD, or less than about 1 kD. In some embodiments, the low molecular weight is less than about 800 daltons (D), less than about 600 D, less than about 500 D, less than about 400 D, less than about 300 D, less than about 200 D, or less than about 100 D. In some embodiments, the low molecular weight is less than about 2000 g / mol, less than about 1500 g / mol, less than about 1000 g / mol, less than about 800 g / mol, or less than about 500 g / mol. In some embodiments, the low molecular weight is nonpolymeric. In some embodiments, according to this disclosure, the small molecule is not a protein, polypeptide, oligopeptide, peptide, polynucleotide, oligonucleotide, polysaccharide, glycoprotein, proteoglycan, etc. In some embodiments, the small molecule is a therapeutic agent. In some embodiments, the small molecule is an adjuvant. In some embodiments, the small molecule is a drug.
[0076]
[0117] In certain embodiments, the TGFβ inhibitory portion of a conjugate molecule can interfere with the interaction between TGFβ and the TGFβ receptor. In certain embodiments, the interaction between TGFβ and the TGFβ receptor is blocked by a drug that disrupts the signaling cascade within the TGFβ signaling pathway and can disrupt or prevent TGFβ or TGFβ superfamily ligands from binding to their endogenous receptors. Exemplary assays that can be used to determine the inhibitory activity of TGFβ signaling pathway inhibitors include, but are not limited to, electrophoretic mobility shift assays, antibody supershift assays, and the TGFβ-inducible gene reporter assay described in WO2006 / 012954.
[0077]
[0118] In a particular embodiment, the TGFβ inhibitory portion of the conjugate molecule is a TGFβ antagonist selected from the group consisting of a TGFβ binder, an RNAi targeting the coding sequence of TGFβ, an antisense nucleotide targeting the coding sequence of TGFβ, and a drug that competes with TGFβ to bind to its receptor (e.g., TGFβRI, TGFβRII, or TGFβRIII).
[0078]
[0119] A molecule is considered to inhibit the expression level or activity of TGFβ if it significantly reduces the expression level (either transcriptional or translational) or activity of TGFβ. Similarly, a molecule is considered to inhibit the binding between TGFβ and its receptor (e.g., TGFβRI, TGFβRII, or TGFβRIII) if it significantly reduces the binding between TGFβ and its receptor. This significantly reduces downstream signaling and function mediated by TGFβ. The reduction is considered significant if, for example, the reduction is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
[0079]
[0120] TGFβ-binding agents (antagonists) can act in two ways. In some embodiments, the TGFβ-binding agents of this disclosure can compete with TGFβ to bind to its receptor, thereby interfering, blocking, or otherwise preventing TGFβ from binding to its receptor. This type of antagonist, which binds to the receptor but does not induce the expected signaling, is also known as a “competitive antagonist.” In other embodiments, the TGFβ-binding agents of this disclosure can bind to and sequester TGFβ with sufficient affinity and specificity to substantially interfering, blocking, or otherwise preventing TGFβ from binding to its receptor. This type of antagonist is also known as a “neutralizing antagonist” and may include, for example, an antibody or aptamer directed to TGFβ that specifically binds to TGFβ.
[0080]
[0121] In a particular embodiment, the TGFβ conjugate is selected from the group consisting of an antibody that specifically recognizes TGFβ or an antigen-binding fragment thereof, and a small molecule compound that binds to TGFβ.
[0081]
[0122] In certain embodiments, the conjugate molecule of the present disclosure is a fusion protein comprising a CD39-binding domain linked to a TGFβ-binding domain.
[0123] As used herein, the term “binding domain” means a portion that has the ability to specifically bind to a target molecule or complex. A binding domain may include small molecules, peptides, modified peptides (e.g., peptides with non-natural amino acid residues), polypeptides, proteins, antibodies or their antigen-binding fragments, ligands, nucleic acids, or any combination thereof. For example, the term “CD39 binding domain” means a portion that has the ability to specifically bind to CD39 (e.g., human and / or mouse CD39). The term “TGFβ binding domain” means a portion that has the ability to specifically bind to one or more family members or isoforms of the TGFβ family (e.g., TGFβ1, TGFβ2, or TGFβ3). “TGFβ binding domain” may also be referred to herein as “TGFβ Trap.” Therefore, a protein containing a CD39 binding domain linked to a TGFβ binding domain as described herein may also be referred to herein as “anti-CD39 / TGFβ Trap.”
[0082]
[0124] In certain embodiments, the conjugate molecule of the Disclosure specifically binds to human TGFβ1, human TGFβ2, and / or human TGFβ3. In certain embodiments, the conjugate molecule of the Disclosure specifically binds to human TGFβ1 and mouse TGFβ1 with similar affinity. In certain embodiments, the conjugate molecule of the Disclosure is measured by an ELISA assay at 3 × 10⁻⁶ -11 M or less (for example, 2 × 10) -11 M or less, 1×10 -11 M or less, 0.9×10 -11 M or less, 0.8×10-11 M or less, 0.7×10 -11 M or less, 0.6×10 -11 M or less, 0.5×10 -11 EC (M or below) 50 It specifically binds to human TGFβ1. In certain embodiments, the conjugate molecule of this disclosure is measured by a blocking assay at 4 × 10⁶ -10 M or less (for example, 3 × 10 -10 M or less, 2×10 -10 M or less, 1×10 -10 M or less, 0.5×10 -10 ICs (M or less) 50 This can block the binding of human TGFβ1 and TGFβRII. In certain embodiments, the conjugate molecule of the Disclosure can bind to human CD39 in a dose-dependent manner, as measured by a FACS assay. In certain embodiments, the conjugate molecule of the Disclosure can bind to CD39 and TGFβ simultaneously, as measured by an ELISA assay or a FACS assay. In certain embodiments, the conjugate molecule of the Disclosure can bind to 4 × 10⁻¹⁶ times, as measured by a TGF-β SMAD reporter assay. -11 ICs below M 50 This can inhibit TGFβ signaling. In certain embodiments, the conjugate molecule of the present disclosure is measured by an ATPase activity assay at 7 × 10⁻⁶ -10 M or less (for example, 6 × 10 -10 M or less, 5×10 -10 M or less, 4×10 -10 M or less, 3×10 -10 M or less, 2×10 -10 M or less, 1×10 -10 M or less, 0.5×10 -10 ICs (M or less) 50 This can inhibit ATPase activity in CD39-expressing cells. In certain embodiments, the conjugate molecule of this disclosure can be measured by Octet assay at 4 × 10⁶ -10 M or less (for example, 3 x 10) -10 M or less, 2×10 -10 M or less, 1×10 -10 M or less, or 0.5 × 10-10 K (M or below) D It can specifically bind to human CD39 at a value of 4 × 10⁶. In certain embodiments, the conjugate molecule of this disclosure can be measured by Octet assay at 4 × 10⁶. -11 M or less (for example, 3 x 10) -11 M or less, 2×10 -11 M or less, 1×10 -11 M or less, 0.5×10 -11 K (M or below) D It can specifically bind to human TGFβ1 at a specific value. In certain embodiments, the conjugate molecule of the Disclosure can restore T cell function as measured by a Treg suppression assay. In certain embodiments, the conjugate molecule of the Disclosure can inhibit apoptosis of human T cells in a dose-dependent manner. In certain embodiments, the conjugate molecule of the Disclosure can promote the survival and activation of human T cells upon stimulation. In certain embodiments, the conjugate molecule of the Disclosure can block TGFβ-induced Foxp3 expression in all T cells. In certain embodiments, the conjugate molecule of the Disclosure can restore ATP-induced inhibition of human T cell proliferation.
[0083] TGFβ-binding domain
[0125] In certain embodiments, the TGFβ-binding domain binds to human and / or mouse TGFβ. In certain embodiments, the TGFβ-binding domain can antagonize and / or inhibit the TGFβ signaling pathway. In certain embodiments, the TGFβ-binding domain can antagonize and / or inhibit TGFβ. In this disclosure, the TGFβ-binding domain may be any portion that specifically binds to one or more family members or isoforms of the TGFβ family. In certain embodiments, the TGFβ-binding domain includes proteins that bind to TGFβ1 (e.g., human TGFβ1), TGFβ2 (e.g., human TGFβ2), and / or TGFβ3 (e.g., human TGFβ3), or variants thereof having similar or improved TGFβ-binding affinity. In certain embodiments, the TGFβ-binding domain binds to TGFβ1 (e.g., human TGFβ1). In certain embodiments, the TGFβ-binding domain binds to TGFβ2 (e.g., human TGFβ2). In certain embodiments, the TGFβ-binding domain binds to TGFβ3 (e.g., human TGFβ3). In certain embodiments, the TGFβ-binding domain specifically binds to TGFβ1 (e.g., human TGFβ1) and TGFβ2 (e.g., human TGFβ2). In certain embodiments, the TGFβ-binding domain specifically binds to TGFβ1 (e.g., human TGFβ1) and TGFβ3 (e.g., human TGFβ3). In certain embodiments, the TGFβ-binding domain specifically binds to TGFβ2 (e.g., human TGFβ2) and TGFβ3 (e.g., human TGFβ3). In certain embodiments, the TGFβ-binding domain specifically binds to TGFβ1 (e.g., human TGFβ1), TGFβ2 (e.g., human TGFβ2), and TGFβ3 (e.g., human TGFβ3). Those skilled in the art will understand that a TGFβ-binding domain that binds to one family member or isoform of the TGFβ family can bind to one or more other family members or isoforms of the TGFβ family with similar or higher affinity.
[0084]
[0126] The TGFβ-binding domain of this disclosure may be an anti-TGFβ antibody moiety or an antigen-binding fragment thereof. Exemplary anti-TGFβ antibody moieties include fresolimmab and metelimumab, as well as anti-TGFβ antibody moieties or antigen-binding fragments described in, for example, US7494651B2, US8383780B2, US8012482B2, and WO2017141208A1, each of which is incorporated herein by reference in whole.
[0085]
[0127] The TGFβ-binding domain of this disclosure may also be a TGFβ receptor (e.g., TGFβRI, TGFβRII, TGFβRIII) or a fragment thereof. In certain embodiments, the TGFβ-binding domain comprises a soluble TGFβ receptor (e.g., a soluble human TGFβ receptor) or a fragment thereof. In certain embodiments, the TGFβ-binding domain comprises the extracellular domain (ECD) of a TGFβ receptor (e.g., a human TGFβ receptor). In certain embodiments, the TGFβ receptor is selected from the group consisting of TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), or TGFβ receptor III (TGFβRIII), and any combination thereof. In certain embodiments, the TGFβ receptor is TGFβRI (e.g., human TGFβRI). In certain embodiments, the TGFβ receptor is TGFβRII (e.g., human TGFβRII). In certain embodiments, the TGFβ receptor is TGFβRIII (e.g., human TGFβRIII).
[0086]
[0128] In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRI (e.g., human TGFβRI), the ECD of TGFβRII (e.g., human TGFβRII), the ECD of TGFβRIII (e.g., human TGFβRIII), or any combination thereof. In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRI (e.g., human TGFβRI). In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRII (e.g., human TGFβRII). In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRIII (e.g., human TGFβRIII). In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRI (e.g., human TGFβRI) and the ECD of TGFβRII (e.g., human TGFβRII). In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRI (e.g., human TGFβRI) and the ECD of TGFβRIII (e.g., human TGFβRIII). In certain embodiments, the TGFβ-binding domain includes the ECD of TGFβRII (e.g., human TGFβRII) and the ECD of TGFβRIII (e.g., human TGFβRIII).
[0087]
[0129] In a particular embodiment, the ECD of the TGFβ receptor includes or comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereof, and retaining binding specificity to TGFβ.
[0088]
[0130] In certain embodiments, the TGFβ-binding domain comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, etc.) ECDs of the TGFβ receptor. In certain embodiments, the two or more ECDs are derived from the same TGFβ receptor. For example, the two or more ECDs are derived from TGFβRI (e.g., human TGFβRI) and are also referred to herein as "TGFβRI ECD" or "TGFβRI ECDs". In another example, the two or more ECDs are derived from TGFβRII (e.g., human TGFβRII) and are also referred to herein as "TGFβRII ECD" or "TGFβRII ECDs". In yet another example, the two or more ECDs are derived from TGFβRIII (e.g., human TGFβRIII) and are also referred to herein as "TGFβRIII ECD" or "TGFβRIII ECDs". In certain embodiments, the amino acid sequences of the two or more ECDs are identical. In certain embodiments, the amino acid sequences of two or more ECDs differ by only 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid or less. In certain embodiments, the amino acid sequences of two or more ECDs differ but have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with each other. In certain embodiments, the amino acid sequences of two or more ECDs differ but each has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with any one of sequence numbers 163 to 165 and retains binding specificity to TGFβ.
[0089]
[0131] In certain embodiments, two or more ECDs are derived from at least two different TGFβ receptors. For example, two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, etc.) ECDs are derived from at least two (e.g., 2, 3) different TGFβ receptors selected from TGFβRI (e.g., human TGFβRI), TGFβRII (e.g., human TGFβRII), and TGFβRIII (e.g., human TGFβRIII). In certain embodiments, two or more ECDs include a first ECD derived from TGFβRI (e.g., human TGFβRI) and a second ECD derived from TGFβRII (e.g., human TGFβRII). In certain embodiments, two or more ECDs include a first ECD derived from TGFβRI (e.g., human TGFβRI) and a second ECD derived from TGFβRIII (e.g., human TGFβRIII). In a particular embodiment, two or more ECDs include a first ECD derived from TGFβRII (e.g., human TGFβRII) and a second ECD derived from TGFβRIII (e.g., human TGFβRIII).
[0090]
[0132] In certain embodiments, the ability of an anti-CD39 / TGFβ trap to block the interaction between TGFβ and the TGFβ receptor increases with increasing TGFβ receptor ECDs. For example, an anti-CD39 / TGFβ trap with four TGFβRII ECDs is more potent in blocking the interaction between TGFβ and TGFβRII than an anti-CD39 / TGFβ trap with two TGFβRII ECDs.
[0091]
[0133] In certain embodiments, two or more ECDs are connected in a sequentially operable manner. In certain embodiments, two or more ECDs are connected to each other covalently or non-covalently. In certain embodiments, two or more ECDs are connected to each other directly or via a linker. In certain embodiments, two or more ECDs are connected via a first linker.
[0092]
[0134] As used herein, the term "linker" refers to an artificial amino acid sequence having 1, 2, 3, 4, or 5 amino acid residues, or 5 to 15, 20, 30, or 50 or more amino acid residues, linked by peptide bonds, and used to link one or more polypeptides. Linkers may or may not have a secondary structure. Linker sequences are known in the art; see, for example, Holliger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993); Poljak et al., Structure 2:1121-1123 (1994).
[0093]
[0135] In certain embodiments, the first linker is selected from the group consisting of cleavable linkers, non-cleavable linkers, peptide linkers, flexible linkers, rigid linkers, helix linkers, and non-helix linkers. Any suitable linker known in the art may be used. In certain embodiments, the first linker includes a peptide linker. For example, useful linkers in this disclosure may be rich in glycine and serine residues. Examples include linkers having a single or repeat sequence containing threonine / serine and glycine, such as TGGGG (SEQ ID NO: 172), GGGGS (SEQ ID NO: 173), or SGGGG (SEQ ID NO: 174) or their tandem repeats (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more repeats). In certain embodiments, the first linker used in this disclosure includes GGGGSGGGGSGGGGS (SEQ ID NO: 175). Alternatively, the linker may be a long peptide chain containing one or more consecutive or tandem repeats of the amino acid sequence GAPGGGGGAAAAAGGGGG (SEQ ID NO: 176). In certain embodiments, the first linker contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more consecutive or tandem repeats of SEQ ID NO: 176. In certain embodiments, the peptide linker contains a GS linker. In certain embodiments, the GS linker contains one or more repeats of GGGS (SEQ ID NO: 177) or SEQ ID NO: 173. In certain embodiments, the peptide linker contains the amino acid sequence GGGGSGGGGSGGGGSG (SEQ ID NO: 182). In a particular embodiment, the first linker comprises or consists of amino acid sequences having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99% sequence identity with any one of sequence numbers 172-177 and 182. The above description of the first linker is also applicable to the following first linkers.
[0094]
[0136] In certain embodiments, the TGFβ binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, or any combination thereof.
[0095]
[0137] Amino acid sequences of some exemplary ECDs of TGFβ receptors are shown in Table 30 below. The first linker is underlined.
[0096]
Table 2-1
[0097]
Table 2-2
[0098]
Table 2-3
[0099] CD39 binding domain
[0138] In certain embodiments, the CD39 binding domain of the present disclosure binds to CD39 (e.g., human CD39, cynomolgus CD39, or mouse CD39). In certain embodiments, the CD39 binding domain of the present disclosure binds to human CD39.
[0100]
[0139] In certain embodiments, the CD39 binding domain of the present disclosure comprises an anti-CD39 antibody moiety. Exemplary anti-CD39 antibody moieties include, for example, anti-CD39 antibodies or antigen-binding fragments thereof described in US10556959B2, US20200277394A1, EP3429692A1, WO2018065552A1, each of which is incorporated herein by reference in its entirety. In certain embodiments, the exemplary anti-CD39 antibody moiety is disclosed in the section of the anti-CD39 antibody moiety of the present disclosure and the section of the anti-CD39 antibody moiety that serves as an example.
[0101]
[0140] In certain embodiments, the anti-CD39 antibody portion comprises one or more CDRs. In certain embodiments, the anti-CD39 antibody portion comprises one or more CDRs described in the section of anti-CD39 antibody portions that are examples of the present disclosure. In certain embodiments, the anti-CD39 antibody portion comprises a heavy chain variable region (VH) and a light chain variable region (VL). In certain embodiments, the anti-CD39 antibody portion comprises the VH and VL of an anti-CD39 antibody disclosed in the section of anti-CD39 antibody portions that are examples of the present disclosure.
[0102]
[0141] In certain embodiments, the anti-CD39 antibody portion further comprises a heavy chain constant domain added to the carboxyl terminus of the heavy chain variable region. In certain embodiments, the heavy chain constant region is derived from the group consisting of IgA, IgD, IgE, IgG, and IgM. In certain embodiments, the heavy chain constant region is derived from human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgM. In certain embodiments, the heavy chain constant region is derived from human IgG1 (SEQ ID NO: 178) or IgG4 (SEQ ID NO: 179). In certain embodiments, the anti-CD39 antibody portion further comprises a light chain constant domain added to the carboxyl terminus of the light chain variable region. In certain embodiments, the light chain constant region is derived from a kappa light chain or a lambda light chain. The amino acid sequences of the kappa light chain constant region and the lambda light chain constant region are shown in SEQ ID NO: 180 and SEQ ID NO: 181, respectively. The amino acid sequences of some exemplary constant regions are shown in Table 31 below.
[0103] [[ID=⑨]]
Table 3
[0104] Linkage between the TGFβ binding domain and the CD39 binding domain
[0142] In this disclosure, the TGFβ-binding domain may be ligated to any portion of the CD39-binding domain (for example, the anti-CD39 antibody moiety). In a particular embodiment, the TGFβ-binding domain is ligated to the anti-CD39 antibody moiety at a position selected from the group consisting of 1) the amino terminus of the heavy chain variable region, 2) the amino terminus of the light chain variable region, 3) the carboxyl terminus of the heavy chain variable region, 4) the carboxyl terminus of the light chain variable region, 5) the carboxyl terminus of the heavy chain constant region, and 6) the carboxyl terminus of the light chain constant region.
[0105]
[0143] The TGFβ-binding domain can be linked (covalently or noncovalently) to any portion of the anti-CD39 antibody moiety (e.g., the amino-terminus or carboxyl-terminus of the immunoglobulin chain) (e.g., directly or via a second linker). The covalent linkage may be chemical or genetic. In certain embodiments, the second linker is selected from the group consisting of cleavable linkers, non-cleavable linkers, peptide linkers, flexible linkers, rigid linkers, helix linkers, and non-helix linkers. Any suitable linker known in the art may be used. In certain embodiments, the second linker includes a peptide linker. For example, useful linkers in this disclosure may be rich in glycine and serine residues. Examples include linkers having a single or repeat sequence of threonine / serine and glycine, such as TGGGG (SEQ ID NO: 172), GGGGS (SEQ ID NO: 173), or SGGGG (SEQ ID NO: 174) or its tandem repeats (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more repeats). In certain embodiments, the second linker used in this disclosure includes GGGGSGGGGSGGGGS (SEQ ID NO: 175). Alternatively, the linker may be a long peptide chain containing one or more consecutive or tandem repeats of the amino acid sequence GAPGGGGGAAAAAGGGGG (SEQ ID NO: 176). In certain embodiments, the second linker includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more consecutive or tandem repeats of SEQ ID NO: 176. In certain embodiments, the peptide linker includes a GS linker. In certain embodiments, the GS linker includes one or more repeats of GGGS (SEQ ID NO: 177) or SEQ ID NO: 173. In a particular embodiment, the peptide linker contains the amino acid sequence GGGGSGGGGSGGGGSG (SEQ ID NO: 182).In certain embodiments, the second linker comprises or consists of amino acid sequences having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, and at least 99% sequence identity with any one of sequence numbers 172-177 and 182. The above description of the second linker is also applicable to the following second linkers.
[0106]
[0144] In certain embodiments, the TGFβ-binding domain is ligated to the heavy chain variable region of the anti-CD39 antibody moiety. The TGFβ-binding domain may be ligated to any portion of the heavy chain variable region, including the amino-terminus (N-terminus) or carboxyl-terminus (C-terminus) amino acid residue of the heavy chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the TGFβ-binding domain is ligated to the amino terminus of the heavy chain variable region of the anti-CD39 antibody moiety (for example, directly or via a second linker). In certain embodiments, the TGFβ-binding domain is ligated to the carboxyl terminus of the heavy chain variable region of the anti-CD39 antibody moiety (for example, directly or via a second linker).
[0107]
[0145] A schematic diagram of an exemplary anti-CD39 / TGFβ trap molecule, including two TGFβRII ECDs linked to the amino terminus of each heavy chain variable region of the anti-CD39 antibody moiety, is shown in Figure 24C of this disclosure.
[0108]
[0146] In certain embodiments, the TGFβ-binding domain is ligated to the light chain variable region of the anti-CD39 antibody moiety. The TGFβ-binding domain may be ligated to any portion of the light chain variable region of the anti-CD39 antibody moiety, including the amino-terminus or carboxyl-terminus amino acid residue of the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the TGFβ-binding domain is ligated to the amino terminus of the light chain variable region of the anti-CD39 antibody moiety (for example, directly or via a second linker). In certain embodiments, the TGFβ-binding domain is ligated to the carboxyl terminus of the light chain variable region of the anti-CD39 antibody moiety (for example, directly or via a second linker).
[0109]
[0147] A schematic diagram of an exemplary anti-CD39 / TGFβ trap molecule, including two TGFβRII ECDs linked to the amino terminus of each light chain variable region of the anti-CD39 antibody moiety, is shown in Figure 24D of this disclosure.
[0110]
[0148] In certain embodiments, the TGFβ-binding domain is ligated to the heavy chain constant region of the anti-CD39 antibody moiety. The TGFβ-binding domain may be ligated to any portion of the heavy chain constant region of the anti-CD39 antibody moiety, including the amino-terminus or carboxyl-terminus amino acid residue of the heavy chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the TGFβ-binding domain is ligated to the amino terminus of the heavy chain constant region of the anti-CD39 antibody moiety (for example, directly or via a second linker). In certain embodiments, the TGFβ-binding domain is ligated to the carboxyl terminus of the heavy chain constant region of the anti-CD39 antibody moiety (for example, directly or via a second linker).
[0111]
[0149] A schematic diagram of an exemplary anti-CD39 / TGFβ trap molecule, containing one TGFβRII ECD ligated to the carboxyl terminus of each heavy chain constant region of the anti-CD39 antibody moiety, is shown in Figure 24A of this disclosure. A schematic diagram of an exemplary anti-CD39 / TGFβ trap molecule, containing two TGFβRII ECDs ligated to the carboxyl terminus of each heavy chain constant region of the anti-CD39 antibody moiety, is shown in Figure 24B of this disclosure.
[0112]
[0150] In certain embodiments, the TGFβ-binding domain is ligated to the constant region of the light chain of the anti-CD39 antibody moiety. The TGFβ-binding domain may be ligated to any portion of the constant region of the light chain of the anti-CD39 antibody moiety, including the amino-terminus or carboxyl-terminus amino acid residue of the constant region of the light chain of the anti-CD39 antibody moiety. In certain embodiments, the TGFβ-binding domain is ligated to the amino terminus of the constant region of the light chain of the anti-CD39 antibody moiety (for example, directly or via a second linker). In certain embodiments, the TGFβ-binding domain is ligated to the carboxyl terminus of the constant region of the light chain of the anti-CD39 antibody moiety (for example, directly or via a second linker).
[0113]
[0151] A schematic diagram of an exemplary anti-CD39 / TGFβ trap molecule, which includes two TGFβRII ECDs linked to the carboxyl termini of each light chain constant region of the anti-CD39 antibody moiety, is shown in Figure 24F of this disclosure.
[0114]
[0152] In certain embodiments, the protein of the disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the heavy chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the amino terminus of the heavy chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the carboxyl terminus of the heavy chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked (e.g., directly or via a second linker) to the amino-terminus and carboxyl-terminus of the heavy chain variable region of the anti-CD39 antibody moiety, respectively. In certain embodiments, the two or more TGFβ-binding domains are linked to each other directly or via a first linker.
[0115]
[0153] In certain embodiments, the proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the amino terminus of the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the CD39 and TGFβ-targeting proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the carboxyl terminus of the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked (e.g., directly or via a second linker) to the amino-terminus and carboxyl-terminus of the light chain variable region of the anti-CD39 antibody moiety, respectively. In certain embodiments, the two or more TGFβ-binding domains are linked to each other directly or via a first linker.
[0116]
[0154] In certain embodiments, the CD39 and TGFβ-targeting proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the heavy chain and light chain variable regions of the anti-CD39 antibody moiety, respectively. In certain embodiments, the proteins of the Disclosure include at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domain linked to the amino terminus of the heavy chain variable region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domain linked to the amino terminus of the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the carboxyl terminus of the heavy chain variable region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the carboxyl terminus of the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the amino terminus of the heavy chain variable region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the carboxyl terminus of the light chain variable region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains ligated to the carboxyl terminus of the heavy chain variable region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains ligated to the amino terminus of the light chain variable region of the anti-CD39 antibody moiety.
[0117]
[0155] A schematic diagram of an exemplary anti-CD39 / TGFβ Trap molecule is shown in Figure 24E of this disclosure, which includes one TGFβRII ECD ligated to the amino terminus of each heavy chain variable region of the anti-CD39 antibody moiety, and one TGFβRII ECD ligated to the amino terminus of each light chain variable region of the anti-CD39 antibody moiety.
[0118]
[0156] In certain embodiments, the CD39 and TGFβ-targeting proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the heavy chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the amino terminus of the heavy chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the carboxyl terminus of the heavy chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked (e.g., directly or via a second linker) to the amino-terminus and carboxyl-terminus of the heavy chain constant region of the anti-CD39 antibody moiety, respectively. In certain embodiments, the two or more TGFβ-binding domains are linked to each other directly or via a first linker.
[0119]
[0157] In certain embodiments, the CD39 and TGFβ-targeting proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the constant light chain region of the anti-CD39 antibody moiety. In certain embodiments, the CD39 and TGFβ-targeting proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the amino terminus of the constant light chain region of the anti-CD39 antibody moiety. In certain embodiments, the proteins of the Disclosure include two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains, all of which are linked (e.g., directly or via a second linker) to the carboxyl terminus of the constant light chain region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked (e.g., directly or via a second linker) to the amino-terminus and carboxyl-terminus of the light chain constant region of the anti-CD39 antibody moiety, respectively. In certain embodiments, the two or more TGFβ-binding domains are linked to each other directly or via a first linker.
[0120]
[0158] In certain embodiments, the protein of the Disclosure comprises two or more TGFβ-binding domains ligated (e.g., directly or via a second linker) to the heavy chain and light chain constant regions of the anti-CD39 antibody moiety, respectively. In certain embodiments, the protein of the Disclosure comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domain ligated to the amino terminus of the heavy chain constant region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domain ligated to the amino terminus of the light chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the disclosure includes at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the carboxyl terminus of the heavy chain constant region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the carboxyl terminus of the light chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the disclosure includes at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the amino terminus of the heavy chain constant region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains linked to the carboxyl terminus of the light chain constant region of the anti-CD39 antibody moiety. In certain embodiments, the protein of the Disclosure comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains ligated to the carboxyl terminus of the heavy chain constant region of the anti-CD39 antibody moiety, and at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) TGFβ-binding domains ligated to the amino terminus of the light chain constant region of the anti-CD39 antibody moiety.
[0121]
[0159] A schematic diagram of an exemplary anti-CD39 / TGFβ Trap molecule, which includes one TGFβRII ECD linked to the carboxyl terminus of each heavy chain constant region of the anti-CD39 antibody portion and two TGFβRII ECDs linked to the carboxyl terminus of each light chain constant region of the anti-CD39 antibody portion, is shown in FIG. 24G of the present disclosure.
[0122]
[0160] In certain embodiments, an anti-CD39 / TGFβ Trap molecule comprising a TGFβ binding domain linked to the C-terminus of the heavy chain (e.g., heavy chain variable region, heavy chain constant region) or light chain (e.g., light chain variable region, light chain constant region) of the anti-CD39 antibody portion has a higher effect of binding to CD39 and / or TGFβ than an anti-CD39 / TGFβ Trap molecule comprising a TGFβ binding domain linked to the N-terminus of the heavy chain (e.g., heavy chain variable region, heavy chain constant region) or light chain (e.g., light chain variable region, light chain constant region) of the anti-CD39 antibody portion. In certain embodiments, an anti-CD39 / TGFβ Trap molecule comprising a TGFβ binding domain linked to the N-terminus of the heavy chain (e.g., heavy chain variable region, heavy chain constant region) or light chain (e.g., light chain variable region, light chain constant region) of the anti-CD39 antibody portion has a higher effect of binding to CD39 and / or TGFβ than an anti-CD39 / TGFβ Trap molecule comprising a TGFβ binding domain linked to the C-terminus of the heavy chain (e.g., heavy chain variable region, heavy chain constant region) or light chain (e.g., light chain variable region, light chain constant region) of the anti-CD39 antibody portion.
[0123] Anti-CD39 antibody portion
[0161] In certain embodiments, the CD39 binding domain of the conjugate molecules provided herein comprises an anti-CD39 antibody portion or an antigen-binding fragment thereof. In certain embodiments, the anti-CD39 antibody portion and its antigen-binding fragment can specifically bind to CD39.
[0124]
[0162] In certain embodiments, the anti-CD39 antibody portion and its antigen-binding fragment provided herein are 10 -7 M or less, 8×10 -8M or less, 5×10 -8 M or less, 2×10 -8 M or less, 8×10 -9 M or less, 5×10 -9 M or less, 2×10 -9 M or less, 10 -9 M or less, 8×10 -10 M or less, 7×10 -10 M or less, or 6×10 -10 K value of M or less that specifically binds to human CD39. The Biacore assay is based on surface plasmon resonance technology. See, for example, Murphy, M. et al., Current protocols in protein science, Chapter 19, unit 19.14, 2006. In certain embodiments, the K D value is measured by the method described in Example 5.1 of the present disclosure. In certain embodiments, the K D value is measured at about 25°C or about 37°C. In certain embodiments, the antibodies and antigen-binding fragments thereof provided herein have a K D value that is comparable to the K D value measured at 37°C, for example, about 80% to about 150%, about 90% to about 130%, or about 90% to about 120%, about 90% to about 110% of the K D value measured at 37°C. D value.
[0125]
[0163] In certain embodiments, the anti-CD39 antibody moieties and antigen-binding fragments thereof provided herein have a K of 10 -8 M or less, 8×10 -9 M or less, 5×10 -9 M or less, 4×10 -9 M or less, 3×10 -9 M or less, 2×10 -9 M or less, 1×10 -9 M or less, 9×10 -10 M or less, 8×10 -10 M or less, 7×10 -10 M or less, or 6×10 -10 K value of M or less DThe value specifically binds to human CD39. The Octet assay is based on biolayer interference spectroscopy techniques. See, for example, Abdiche, Yasmina N., et al. Analytical biochemistry 386.2(2009):172-180 and Sun Y S., Instrumentation Science & Technology, 2014, 42(2):109-127. In certain embodiments, K D The value is measured by the method described in Example 5.1 of this disclosure.
[0126]
[0164] The binding of the antibody moiety or antigen-binding fragment provided herein to human CD39 is "50% effective concentration" (EC2). 50 It can also be expressed by the EC value. 50 The value represents the concentration of the antibody portion where 50% of the maximum binding is observed. EC 50 The values can be measured by binding assays known in the art, such as direct or indirect binding assays including enzyme-linked immunosorbent assay (ELISA), FACS assays, and other binding assays. In certain embodiments, the antibody portion and its antigen-binding fragment provided herein are measured by a FACS (fluorescence-activated cell sorting) assay, and 10 -7 M or less, 8×10 -8 M or less, 5×10 -8 M or less, 2×10 -8 M or less, 10 -8 M or less, 8×10 -9 M or less, 5×10 -9 M or less, 2×10 -9 M or less, 10 -9 M or less, 8×10 -10 M or less, 7×10 -10 M or less, or 6×10 -10 E-commerce below M 50 It specifically binds to human CD39 at a 50% binding concentration. In certain embodiments, binding is measured by ELISA or FACS assay.
[0127]
[0165] In some embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein specifically binds to human CD39 (i.e., ENTPDase 1). In some embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein does not bind to other members of the ENTPDase family. In some embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein specifically binds to human CD39, as measured, for example, by an ELISA assay, but does not specifically bind to ENTPDases 2, 3, 5, or 6.
[0128]
[0166] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein specifically bind to human CD39, but not to mouse CD39, as measured, for example, by a FACS assay.
[0129]
[0167] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein are subjected to a FACS assay. -7 M or less, 8×10 -8 M or less, 5×10 -8 M or less, 2×10 -8 M or less, 10 -8 M or less, 8×10 -9 M or less, 5×10 -9 M or less, 2×10 -9 M or less, 10 -9 M or less, 8×10 -10 M or less, 7×10 -10 M or less, or 6×10 -10 E-commerce below M 50 It specifically binds to CD39 in cynomolgus monkeys.
[0130]
[0168] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein are measured by an ATPase activity assay and have an IC of 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 8 nM or less, 5 nM or less, 3 nM or less, 1 nM or less, 0.9 nM or less, 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, 0.1 nM or less, 0.09 nM or less, 0.08 nM or less, 0.07 nM or less, 0.06 nM or less, or 0.05 nM or less. 50 This inhibits ATPase activity in CD39-expressing cells. The ATPase activity assay can be determined using any method known in the art, for example, by colorimetric detection of phosphate released as a result of ATPase activity. In certain embodiments, ATPase activity is determined by the method described in Example 3.3 of this disclosure.
[0131]
[0169] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein can enhance ATP-mediated monocyte activation at concentrations of 50 nM or less (e.g., 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, or 0.2 nM or less), as measured by analysis of CD80, CD86, and / or CD40 expression by FACS assay, where upregulation of CD80, CD86, and / or CD40 indicates monocyte activation. ATP-mediated monocyte activity can be determined using methods known in the art, for example, by the method described in Example 5.5 of this disclosure.
[0132]
[0170] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein stimulate the secretion of IL-2, or IFN-γ, or CD4 + Or CD8 +Measured by the proliferation of T cells, ATP-mediated T cell activation in PBMCs can be enhanced at concentrations of 25 nM or less, 20 nM or less, 15 nM or less, 10 nM or less, 9 nM or less, 8 nM or less, 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, or 1 nM or less, for example, by the method described in Example 5.5 of this disclosure.
[0133]
[0171] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein can enhance ATP-mediated dendritic cell (DC) activation at concentrations of 25 nM or less (or 10 nM or less, or 5 nM or less, or 1 nM or less, or 0.5 nM or less), as measured by analysis of CD83 expression by FACS assay.
[0134]
[0172] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein can enhance ATP-mediated DC activation at concentrations of 25 nM or less (or 10 nM or less, or 5 nM or less, or 1 nM or less, or 0.5 nM or less), as measured by the ability of activated DCs to promote T cell proliferation.
[0135]
[0173] The anti-CD39 antibody moiety and its antigen-binding fragment provided herein can enhance ATP-mediated DC activation at concentrations of 25 nM or less (or 10 nM or less, or 5 nM or less, or 1 nM or less, or 0.5 nM or less), as measured by the ability of activated DCs to promote IFN-γ production in a mixed lymphocyte reaction (MLR) assay.
[0136]
[0174] The activity of ATP-mediated DC maturation can be determined using methods known in the art, such as the method described in Example 5.5 of this disclosure.
[0175] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein are measured by a FACS assay at concentrations of ≤1 nM (e.g., ≤0.1 nM, ≤0.01 nM) and are induced by adenosine (hydrolyzed from ATP) CD4 + The inhibition of T cell proliferation can be blocked. T cell proliferation can be determined using methods known in the art, for example, the method described in Example 3.4 of this disclosure.
[0137]
[0176] In certain embodiments, the anti-CD39 antibody portion and its antigen-binding fragment provided herein can inhibit tumor growth in mammals in a manner dependent on NK cells or macrophages.
[0138]
[0177] In certain embodiments, the anti-CD39 antibody portion and its antigen-binding fragment provided herein are used for T cell proliferation and CD25 + Human CD8 inhibited by eATP was measured in cells and living cell populations. + It is possible to reverse T cell proliferation. (T cell proliferation percentage, CD25) + The percentage of cells and the percentage of live cells can be determined using methods known in the art, for example, the method described in Example 3.4 of this disclosure.
[0139]
[0178] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein can enhance LPS-induced IL1β release from human macrophages at concentrations of 50 nM or less (or 12.5 nM or less, or 3.13 nM or less, or 0.78 nM or less, or 0.2 nM or less, or 0.049 nM or less, or 0.012 nM or less, or 0.003 nM or less, or 0.0008 nM or less) as measured by an ELISA assay. Macrophage IL1β release can be determined using methods known in the art, for example, the method described in Example 5.5.4 of this disclosure.
[0140] The example of the anti-CD39 antibody portion
[0179] In certain embodiments, the anti-CD39 antibody portion of the Disclosure (e.g., the anti-human CD39 antibody portion) and its antigen-binding fragment are NYGMN (SEQ ID NO: 1), KYWMN (SEQ ID NO: 2), NYWMN (SEQ ID NO: 3), DTFLH (SEQ ID NO: 4), DYNMY (SEQ ID NO: 5), DTYVH (SEQ ID NO: 6), LINTYTGEPTYADDFKD (SEQ ID NO: 7), EIRLKSNKYGTHYAESVKG (SEQ ID NO: 8), QIRLNPDNYATHX1AESVKG (SEQ ID NO: 9), X 58 IDPAX 59 X 60 NIKYDPKFQG (SEQ ID NO: 151), FIDPYNGYTSYNQKFKG (SEQ ID NO: 11), RIDPAIDNSKYDPKFQG (SEQ ID NO: 12), KGIYYDYVWFFDV (SEQ ID NO: 13), QLDLYWFFDV (SEQ ID NO: 14), HGX2RGFAY (SEQ ID NO: 15), SPYYYGSGYRIFDV (SEQ ID NO: 16), IYGYDDAYYFDY (SEQ ID NO: 17), YYCALYDGYNVYAMDY (SEQ ID NO: 18), KASQDINRYIA (SEQ ID NO: 19), RASQSISDYLH (SEQ ID NO: 20), KSSQSLLDSDGRTHLN (SEQ ID NO: 21), SAFSSVNYMH (SEQ ID NO: 22), SATSSVSYMH (SEQ ID NO: 23), RSSK The CDR comprises one or more (e.g., 1, 2, 3, 4, 5, or 6) CDRs containing sequences selected from the group consisting of NLLHSNGITYLY (SEQ ID NO: 24), YTSTLLP (SEQ ID NO: 25), YASQSIS (SEQ ID NO: 26), LVSKLDS (SEQ ID NO: 27), TTSNLAS (SEQ ID NO: 28), STSNLAS (SEQ ID NO: 29), RASTLAS (SEQ ID NO: 30), LQYSNLLT (SEQ ID NO: 31), QNGHSLPLT (SEQ ID NO: 32), WQGTLFPWT (SEQ ID NO: 33), QQRSTYPFT (SEQ ID NO: 34), QQRITYPFT (SEQ ID NO: 35), and AQLLELPHT (SEQ ID NO: 36), where X1 is Y or F, X2 is S or T, and X 58 is R or K, and X 59 is N, G, S, or Q, and X 60is G, A, or D. In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragment have substitutions of one, two, or three or fewer amino acid residues from any of SEQ ID NOs: 1-9, 11-36, and 151.
[0141]
[0180] As used herein, the antibody "mAb13" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 42 and a light chain variable region having the sequence of SEQ ID NO: 51.
[0142]
[0181] As used herein, the antibody "mAb14" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 43 and a light chain variable region having the sequence of SEQ ID NO: 52.
[0143]
[0182] As used herein, the antibody "mAb19" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 44 and a light chain variable region having the sequence of SEQ ID NO: 53.
[0144]
[0183] As used herein, the antibody "mAb21" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 45 and a light chain variable region having the sequence of SEQ ID NO: 54.
[0145]
[0184] As used herein, the antibody "mAb23" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 47 and a light chain variable region having the sequence of SEQ ID NO: 56.
[0146]
[0185] As used herein, the antibody "mAb34" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 49 and a light chain variable region having the sequence of SEQ ID NO: 58.
[0147]
[0186] As used herein, the antibody "mAb35" refers to a monoclonal antibody containing a heavy chain variable region having the sequence of SEQ ID NO: 50 and a light chain variable region having the sequence of SEQ ID NO: 59.
[0148]
[0187] In certain embodiments, the anti-CD39 antibody moiety of the Disclosure and its antigen-binding fragment comprises one or more (e.g., 1, 2, 3, 4, 5, or 6) CDR sequences of antibody mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, or mAb35.
[0149]
[0188] In a particular embodiment, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 6, HCDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 to 9, 11 to 12, and 151, and HCDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 to 18, and / or LCDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 24, LCDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 25 to 30, and LCDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 31 to 36.
[0150]
[0189] In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 1, HCDR2 containing the sequence of SEQ ID NO: 7, HCDR3 containing the sequence of SEQ ID NO: 13, and / or LCDR1 containing the sequence of SEQ ID NO: 19, LCDR2 containing the sequence of SEQ ID NO: 25, and LCDR3 containing the sequence of SEQ ID NO: 31.
[0151]
[0190] In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 2, HCDR2 containing the sequence of SEQ ID NO: 8, HCDR3 containing the sequence of SEQ ID NO: 14, and / or LCDR1 containing the sequence of SEQ ID NO: 20, LCDR2 containing the sequence of SEQ ID NO: 26, and LCDR3 containing the sequence of SEQ ID NO: 32.
[0152]
[0191] In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 3, HCDR2 containing the sequence of SEQ ID NO: 37, HCDR3 containing the sequence of SEQ ID NO: 40, and / or LCDR1 containing the sequence of SEQ ID NO: 21, LCDR2 containing the sequence of SEQ ID NO: 27, and LCDR3 containing the sequence of SEQ ID NO: 33.
[0153]
[0192] In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 3, HCDR2 containing the sequence of SEQ ID NO: 38, HCDR3 containing the sequence of SEQ ID NO: 41, and / or LCDR1 containing the sequence of SEQ ID NO: 21, LCDR2 containing the sequence of SEQ ID NO: 27, and LCDR3 containing the sequence of SEQ ID NO: 33.
[0154]
[0193] In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 4, HCDR2 containing the sequence of SEQ ID NO: 10, HCDR3 containing the sequence of SEQ ID NO: 16, and / or LCDR1 containing the sequence of SEQ ID NO: 22, LCDR2 containing the sequence of SEQ ID NO: 28, and LCDR3 containing the sequence of SEQ ID NO: 34.
[0155]
[0194] In certain embodiments, the anti-CD39 antibody moiety of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 5, HCDR2 containing the sequence of SEQ ID NO: 11, HCDR3 containing the sequence of SEQ ID NO: 17, and / or LCDR1 containing the sequence of SEQ ID NO: 23, LCDR2 containing the sequence of SEQ ID NO: 29, and LCDR3 containing the sequence of SEQ ID NO: 35.
[0156]
[0195] In certain embodiments, the anti-CD39 antibody of the present disclosure and its antigen-binding fragments include HCDR1 containing the sequence of SEQ ID NO: 6, HCDR2 containing the sequence of SEQ ID NO: 12, HCDR3 containing the sequence of SEQ ID NO: 18, and / or LCDR1 containing the sequence of SEQ ID NO: 24, LCDR2 containing the sequence of SEQ ID NO: 30, and LCDR3 containing the sequence of SEQ ID NO: 36.
[0157]
[0196] Table 1 below shows the CDR amino acid sequences of antibody portions mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, and mAb35. The CDR boundaries were defined or identified by Kabat rules. Table 2 below shows the amino acid sequences of the variable regions of the heavy and light chains of antibody portions mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, and mAb35.
[0158] [Table 4]
[0159] [Table 5-1]
[0160] [Table 5-2]
[0161]
[0197] Given that each of the antibody portions mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, and mAb35 can bind to CD39, and that antigen-binding specificity is primarily provided by the CDR1, CDR2, and CDR3 regions, the sequences of HCDR1, HCDR2, and HCDR3 of the antibody portions mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, and mAb35, as well as the sequences of LCDR1, LCDR2, and LCDR3, can be "mixed and matched" (i.e., the CDRs of different antibody portions are mixed and matched, but each antibody portion must contain HCDR1, HCDR2, and HCDR3, as well as LCDR1, LCDR2, and LCDR3) to create the anti-CD39 binding molecule of this disclosure. The CD39 binding of such "mixed and matched" antibodies can be tested using the binding assays described above and in the examples. Preferably, when VH CDR sequences are mixed and matched, the HCDR1, HCDR2, and / or HCDR3 sequences from a particular VH sequence are replaced with structurally similar CDR sequences. Similarly, when VL CDR sequences are mixed and matched, the LCDR1, LCDR2, and / or LCDR3 sequences from a particular VL sequence are preferably replaced with structurally similar CDR sequences. For example, the HCDR1 sequences of antibody portions mAb13 and mAb19 share some structural similarities and are therefore easily mixed and matched. It will be readily apparent to those skilled in the art that novel VH and VL sequences can be created by replacing one or more VH and / or VL CDR sequences from monoclonal antibody portions mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, and mAb35 with structurally similar sequences from the CDR sequences disclosed herein.
[0162]
[0198] CDRs are known to be involved in antigen binding. However, it has been found that not all six CDRs are essential or immutable. In other words, it is possible to replace, alter, or modify one or more CDRs in the anti-CD39 antibody moieties mAb13, mAb14, mAb19, mAb21, mAb23, mAb34, and mAb35 while substantially maintaining specific binding affinity to CD39.
[0163]
[0199] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment of the present disclosure include a suitable framework region (FR) sequence, insofar as the antibody moiety and its antigen-binding fragment can specifically bind to CD39. The CDR sequences provided in Table 1 above are obtained from mouse antibodies, but these can be grafted onto any suitable FR sequence of any suitable species, particularly mouse, human, rat, rabbit, etc., using preferred methods known in the art, such as recombinant methods.
[0164]
[0200] In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment of the Disclosure are humanized. The humanized antibody moiety or its antigen-binding fragment is desirable for its reduced immunogenicity in humans. The humanized antibody moiety is chimeric in its variable region because a non-human CDR sequence is grafted onto a human or substantially human FR sequence. Humanization of the antibody moiety or antigen-binding fragment can essentially be carried out by substituting a non-human (e.g., mouse) CDR gene with the corresponding human CDR gene in a human immunoglobulin gene (see, for example, Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536).
[0165]
[0201] To achieve this objective, suitable human heavy and light chain variable domains can be selected using methods known in the art. In a descriptive example, a “best-fit” approach can be used, in which variable domain sequences of non-human (e.g., rodent) antibodies are screened or BLAST-treated against known human variable domain sequences to identify the human sequence that most closely matches the non-human query sequence, and which is used as a human scaffold for grafting the non-human CDR sequence (see, for example, Sims et al., (1993) J.Immunol.151:2296; Chothia et al. (1987) J.Mot.Biol.196:901). Alternatively, a framework derived from the consensus sequences of all human antibodies may be used for grafting non-human CDRs (see, for example, Carter et al. (1992) Proc. Natl. Acad. Sci. USA, 89:4285; Presta et al. (1993) J. Immunol., 151:2623).
[0166]
[0202] In some embodiments, this disclosure provides 16 humanized antibody moieties of c14, denoted as hu14.H1L1, hu14.H2L1, hu14.H3L1, hu14.H4L1, hu14.H1L2, hu14.H2L2, hu14.H3L2, hu14.H4L2, hu14.H1L3, hu14.H2L3, hu14.H3L3, hu14.H4L3, hu14.H1L4, hu14.H2L4, hu14.H3L4, and hu14.H4L4, respectively. The sequence numbers of the variable regions of the heavy and light chains of each humanized antibody moiety of c14 are shown in Table 16 of Example 5.1. Each of the 16 humanized antibody moieties of c14 contains HCDR1 containing the sequence of SEQ ID NO: 2, HCDR2 containing the sequence of SEQ ID NO: 8, HCDR3 containing the sequence of SEQ ID NO: 14, LCDR1 containing the sequence of SEQ ID NO: 20, LCDR2 containing the sequence of SEQ ID NO: 26, and LCDR3 containing the sequence of SEQ ID NO: 32. The boundaries of the CDRs were defined or identified by Kabat rules.
[0167]
[0203] In some embodiments, the Disclosure is defined as hu23.H1L1, hu23.H2L1, hu23.H3L1, hu23.H4L1, hu23.H1L2, hu23.H2L2, hu23.H3L2, hu23.H4L2, hu23.H1L3, hu23.H2L3, hu23.H3L3, hu23.H4L3, hu23.H1L4, hu23.H2L4, hu23.H3L4, hu23.H4L4, This provides 31 types of humanized antibody moieties of c23, denoted as hu23.H5L1, hu23.H6L1, hu23.H7L1, hu23.H1L5, hu23.H5L5, hu23.H6L5, hu23.H7L5, hu23.H1L6, hu23.H5L6, hu23.H6L6, hu23.H7L6, hu23.H1L7, hu23.H5L7, hu23.H6L7, and hu23.H7L7. The sequence numbers of the variable regions of the heavy and light chains of each humanized antibody moiety of c23 are shown in Tables 13 and 14 of Example 5.1. Each of the 31 humanized antibody moieties for the antibody moiety c23 above includes HCDR1 containing the sequence of SEQ ID NO: 4, HCDR2 containing the sequence of SEQ ID NO: 10, HCDR3 containing the sequence of SEQ ID NO: 16, LCDR1 containing the sequence of SEQ ID NO: 22, LCDR2 containing the sequence of SEQ ID NO: 28, and LCDR3 containing the sequence of SEQ ID NO: 34. The boundaries of the CDRs were defined or identified by Kabat rules.
[0168]
[0204] In some embodiments, the disclosure also provides six humanized antibody moieties having the same CDR as c23 except that the amino acid sequence of HCDR2 is different. In some embodiments, the amino acid sequence of HCDR2 in the humanized antibody moieties of these c23 variants (c23') is X 58 IDPAX 59 X 60 The amino acid sequence NIKYDPKFQG (SEQ ID NO: 151) is included, where X 58 is R or K, and X 59 is N, G, S, or Q, and X 60is G, A, or D. In some embodiments, the amino acid sequence of the HCDR2 of the humanized antibody portion of these c23 variants (c23') includes a sequence selected from the group consisting of RIDPAGGNIKYDPKFQG (SEQ ID NO: 134), RIDPASGNIKYDPKFQG (SEQ ID NO: 135), RIDPAQGNIKYDPKFQG (SEQ ID NO: 136), RIDPANANIKYDPKFQG (SEQ ID NO: 137), RIDPANDNIKYDPKFQG (SEQ ID NO: 138), and KIDPANGNIKYDPKFQG (SEQ ID NO: 139). The CDR boundary was defined or identified by Kabat's rules.
[0169]
[0205] In some embodiments, the disclosure also provides four humanized antibodies against a yeast-displayed c23 variant, denoted as hu23.201, hu23.203, hu23.207, and hu23.211. The heavy-chain and light-chain variable regions of the humanized antibody moieties hu23.201, hu23.203, hu23.207, and hu23.211 are shown in Table 15 of Example 5.1. Each of the four humanized antibody moieties hu23.201, hu23.203, hu23.207, and hu23.211 includes HCDR1 containing the sequence of SEQ ID NO: 4, HCDR2 containing the sequence of SEQ ID NO: 10, HCDR3 containing the sequence of SEQ ID NO: 16, LCDR1 containing the sequence of SEQ ID NO: 22, LCDR2 containing the sequence of SEQ ID NO: 28, and LCDR3 containing the sequence of SEQ ID NO: 34. The boundaries of the CDRs were defined or identified by Kabat rules.
[0170]
[0206] Table 3 below shows the four variants of the humanized c14 heavy chain variable region (i.e., hu14.VH_1, hu14.VH_2, hu14.VH_3, and hu14.VH_4) and the four variants of the humanized c14 light chain variable region (i.e., hu14.VL_1, hu14.VL_2, hu14.VL_3, and hu14.VL_4). Table 4 below shows the amino acid sequences of FR for the heavy and light chain variable regions of humanized c14. Table 5 below shows the heavy and light chain FR amino acid sequences of 16 humanized antibody moieties for the chimeric antibody moiety c14, denoted as hu14.H1L1, hu14.H2L1, hu14.H3L1, hu14.H4L1, hu14.H1L2, hu14.H2L2, hu14.H3L2, hu14.H4L2, hu14.H1L3, hu14.H2L3, hu14.H3L3, hu14.H4L3, hu14.H1L4, hu14.H2L4, hu14.H3L4, and hu14.H4L4, respectively. The heavy chain variable regions and light chain variable regions of these 16 humanized antibody moieties are shown in Table 16 of Example 5.1.
[0171] [Table 6]
[0172] [Table 7]
[0173] [Table 8]
[0174]
[0207] Table 6 below shows seven variants of the humanized c23 heavy chain variable region (i.e., hu23.VH_1, hu23.VH_2, hu23.VH_3, hu23.VH_4, hu23.VH_5, hu23.VH_6, and hu23.VH_7) and seven variants of the humanized c23 light chain variable region (i.e., hu23.VL_1, hu23.VL_2, hu23.VL_3, hu23.VL_4, hu23.VL_5, hu23.VL_6, and hu23.VL_7). Table 7 below shows the amino acid sequences of the heavy and light chain variable regions of four humanized antibody moieties for the chimeric antibody moiety c23 obtained by yeast display. Table 8 below shows the FR amino acid sequences of 35 humanized antibody moieties of c23. Table 9 below shows the FR amino acid sequences for the heavy and light chains of each of the 35 humanized antibody moieties of c23.
[0175] [Table 9-1]
[0176] [Table 9-2]
[0177] [Table 10]
[0178] [Table 11-1]
[0179] [Table 11-2]
[0180] [Table 12]
[0181]
[0208] In certain embodiments, the humanized anti-CD39 antibody moiety or its antigen-binding fragment provided herein consists substantially of human sequences, with the exception of the non-human CDR sequence. In some embodiments, the variable region FR and, if present, the constant region are entirely or substantially derived from human immunoglobulin sequences. The human FR sequence and the human constant region sequence may originate from different human immunoglobulin genes; for example, the FR sequence may originate from one human antibody and the constant region from another human antibody. In some embodiments, the humanized antibody moiety or its antigen-binding fragment comprises human heavy chain HFR1-4 and / or light chain LFR1-4.
[0182]
[0209] In some embodiments, the human-derived FR region may contain the same amino acid sequence as the original human immunoglobulin from which it is derived. In some embodiments, one or more amino acid residues of the human FR are substituted with corresponding residues from the parent non-human antibody. This is desirable in certain embodiments to closely approximate the structure of the humanized antibody or fragment to that of the non-human parent antibody, thereby optimizing the binding properties (e.g., increasing binding affinity). In certain embodiments, the humanized antibody moiety or antigen-binding fragment provided herein includes substitutions of 10, 9, 8, 7, 6, 5, 4, 3, 2, or one or fewer amino acid residues in each of the human FR sequences, or substitutions of 10, 9, 8, 7, 6, 5, 4, 3, 2, or one or fewer amino acid residues in all FR sequences of the heavy chain or light chain variable domain. In some embodiments, such changes in amino acid residues may be present only in the heavy chain FR region, only in the light chain FR region, or in both chains. In certain embodiments, one or more amino acids in the human FR sequence are randomly mutated to increase binding affinity. In certain embodiments, one or more amino acids in a human FR sequence undergo a reversion mutation to the corresponding amino acid in the parental non-human antibody, thereby increasing the binding affinity.
[0183]
[0210] In certain embodiments, the humanized anti-CD39 antibody portion of the present disclosure and its antigen-binding fragment are X 19 VQLVX 20 SGX21 X 22 X 23 X 24 KPGX 25 SX 26 X 27 X 28 SCX 29 ASGX 30 X 31 X 32 X 33 Heavy chain HFR1, WVX containing the sequence of (SEQ ID NO: 76) or a homologous sequence with at least 80% sequence identity. 34 QX 35 PGX 36 X 37 LEWX 38 X 39 Heavy chain HFR2, X containing the sequence of (SEQ ID NO: 77) or a homologous sequence with at least 80% sequence identity. 40 X 41 TX 42 X 43 X 44 DX 45 SX 46 X 47 TX 48 YX 49 X 50 X 51 X 52 SLX 53 X 54 EDTAVYYCX 55 X 56 Heavy chain HFR3 containing the sequence of (SEQ ID NO: 78) or a homologous sequence with at least 80% sequence identity, and WGQGTX 57 VTVSS (SEQ ID NO: 126) contains a heavy chain HFR4 containing the sequence or a homologous sequence with at least 80% sequence identity, where X 19 is Q or E, and X 20 is E or Q, and X 21 is G or A, X 22 is G or E, X 23 is L or V, X 24 is V or K, and X 25 is G or A, X 26 is L, M, or V, X 27 is R or K, and X 28 is V or L, X29 is A or K, and X 30 is F or Y, and X 31 is N or T, X 32 is F or L, X 33 is S or K, X 34 is R or K, and X 35 is A or S, X 36 is K or Q, and X 37 is R or G, X 38 is M, I, or V, X 39 is G or A, X 40 is R or K, and X 41 is V, A, or F, and X 42 is I or L, X 43 is S or T, X 44 is R or A, X 45 is D or T, X 46 is K, A, or S, X 47 is S or N, X 48 is L, V, or A, and X 49 is M or L, X 50 is Q or E, and X 51 is M or L, X 52 is S, I, or N, and X 53 is R or K, and X 54 is S or T, X 55 is A or T, and X 56 is R, N, or T, and X 57 It is either T or L.
[0184]
[0211] In certain embodiments, the humanized anti-CD39 antibody moiety of the Disclosure and its antigen-binding fragment include the light chain LFR1, WYQQKPGQX containing the sequence X3IVX4TQSPATLX5X6SPGERX7TX8X9C (SEQ ID NO: 80) or a homologous sequence with at least 80% sequence identity. 10 PX 11 Light chain LFR2, GX containing the sequence of LLIY (sequence number 81) or a homologous sequence with at least 80% sequence identity. 12 PX 13RFSGSGSGTX 14 X 15 TLTISSX 16 EPEDFAVYX 17 Light chain LFR3 containing the sequence of C (Sequence ID 82) or a homologous sequence with at least 80% sequence identity, and FGX 18 The light chain LFR4 contains the sequence of GTKLEIK (sequence ID 152) or at least 80% homologous sequences thereof, where X3 is E or Q, X4 is L or M, X5 is S or T, X6 is L, V, or A, X7 is A or V, X8 is L or I, X9 is S or T, X 10 is A or S, X 11 is R or K, and X 12 is I or V, X 13 is A or T, and X 14 is D or S, X 15 is F or Y, and X 16 is L, M, or V, X 17 is Y or F, and X 18 It is either G or Q.
[0185]
[0212] In certain embodiments, the humanized anti-CD39 antibody portion of the Disclosure and its antigen-binding fragment are EVQLVESGGGLVKPGGSX 61 Heavy chain HFR1, WVRQX containing the sequence of RLSCAASGFTFS (SEQ ID NO: 154) or a homologous sequence with at least 80% sequence identity. 62 PGKGLEWVX 63 Heavy chain HFR2 containing the sequence of (SEQ ID NO: 155) or a homologous sequence with at least 80% sequence identity, RFTISRDDSKNTX 64 The heavy chain HFR3 contains the sequence YLQMNSLKTEDTAVYYCTT (SEQ ID NO: 156) or a homologous sequence with at least 80% sequence identity, and the heavy chain HFR4 contains the sequence WGQGTTVTVSS (SEQ ID NO: 79) or a homologous sequence with at least 80% sequence identity, where X 61 is L or M, X 62 is A or S, X 63 is G or A, X64 It is L or V.
[0186]
[0213] In certain embodiments, the humanized anti-CD39 antibody portion of the Disclosure and its antigen-binding fragment are used in EIVX 65 TQSPATLSX 66 SPGERX 67 TLSC (SEQ ID NO: 157) or a light chain LFR1 containing a homologous sequence with at least 80% sequence identity, WYQQKPGQX 68 Light chain LFR2 containing the sequence of PRLLIY (sequence number 158) or a homologous sequence with at least 80% sequence identity, GIPARFSGSGSGTDFTLTISSX 69 EPEDFAVYX 70 The light chain LFR3 includes the sequence of C (SEQ ID NO: 159) or a homologous sequence with at least 80% sequence identity, and the light chain LFR4 includes FGGGTKLEIK (SEQ ID NO: 153) or a homologous sequence with at least 80% sequence identity, where X 65 is L or M, X 66 is L or V, X 67 is A or V, X 68 is A or S, X 69 is L or V, X 70 It is either Y or F.
[0187]
[0214] In certain embodiments, the humanized anti-CD39 antibody portion of the present disclosure and its antigen-binding fragment are X 71 VQLVQSGAEVKKPGASVKX 72 SCKASGYX 73 Heavy chain HFR1, WVX containing the sequence of LK (SEQ ID NO: 160) or a homologous sequence with at least 80% sequence identity. 74 QAPGQX 75 LEWX 76 Heavy chain HFR2 containing the sequence of G (Sequence ID 161) or a homologous sequence with at least 80% sequence identity, X 77 X 78 TX 79 TX 80 DTSX 81 X 82TAYX 83 ELX 84 SLRSEDTAVYYCAX 85 Heavy chain HFR3 containing the sequence of (SEQ ID NO: 149) or a homologous sequence with at least 80% sequence identity, WGQGTX 57 VTVSS (SEQ ID NO: 126) or a heavy chain HFR4 containing a homologous sequence with at least 80% sequence identity, where X 57 As defined above, X 71 is Q or E, and X 72 is V or L, X 73 is N or T, X 74 is R or K, and X 75 is R or G, X 76 is M or I, X 77 is R or K, and X 78 is V or A, X 79 is I or L, X 80 is R or A, X 81 is A or S, X 82 is S or N, X 83 is M or L, X 84 is S or I, X 85 It is either R or N.
[0188]
[0215] In certain embodiments, the humanized anti-CD39 antibody portion of the present disclosure and its antigen-binding fragment are X 86 IVLTQSPATLX 87 X 88 SPGERX 89 TX 90 X 91 Light chain LFR1, WYQQKPGQX containing the sequence of C (SEQ ID NO: 150) or a homologous sequence with at least 80% sequence identity. 10 PX 11 Light chain LFR2, GX containing the sequence of LLIY (sequence number 81) or a homologous sequence with at least 80% sequence identity. 92 PX 93 RFSGSGSGTX 94 X 95 TLTISSX 96It comprises a light chain LFR3 containing the sequence of EPEDFAVYYC (SEQ ID NO: 148) or a homologous sequence with at least 80% sequence identity, and a light chain LFR4 containing the sequence of FGQGTKLEIK (SEQ ID NO: 83) or a homologous sequence with at least 80% sequence identity, where X 10 and X 11 As defined above, X 86 is E or Q, and X 87 is S or T, X 88 is L or A, X 89 is A or V, X 90 is L or I, X 91 is S or T, X 92 is I or V, X 93 is A or T, and X 94 is D or S, X 95 is F or Y, and X 96 It is L or M.
[0189]
[0216] In a particular embodiment, the humanized anti-CD39 antibody moiety of the Disclosure and its antigen-binding fragment comprises a heavy chain HFR1 containing a sequence selected from the group consisting of SEQ ID NOs: 84-86, 115, 119-120, and 131; a heavy chain HFR2 containing a sequence of SEQ ID NOs: 87-90 and 121-123; a heavy chain HFR3 containing a sequence selected from the group consisting of SEQ ID NOs: 91-97, 116-117, and 124-125; and a heavy chain HFR4 containing a sequence selected from the group consisting of SEQ ID NOs: 79 and 118; and / or a light chain LFR1 containing a sequence from the group consisting of SEQ ID NOs: 98-103 and 127-129; a light chain LFR2 containing a sequence selected from the group consisting of SEQ ID NOs: 104, 105, and 130; a light chain LFR3 containing a sequence selected from the group consisting of SEQ ID NOs: 106-110 and 132-133; and a light chain LFR4 containing a sequence selected from the group consisting of SEQ ID NOs: 83 and 153.
[0190]
[0217] In certain embodiments, the humanized anti-CD39 antibody moiety and its antigen-binding fragment of the present disclosure are hu14.VH_1 (SEQ ID NO: 68), hu14.VH_2 (SEQ ID NO: 70), hu14.VH_3 (SEQ ID NO: 72), hu14.VH_4 (SEQ ID NO: 74), hu23.VH_1 (SEQ ID NO: 60), hu23.VH_2 (SEQ ID NO: 62), hu23.VH_3 (SEQ ID NO: 64), hu23.VH_4 ( It includes HFR1, HFR2, HFR3, and / or HFR4 sequences contained in a heavy chain variable region selected from the group consisting of SEQ ID NO: 66), hu23.VH_5 (SEQ ID NO: 140), hu23.VH_6 (SEQ ID NO: 141), hu23.VH_7 (SEQ ID NO: 142), hu23.201H (SEQ ID NO: 146), hu23.207H (SEQ ID NO: 147), and hu23.211H (SEQ ID NO: 39).
[0191]
[0218] In certain embodiments, the humanized anti-CD39 antibody moiety and its antigen-binding fragment of the present disclosure are hu14.VL_1 (SEQ ID NO: 69), hu14.VL_2 (SEQ ID NO: 71), hu14.VL_3 (SEQ ID NO: 73), hu14.VL_4 (SEQ ID NO: 75), hu23.VL_1 (SEQ ID NO: 61), hu23.VL_2 (SEQ ID NO: 63), hu23.VL_3 (SEQ ID NO: 65), hu23.VL_4 ( It includes LFR1, LFR2, LFR3, and / or LFR4 sequences contained in a light chain variable region selected from the group consisting of SEQ ID NO: 67), hu23.VL_5 (SEQ ID NO: 143), hu23.VL_6 (SEQ ID NO: 144), hu23.VL_7 (SEQ ID NO: 145), hu23.201L (SEQ ID NO: 111), hu23.203L (SEQ ID NO: 112), and hu23.211L (SEQ ID NO: 63).
[0192]
[0219] In certain embodiments, the humanized anti-CD39 antibody moiety and its antigen-binding fragment provided herein comprises a heavy chain variable domain sequence selected from the group consisting of SEQ ID NOs: 39, 60, 62, 64, 66, 68, 70, 72, 74, 140, 141, 142, 146, and 147, and / or a light chain variable domain sequence selected from the group consisting of SEQ ID NOs: 61, 63, 65, 67, 69, 71, 73, 75, 111, 112, 143, 144, and 145.
[0193]
[0220] The exemplary humanized antibody portion of the chimeric antibody portion c14 of this disclosure is 1) "hu14.H1L1" which includes the heavy chain variable region of hu14.VH_1 (sequence number 68) and the light chain variable region of hu14.VL_1 (sequence number 69), 2) "hu14.H2L1" which includes the heavy chain variable region of hu14.VH_2 (sequence number 70) and the light chain variable region of hu14.VL_1 (sequence number 69), 3) "hu14.H3L1" which includes the heavy chain variable region of hu14.VH_3 (sequence number 72) and the light chain variable region of hu14.VL_1 (sequence number 69), 4) "hu14.H4L1" which includes the heavy chain variable region of hu14.VH_4 (sequence number 74) and the light chain variable region of hu14.VL_1 (sequence number 69), 5) "hu14.H1L2" which includes the heavy chain variable region of hu14.VH_1 (sequence number 68) and the light chain variable region of hu14.VL_2 (sequence number 71), 6) "hu14.H2L2" which includes the heavy chain variable region of hu14.VH_2 (sequence number 70) and the light chain variable region of hu14.VL_2 (sequence number 71), 7) "hu14.H3L2" which includes the heavy chain variable region of hu14.VH_3 (sequence number 72) and the light chain variable region of hu14.VL_2 (sequence number 71), 8) "hu14.H4L2" which includes the heavy chain variable region of hu14.VH_4 (sequence number 74) and the light chain variable region of hu14.VL_2 (sequence number 71), 9) "hu14.H1L3" which includes the heavy chain variable region of hu14.VH_1 (sequence number 68) and the light chain variable region of hu14.VL_3 (sequence number 73), 10) "hu14.H2L3" which includes the heavy chain variable region of hu14.VH_2 (sequence number 70) and the light chain variable region of hu14.VL_3 (sequence number 73), 11) "hu14.H3L3" which includes the heavy chain variable region of hu14.VH_3 (sequence number 72) and the light chain variable region of hu14.VL_3 (sequence number 73), 12) "hu14.H4L3" which includes the heavy chain variable region of hu14.VH_4 (sequence number 74) and the light chain variable region of hu14.VL_3 (sequence number 73), 13) "hu14.H1L4" which includes the heavy chain variable region of hu14.VH_1 (sequence number 68) and the light chain variable region of hu14.VL_4 (sequence number 75), 14) "hu14.H2L4" which includes the heavy chain variable region of hu14.VH_2 (sequence number 70) and the light chain variable region of hu14.VL_4 (sequence number 75), 15) "hu14.H3L4" which includes the heavy chain variable region of hu14.VH_3 (sequence number 72) and the light chain variable region of hu14.VL_4 (sequence number 75), 16) "hu14.H4L4" which includes the heavy chain variable region of hu14.VH_4 (sequence number 74) and the light chain variable region of hu14.VL_4 (sequence number 75), Includes.
[0194]
[0221] The exemplary humanized antibody portion of the chimeric antibody portion c23 of this disclosure is 1) "hu23.H1L1" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_1 (sequence number 61), 2) "hu23.H2L1" which includes the heavy chain variable region of hu23.VH_2 (sequence number 62) and the light chain variable region of hu23.VL_1 (sequence number 61), 3) "hu23.H3L1" which includes the heavy chain variable region of hu23.VH_3 (sequence number 64) and the light chain variable region of hu23.VL_1 (sequence number 61), 4) "hu23.H4L1" which includes the heavy chain variable region of hu23.VH_4 (sequence number 66) and the light chain variable region of hu23.VL_1 (sequence number 61), 5) "hu23.H1L2" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_2 (sequence number 63), 6) "hu23.H2L2" which includes the heavy chain variable region of hu23.VH_2 (sequence number 62) and the light chain variable region of hu23.VL_2 (sequence number 63), 7) "hu23.H3L2" which includes the heavy chain variable region of hu23.VH_3 (sequence number 64) and the light chain variable region of hu23.VL_2 (sequence number 63), 8) "hu23.H4L2" which includes the heavy chain variable region of hu23.VH_4 (sequence number 66) and the light chain variable region of hu23.VL_2 (sequence number 63), 9) "hu23.H1L3" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_3 (sequence number 65), 10) "hu23.H2L3" which includes the heavy chain variable region of hu23.VH_2 (sequence number 62) and the light chain variable region of hu23.VL_3 (sequence number 65), 11) "hu23.H3L3" which includes the heavy chain variable region of hu23.VH_3 (sequence number 64) and the light chain variable region of hu23.VL_3 (sequence number 65), 12) "hu23.H4L3" which includes the heavy chain variable region of hu23.VH_4 (sequence number 66) and the light chain variable region of hu23.VL_3 (sequence number 65), 13) "hu23.H1L4" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_4 (sequence number 67), 14) "hu23.H2L4" which includes the heavy chain variable region of hu23.VH_2 (sequence number 62) and the light chain variable region of hu23.VL_4 (sequence number 67), 15) "hu23.H3L4" which includes the heavy chain variable region of hu23.VH_3 (sequence number 64) and the light chain variable region of hu23.VL_4 (sequence number 67), 16) "hu23.H4L4" which includes the heavy chain variable region of hu23.VH_4 (sequence number 66) and the light chain variable region of hu23.VL_4 (sequence number 67), 17) "hu23.H5L1" which includes the heavy chain variable region of hu23.VH_5 (sequence number 140) and the light chain variable region of hu23.VL_1 (sequence number 61), 18) "hu23.H6L1" which includes the heavy chain variable region of hu23.VH_6 (sequence number 141) and the light chain variable region of hu23.VL_1 (sequence number 61), 19) "hu23.H7L1" which includes the heavy chain variable region of hu23.VH_7 (sequence number 142) and the light chain variable region of hu23.VL_1 (sequence number 61), 20) "hu23.H1L5" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_5 (sequence number 143), 21) "hu23.H5L5" which includes the heavy chain variable region of hu23.VH_5 (sequence number 140) and the light chain variable region of hu23.VL_5 (sequence number 143), 22) "hu23.H6L5" which includes the heavy chain variable region of hu23.VH_6 (sequence number 141) and the light chain variable region of hu23.VL_5 (sequence number 143), 23) "hu23.H7L5" which includes the heavy chain variable region of hu23.VH_7 (sequence number 142) and the light chain variable region of hu23.VL_5 (sequence number 143), 24) "hu23.H1L6" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_6 (sequence number 144), 25) "hu23.H5L6" which includes the heavy chain variable region of hu23.VH_5 (sequence number 140) and the light chain variable region of hu23.VL_6 (sequence number 144), 26) "hu23.H6L6" which includes the heavy chain variable region of hu23.VH_6 (sequence number 141) and the light chain variable region of hu23.VL_6 (sequence number 144), 27) "hu23.H7L6" which includes the heavy chain variable region of hu23.VH_7 (sequence number 142) and the light chain variable region of hu23.VL_6 (sequence number 144), 28) "hu23.H1L7" which includes the heavy chain variable region of hu23.VH_1 (sequence number 60) and the light chain variable region of hu23.VL_7 (sequence number 145), 29) "hu23.H5L7" which includes the heavy chain variable region of hu23.VH_5 (sequence number 140) and the light chain variable region of hu23.VL_7 (sequence number 145), 30) "hu23.H6L7" which includes the heavy chain variable region of hu23.VH_6 (sequence number 141) and the light chain variable region of hu23.VL_7 (sequence number 145), 31) "hu23.H7L7" which includes the heavy chain variable region of hu23.VH_7 (sequence number 142) and the light chain variable region of hu23.VL_7 (sequence number 145), 32) "hu23.201" including the heavy chain variable region of hu23.201H (sequence number 146) and the light chain variable region of hu23.201L (sequence number 111), 33) "hu23.203" includes the heavy chain variable region of hu23.201H (sequence number 146) and the light chain variable region of hu23.203L (sequence number 112), 34) "hu23.207" includes the heavy chain variable region of hu23.207H (sequence number 147) and the light chain variable region of hu23.201L (sequence number 111), 35) "hu23.211" including the heavy chain variable region of hu23.211H (sequence number 39) and the light chain variable region of hu23.211L (sequence number 63) Includes.
[0195]
[0222] These exemplary humanized anti-CD39 antibody moieties retained specific binding ability or affinity for CD39, and in this respect were at least equal to or better than the parental mouse antibody moieties mAb14 or mAb23.
[0196]
[0223] In some embodiments, the anti-CD39 antibody moiety and antigen-binding fragment provided herein comprises all or part of the heavy chain variable domain and / or all or part of the light chain variable domain. In one embodiment, the anti-CD39 antibody moiety or antigen-binding fragment provided herein is a single-chain domain antibody comprising all or part of the heavy chain variable domain provided herein. Further information on such single-chain domain antibodies is available in the Art (see, for example, U.S. Patent No. 6,248,516).
[0197]
[0224] In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein further comprises a constant region of immunoglobulin (Ig), which optionally further comprises constant regions of the heavy chain and / or light chain. In certain embodiments, the heavy chain constant region comprises CH1, hinge, and / or CH2-CH3 regions (or optionally CH2-CH3-CH4 regions). In certain embodiments, the anti-CD39 antibody or antigen-binding fragment provided herein comprises a heavy chain constant region of human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgM. In certain embodiments, the light chain constant region comprises Cκ or Cλ. The constant region of the anti-CD39 antibody moiety or antigen-binding fragment provided herein may be identical to the sequence of the wild-type constant region, or it may differ in one or more mutations.
[0198]
[0225] In certain embodiments, the heavy chain constant region includes an Fc region. The Fc region is known to mediate effector functions such as antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Fc regions of different Ig isotypes have different abilities to induce effector functions. For example, the Fc regions of IgG1 and IgG3 are recognized to induce both ADCC and CDC more effectively than the Fc regions of IgG2 and IgG4. In certain embodiments, the anti-CD39 antibody moiety and its antigen-binding fragment provided herein include an Fc region of an IgG1 or IgG3 isotype that can induce ADCC or CDC, or a constant region of an IgG4 or IgG2 isotype with reduced or depleted effector function. In some embodiments, the Fc region derived from human IgG1 has reduced effector function. In some embodiments, the Fc region derived from human IgG1 includes the L234A and / or L235A mutation. In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein comprises a wild-type human IgG4 Fc region or other wild-type human IgG4 alleles. In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein comprises a human IgG4 Fc region containing the S228P mutation and / or the L235E mutation, as well as / or the F234A and L235A mutations. In some embodiments, the Fc region derived from human IgG4 comprises the S228P mutation and / or the F234A and L235A mutations.
[0199]
[0226] In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein has sufficient specific binding affinity to human CD39 for use in diagnosis and / or therapy.
[0200]
[0227] The anti-CD39 antibody moiety or antigen-binding fragment provided herein may be a monoclonal antibody, polyclonal antibody, humanized antibody, chimeric antibody, recombinant antibody, bispecific antibody, multispecific antibody, labeled antibody, bivalent antibody, anti-idiotype antibody, or fusion protein. Recombinant antibodies are antibodies prepared in vitro using recombinant methods, rather than in the animal body.
[0201]
[0228] In certain embodiments, the Disclosure provides an anti-CD39 antibody moiety or antigen-binding fragment that competes with the antibody moiety or antigen-binding fragment provided herein for binding to CD39. In certain embodiments, the Disclosure provides an anti-CD39 antibody moiety or antigen-binding fragment that competes with an antibody moiety comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 43 and a light chain variable region comprising the sequence of SEQ ID NO: 52 for binding to human CD39. In certain embodiments, the Disclosure provides an anti-CD39 antibody moiety or antigen-binding fragment that competes with an antibody moiety comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 44 and a light chain variable region comprising the sequence of SEQ ID NO: 53 for binding to human CD39. In certain embodiments, the Disclosure provides an anti-CD39 antibody moiety or antigen-binding fragment that competes with an antibody moiety comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 45 and a light chain variable region comprising the sequence of SEQ ID NO: 54 for binding to human CD39, or with an antibody moiety comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 47 and a light chain variable region comprising the sequence of SEQ ID NO: 56 for binding to human CD39.
[0202]
[0229] In some embodiments, the disclosure provides an anti-CD39 antibody moiety or antigen-binding fragment thereof that specifically binds to an epitope of CD39, where the epitope comprises one or more residues selected from the group consisting of Q96, N99, E143, R147, R138, M139, E142, K5, E100, D107, V81, E82, R111, and V115.
[0203]
[0230] In some embodiments, the epitope comprises one or more residues selected from the group consisting of Q96, N99, E143, and R147. In some embodiments, the epitope comprises all of residues Q96, N99, E143, and R147.
[0204]
[0231] In some embodiments, the epitope comprises one or more residues selected from the group consisting of R138, M139, and E142. In some embodiments, the epitope comprises all of residues R138, M139, and E142.
[0205]
[0232] In some embodiments, the epitope comprises one or more residues selected from the group consisting of K5, E100, and D107. In some embodiments, the epitope comprises all of the residues K5, E100, and D107.
[0206]
[0233] In some embodiments, the epitope comprises one or more residues selected from the group consisting of V81, E82, R111, and V115. In some embodiments, the epitope comprises all of the residues V81, E82, R111, and V115.
[0207]
[0234] In some embodiments, CD39 is human CD39. In some embodiments, CD39 is human CD39 containing the amino acid sequence of SEQ ID NO: 162.
[0235] In some embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein is none other than antibody 9-8B, antibody T895, and antibody I394.
[0208]
[0236] As used herein, "9-8B" refers to an antibody or its antigen-binding fragment comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 46 and a light chain variable region having the amino acid sequence of SEQ ID NO: 48.
[0209]
[0237] As used herein, "T895" refers to an antibody or its antigen-binding fragment comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 55 and a light chain variable region having the amino acid sequence of SEQ ID NO: 57.
[0210]
[0238] As used herein, "I394" means an antibody or its antigen-binding fragment comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 113 and a light chain variable region having the amino acid sequence of SEQ ID NO: 114.
[0211] Antibody variant
[0239] The anti-CD39 antibody moiety and its antigen-binding fragment provided herein also encompass various variants of the antibody sequence provided herein.
[0212]
[0240] In certain embodiments, an antibody variant comprises one or more CDR sequences provided in Table 1 above, one or more non-CDR sequences of heavy chain variable regions or light chain variable regions provided in Tables 4, 5, 8, and 9 above, and / or one or more modifications or substitutions in a constant region (e.g., Fc region). Such variants retain the binding specificity of their parental antibodies to CD39 but possess one or more desirable properties provided by the modifications or substitutions. For example, an antibody variant may have improved antigen-binding affinity, improved glycosylation pattern, reduced glycosylation risk, reduced deamination, reduced or depleted effector function, improved FcRn receptor binding, increased pharmacokinetic half-life, pH sensitivity, and / or compatibility with conjugates (e.g., one or more introduced cysteine residues).
[0213]
[0241] Parental antibody sequences may be screened using methods known in the art, such as "alanine scanning mutagenesis," to identify suitable or preferred residues for modification or substitution (see, for example, Cunningham and Wells (1989) Science, 244:1081-1085). Briefly, target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) can be identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine), and modified antibodies can be produced and screened for desired properties. If a desired functional change is demonstrated by substitution at a specific amino acid position, that position can be identified as a potential residue for modification or substitution. Potential residues may be further evaluated by substitution with different types of residues (e.g., cysteine residues, positively charged residues, etc.).
[0214] affinity variant
[0242] Antibody affinity variants may include modifications or substitutions in one or more CDR sequences provided in Table 1 above, one or more FR sequences provided in Tables 4, 5, 8, and 9 above, or in the variable region sequences of the heavy or light chain provided in Tables 2, 3, 6, and 7 above. Since it is known in the art that a CDR region is adjacent to two FR regions in the variable region, the FR sequences can be readily identified by those skilled in the art based on the CDR sequence in Table 1 above and the variable region sequences in Tables 2, 3, 6, and 7 above. The affinity variants retain the specific binding affinity of the parent antibody to CD39, or even have improved CD39 specific binding affinity than the parent antibody. In certain embodiments, at least one (or all) of the substitutions in the CDR sequence, FR sequence, or variable region sequence include conservative substitutions.
[0215]
[0243] Those skilled in the art will understand that, in the CDR sequences provided in Table 1 above, and the variable region sequences provided in Tables 2, 3, 6, and 7 above, one or more amino acid residues can be substituted, and the resulting antibody or antigen-binding fragment still retains, or even has improved, binding affinity or capacity to CD39. To achieve this objective, various methods known in the art can be used. For example, a library of antibody variants (such as Fab or scFv variants) can be generated and expressed using phage display technology, and then screened for binding affinity to human CD39. Alternatively, computer software can be used to virtually simulate the binding of an antibody to human CD39 and identify amino acid residues on the antibody that form the binding interface. Such residues may be avoided in substitutions to prevent a reduction in binding affinity, or they may be targeted for substitution to provide stronger binding.
[0216]
[0244] In certain embodiments, the humanized anti-CD39 antibody moiety or its antigen-binding fragment provided herein includes substitutions of one or more amino acid residues in one or more CDR sequences and / or in one or more FR sequences. In certain embodiments, the affinity variant includes a total of 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 or fewer substitutions in the CDR sequence and / or FR sequence.
[0217]
[0245] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment comprises one, two, or three CDR sequences having at least 80% (e.g., at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with the CDRs listed in Table 1 above, and maintaining a specific binding affinity to CD39 at a level similar to or even higher than that of its parent antibody.
[0218]
[0246] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment comprises one or more variable region sequences having at least 80% (e.g., at least 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with the variable region sequences listed in Tables 2, 3, 6, and 7 above, while maintaining a specific binding affinity to CD39 at a level similar to or even higher than that of its parent antibody. In some embodiments, a total of 1 to 10 amino acids are substituted, inserted, or deleted in the variable region sequences listed in Tables 2, 3, 6, and 7 above. In some embodiments, the substitutions, insertions, or deletions occur in regions outside the CDR (e.g., within the FR).
[0219] Glycosylated variant
[0247] The anti-CD39 antibody moiety or its antigen-binding fragment provided herein also includes glycosylated variants obtained by increasing or decreasing the degree of glycosylation of the antibody or its antigen-binding fragment.
[0220]
[0248] The anti-CD39 antibody moiety or its antigen-binding fragment may include one or more modifications that introduce or remove glycosylation sites. A glycosylation site is an amino acid residue having a side chain to which a carbohydrate moiety (e.g., an oligosaccharide structure) can be attached. Antibody glycosylation is typically N-linked or O-linked. N-linking means the attachment of a carbohydrate moiety to the side chain of an asparagine residue, such as an asparagine residue, where X is any amino acid other than proline in a tripeptide sequence such as asparagine-X-serine and asparagine-X-threonine. O-linked glycosylation means the attachment of a sugar, one of N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine. Removal of a natural glycosylation site can be conveniently achieved by modifying the amino acid sequence so that one of the above tripeptide sequences (for N-linked glycosylation sites) or serine or threonine residues (for O-linked glycosylation sites) present in the sequence is substituted. By introducing such tripeptide sequences or serine or threonine residues, new glycosylation sites can be similarly created.
[0221]
[0249] In certain embodiments, the anti-CD39 antibody moiety and antigen-binding fragments provided herein include one or more mutations at positions selected from the group consisting of N55, G56, and N239 in order to remove one or more deamidation sites. In certain embodiments, the anti-CD39 antibody moiety and antigen-binding fragments provided herein include mutations at N55 (e.g., N55G, N55S, or N55Q), and / or mutations at G56 (e.g., G56A, G56D), and / or mutations at N297 (e.g., N297A, N297Q, or N297G). These mutations have been tested and are considered not to adversely affect the binding affinity of the antibody moiety provided herein.
[0222] Cysteine-modified variant
[0250] The anti-CD39 antibody moiety or its antigen-binding fragment provided herein also includes cysteine-engineered variants comprising one or more introduced free cysteine amino acid residues.
[0223]
[0251] Free cysteine residues are residues that are not part of the disulfide crosslinking. Cysteine-manipulated variants are useful for conjugating, for example, cytotoxic and / or imaging compounds, labeling, or, above all, radioisotopes, at the manipulated cysteine site, for example, by maleimide or haloacetyl. Methods for introducing free cysteine residues by manipulating antibodies or their antigen-binding fragments are known in the art; see, for example, WO2006 / 034488.
[0224] Fc Variant
[0252] The anti-CD39 antibody moiety or its antigen-binding fragment provided herein also includes Fc variants that include modifications or substitutions of one or more amino acid residues in the Fc region and / or hinge region to provide modified effector functions such as ADCC and CDC. Methods for modifying ADCC activity by antibody manipulation have been described in the art, for example, Shields RL. et al., J Biol Chem. 2001. 276(9): 6591-604; Idusogie EE. et al., J Immunol. 2000. 164(8): 4178-84; Steurer W. et al., J Immunol. 1995, 155(3): 1165-74; Idusogie EE. et al., J Immunol. 2001, 166(4): 2571-5; Lazar GA. et al., PNAS, 2006, 103(11): 4005-4010; Ryan MC. et al., Mol. Cancer Ther., 2007, 6: 3009-3018; Richards JO, et al., Mol Cancer See Ther. 2008, 7(8):2517-27; Shields R. Let al., J. Biol. Chem, 2002, 277:26733-26740; Shinkawa T. et al., J. Biol. Chem, 2003, 278:3466-3473.
[0225]
[0253] The CDC activity of the antibody moieties or antigen-binding fragments provided herein can also be modified, for example, by improving or reducing C1q binding and / or CDC (see, e.g., WO99 / 51642; Duncan & Winter Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO94 / 29351 for other examples of Fe region variants). The complement-dependent cytotoxicity (CDC) can be modified by replacing one or more amino acids selected from amino acid residues 329, 331, and 322 of the Fc region with different amino acid residues (see, e.g., U.S. Patent No. 6,194,551 by Idusogie et al.). The complement-fixing ability of the antibody can also be modified by introducing one or more amino acid substitutions (see, for example, PCT Publication WO 94 / 29351 by Bodmer et al.).
[0226]
[0254] In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein has reduced effector function and includes one or more amino acid substitutions in IgG1 at positions selected from the group consisting of 234, 235, 237, 238, 268, 297, 309, 330, and 331. In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein is of the IgG1 isotype and includes one or more amino acid substitutions, or any combination thereof, selected from the group consisting of N297A, N297Q, N297G, L235E, L234A, L235A, L234F, L235E, and P331S. In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein is of the IgG1 isotype and includes the L234A and L235A mutations. In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein is of the IgG2 isotype and includes substitutions of one or more amino acids selected from the group consisting of H268Q, V309L, A330S, P331S, V234A, G237A, P238S, and H268A, or any combination thereof (e.g., H268Q / V309L / A330S / P331S, V234A / G237A / P238S / H268A / V309L / A330S / P331S). In certain embodiments, the anti-CD39 antibody moiety or antigen-binding fragment provided herein is of the IgG4 isotype and includes substitutions of one or more amino acids selected from the group consisting of S228P, N297A, N297Q, N297G, L235E, F234A, and L235A, or any combination thereof. In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein is an IgG2 / IgG4 cross-isotype. An example of an IgG2 / IgG4 cross-isotype is described in Rother RP et al., Nat Biotechnol 25:1256-1264 (2007).
[0227]
[0255] In certain embodiments, the anti-CD39 antibody moiety and antigen-binding fragment provided herein are of the IgG4 isotype and include one or more amino acid substitutions at one or more points 228, 234, and 235. In certain embodiments, the anti-CD39 antibody moiety and antigen-binding fragment provided herein are of the IgG4 isotype and include S228P mutations and / or L235E mutations and / or F234A and L235A mutations in the Fc region.
[0228]
[0256] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment comprises one or more amino acid substitutions that improve pH-dependent binding to the neonatal Fc receptor (FcRn). Such variants can have an extended pharmacokinetic half-life because they bind to FcRn at an acidic pH, allowing it to escape degradation within lysosomes and then translocate and be released extracellularly. Methods for improving the binding affinity to FcRn by manipulating antibodies or their antigen-binding fragments are known in the art; see, for example, Vaughn, D. et al., Structure, 6(1):63-73, 1998; Kontermann, R. et al., Antibody Engineering, Volume 1, Chapter 27: Engineering of the Fc region for improved PK, published by Springer, 2010; Yeung, Y. et al., Cancer Research, 70:3269-3277 (2010); and Hinton, P. et al., J. Immunology, 176:346-356 (2006).
[0229]
[0257] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment comprises the substitution of one or more amino acids at the interface of the Fc region to facilitate and / or promote heterodimerization. These modifications include the introduction of a protrusion into the first Fc polypeptide and the introduction of a cavity into the second Fc polypeptide, where the protrusion is located within the cavity, thereby promoting the interaction of the first and second Fc polypeptides and forming a heterodimer or complex. Methods for producing antibodies having these modifications are known in the art, for example, as described in U.S. Patent No. 5,731,168.
[0230] antigen-binding fragment
[0258] Anti-CD39 antigen-binding fragments are also provided herein. Various types of antigen-binding fragments are known in the art and can be developed based on exemplary antibody moieties and various variants thereof (affinity variants, glycosylated variants, Fc variants, cysteine-modified variants, and others) provided herein, for example, whose CDRs are shown in Table 1 above and whose variable sequences are shown in Tables 2, 3, 6, and 7.
[0231]
[0259] In certain embodiments, the anti-CD39 antigen-binding fragments provided herein include diabodies, Fab, Fab', F(ab')2, Fd, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (dsdiabodies), single-chain antibody molecules (scFv), scFv dimers (bivalent diabodies), multispecific antibodies, camelized single-chain domain antibodies, nanobodies, domain antibodies, and bivalent domain antibodies.
[0232]
[0260] Various methods can be used to produce such antigen-binding fragments. Exemplary methods include enzymatic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992); and Brennan et al., Science, 229:81 (1985)), recombinant expression by host cells such as E. coli (e.g., for Fab, Fv, and ScFv antibody fragments), screening from phage display libraries discussed above (e.g., for ScFv), and chemical coupling of two Fab'-SH fragments to form an F(ab')2 fragment (Carter et al., Bio / Technology 10:163-167 (1992)). Other methods for antibody fragment production will become apparent to those skilled in the art.
[0233]
[0261] In certain embodiments, the antigen-binding fragment is an scFv. The generation of scFvs is described, for example, in WO 93 / 16185; U.S. Patents 5,571,894 and 5,587,458. ScFvs can be fused with effector proteins at their amino or carboxyl termini to provide fusion proteins (see, for example, Antibody Engineering, edited by Borrebaeck).
[0234]
[0262] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein is bivalent, tetravalent, hexavalent, or polyvalent. Any molecule with more than two valent valents is considered polyvalent, including, for example, trivalent, tetravalent, hexavalent, etc.
[0235]
[0263] A bivalent molecule is monospecific if both binding sites are specific to binding to the same antigen or epitope. In certain embodiments, this provides stronger binding to the antigen or epitope than its monovalent counterpart. Similarly, a polyvalent molecule can also be monospecific. In certain embodiments, in a bivalent or polyvalent antigen-binding moiety, the first valence of the binding site and the second valence of the binding site are either structurally identical (i.e., have the same sequence) or structurally different (i.e., have the same specificity but different sequences).
[0236]
[0264] A bivalent molecule can also be bivalent if its two binding sites are specific to different antigens or epitopes. This also applies to polyvalent molecules. For example, a trivalent molecule can be bivalent if two binding sites are singularly specific to a first antigen (or epitope) and a third binding site is specific to a second antigen (or epitope).
[0237] bispecific antibody
[0265] In certain embodiments, the anti-CD antibody moiety or its antigen-binding fragment is bispecific. In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment is further coupled to a second functional moiety having different binding specificity than the anti-CD39 antibody moiety or its antigen-binding fragment.
[0238]
[0266] In certain embodiments, the bispecific antibody or its antigen-binding fragment provided herein can specifically bind to a second antigen other than CD39, or to a second epitope on CD39. In certain embodiments, the second antigen is selected from the group consisting of TGF-beta, CD73, PD1, PDL1, 4-1BB, CTLA4, TIGIT, GITA, VISTA, TIGIT, B7-H3, B7-H4, B7-H5, CD112R, Siglec-15, LAG3, SIRPα, CD47, and TIM-3.
[0239] Conjugate
[0267] In some embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment further comprises one or more conjugate moieties. The conjugate moieties can be linked to the antibody moiety or its antigen-binding fragment. The conjugate moiety is a portion that can be bound to the antibody moiety or its antigen-binding fragment. Various conjugate moieties are intended to be linked to the antibody moiety or its antigen-binding fragment provided herein (see, for example, "Conjugate Vaccines," Contributions to Microbiology and Immunology, JMCruse and RELewis, Jr. (eds.), Carger Press, New York, (1989)). These conjugate moieties can be linked to the antibody moiety or its antigen-binding fragment, in particular by covalent bonding, affinity bonding, intercalation, coordination bonding, complexation, association, blending, or addition. In some embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment can be linked to one or more conjugates via a linker.
[0240]
[0268] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein may be manipulated to include, outside of the epitope-binding moiety, specific sites that can be used for binding to one or more conjugate moieties. For example, such sites may include one or more reactive amino acid residues, such as cysteine or histidine residues, that facilitate covalent linkage to the conjugate moiety.
[0241]
[0269] In certain embodiments, the anti-CD39 antibody moiety or its antigen-binding fragment may be indirectly linked to a conjugate moiety or through another conjugate moiety. For example, the anti-CD39 antibody moiety or its antigen-binding fragment provided herein may be conjugated to biotin and then indirectly to a second conjugate conjugated to avidin. In some embodiments, the conjugate moiety may include clearance modifiers (e.g., polymers such as PEG that extend half-life), chemotherapeutic agents, toxins, radioisotopes, lantanides, detectable labels (e.g., luminescence labels, fluorescent labels, enzyme substrate labels), DNA alkylating agents, topoisomerase inhibitors, tubulin binders, purified moieties, or other anticancer drugs.
[0242]
[0270] A "toxin" can be any drug that is harmful to, damages, or kills cells. Examples of toxins include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, MMAE, MMAF, DM1, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracine dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, promycin and its analogues, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), and alkylating agents (e.g., mechlore). This includes, but is not limited to, tamin, thioepachlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomanitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum(II) (DDP) cisplatin, anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin and anthramycin (AMC)), antimitotic agents (e.g., vincristine and vinblastine), topoisomerase inhibitors, and tubulin binders.
[0243]
[0271] Examples of detectable labels include fluorescent labels (e.g., fluorescein, rhodamine, dansyl, phycoerythrin, or Texas Red), enzyme substrate labels (e.g., horseradish peroxidase, alkaline phosphatase, luceriferases, glucoamylase, lysozyme, saccharide oxidases, or β-D-galactosidase), and radioisotopes (e.g., 123 I, 124 I, 125 I, 131 I, 35 S, 3 H, 111 In, 112 In, 14C, 64 Cu, 67 Cu, 86 Y, 88 Y, 90 Y, 177 Lu, 211 At, 186 Re, 188 Re, 153 Sm, 212 Bi, and 32 The reagent may contain P (other lanthanides), a luminescent label, a plastid portion, digoxigenin, biotin / avidin, a DNA molecule, or gold for detection.
[0244]
[0272] In certain embodiments, the conjugate moiety may be a clearance modifier that helps extend the half-life of the antibody. Explanatory examples include water-soluble polymers such as PEG, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, ethylene glycol / propylene glycol copolymers, and others. The polymers may have any molecular weight and may be branched or unbranched. The number of polymers conjugated to the antibody varies, and if two or more polymers are conjugated, they may be the same molecule or different molecules.
[0245]
[0273] In certain embodiments, the conjugate portion may be a refined portion such as a magnetic bead.
[0274] In certain embodiments, the anti-CD39 antibody portion or its antigen-binding fragment provided herein is used as a base for a conjugate.
[0246] Polynucleotides and Recombination Methods
[0275] This disclosure provides isolated polynucleotides encoding anti-CD39 / TGFβ traps as provided herein. As used herein, the terms “nucleic acid” or “polynucleotide” mean deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in single-stranded or double-stranded forms, and polymers thereof. Unless otherwise indicated, a particular polynucleotide sequence implicitly includes its conserved modified variants (e.g., degenerate codon substitutions), alleles, orthologues, SNPs, and complementary sequences, as well as explicitly indicated sequences. Specifically, degenerate codon substitution can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced with a mixture of bases and / or deoxyinosine residues (see Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0247]
[0276] The DNA encoding a monoclonal antibody can be readily isolated and sequenced using conventional procedures (for example, by using oligonucleotide probes that can specifically bind to the genes encoding the heavy and light chains of the antibody). The encoding DNA may also be obtained by synthetic methods.
[0248]
[0277] The isolated polynucleotides encoding the anti-CD39 / TGFβ Trap provided herein can be inserted into vectors for further cloning (DNA amplification) or expression using recombinant techniques known in the art. Many vectors are available. Vector components generally include, but are not limited to, one or more of the following: signal sequences, origin of replication, one or more marker genes, enhancer elements, promoters (e.g., SV40, CMV, EF-1α), and transcription termination sequences.
[0249]
[0278] This disclosure provides vectors comprising isolated polynucleotides provided herein. In certain embodiments, the polynucleotides provided herein encode the anti-CD39 / TGFβ Trap provided herein, at least one promoter operably ligated to the nucleic acid sequence (e.g., SV40, CMV, EF-1α), and at least one selection marker. Examples of vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papovaviruses (e.g., SV40), lambda phages, and M13 phages, plasmids pcDNA3.3, pMD18-T, pOptivec, pCMV, pEGFP, pIRES, pQD-Hyg-GSeu, pALTER, pBAD, pcDNA, pCal, pL, pET, p GEMEX, pGEX, pCI, pEGFT, pSV2, pFUSE, pVITRO, pVIVO, pMAL, pMONO, pSELECT, pUNO, pDUO, Psg5L, pBABE, pWPXL, pBI, p15TV-L, pPro18, pTD, pRS10, p Includes LexA, pACT2.2, pCMV-SCRIPT.RTM., pCDM8, pCDNA1.1 / amp, pcDNA3.1, pRc / RSV, PCR2.1, pEF-1, pFB, pSG5, pXT1, pCDEF3, pSVSPORT, pEF-Bos, etc.
[0250]
[0279] Vectors containing polynucleotide sequences encoding the anti-CD39 / TGFβ Trap provided herein can be introduced into host cells for cloning or gene expression. Suitable host cells for cloning or DNA expression in the vectors provided herein are prokaryotic cells, yeast, or the higher eukaryotic cells mentioned above. Suitable prokaryotic cells for this purpose include eubacteria such as Gram-negative or Gram-positive organisms, such as the Enterobacteriaceae family, such as Escherichia, such as Escherichia coli, as well as the Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, such as Salmonella typhimurium, Serratia, such as Serratia marcescans, and Sigella genera, as well as Bacillus such as B. subtilis and B. licheniformis, Pseudomonas such as P. aeruginosa, and Streptomyces.
[0251]
[0280] In addition to prokaryotic cells, eukaryotic microorganisms such as filamentous fungi or yeast are suitable hosts for cloning or expression of vectors encoding anti-CD39 / TGFβ traps. Among lower eukaryotic host microorganisms, Saccharomyces cerevisiae or common baker's yeast are the most commonly used. However, Schizosaccharomyces pombe, such as K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermolerans, and K. marxianus, are hosts of Kluiveromyces, Yarowia (EP 402,226), Pichia pastoris (EP 183,070), Candida, Trichoderma reesia (EP 244,234), Neurospora crassa, and Schwanniomyces. Numerous other genera, species, and strains are commonly available and useful herein, including Schwaniomyces such as occidentalis, filamentous fungi such as Neurospora, Penicillium, and Tolypocladium, and hosts of Aspergillus species such as A. nidulans and A. niger.
[0252]
[0281] Suitable host cells for the expression of glycosylated antibodies or their antigen-binding fragments provided herein are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculovirus strains and variants, as well as corresponding acceptable insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruit fly), and Bombyx mori, have been identified. Various virus strains for transfection, such as the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, are publicly available, and such viruses may be used as the viruses herein in accordance with the present invention, particularly for the transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be used as hosts.
[0253]
[0282] However, interest is greatest in vertebrate cells, and the proliferation of vertebrate cells in culture (tissue culture) has become a standard procedure. Examples of useful mammalian host cell lines include the SV40-transformed monkey kidney CV1 cell line (COS-7, ATCC CRL 1651), human embryonic kidney cell line (293 or 293 cells subcloned for proliferation in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)), baby hamster kidney cells (BHK, ATCC CCL 10), Chinese hamster ovary cells / -DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)), monkey kidney cells (CV1 ATCC CCL 70), African green monkey kidney cells (VERO-76, ATCC CRL-1587), and human cervical cancer cells (HELA, ATCC Examples include CCL 2), canine kidney cells (MDCK, ATCC CCL 34), buffalo rat hepatocytes (BRL 3A, ATCC CRL 1442), human lung cells (W138, ATCC CCL 75), human hepatocytes (Hep G2, HB 8065), mouse mammary tumor cells (MMT 060562, ATCC CCL 51), TRI cells (Mather et al., Annals NYAcad. Sci. 383:44-68 (1982)), MRC5 cells, FS4 cells, and human hepatocellular carcinoma cell line (Hep G2). In some embodiments, the host cells are mammalian cultured cell lines such as CHO, BHK, NS0, 293, and their derivatives.
[0254]
[0283] Host cells are transformed with the above-mentioned expression or cloning vectors for the production of anti-CD39 / TGFβ Trap and cultured in a conventional nutrient medium modified to be suitable for promoter induction, transformant selection, or amplification of the gene encoding the desired sequence. In another embodiment, anti-CD39 / TGFβ Trap may be produced by homologous recombination known in the art. In certain embodiments, host cells can produce anti-CD39 / TGFβ Trap provided herein.
[0255]
[0284] This disclosure also provides a method for expressing the anti-CD39 / TGFβ Trap provided herein, comprising the step of culturing the host cells provided herein under conditions in which the vector of this disclosure is expressed. The host cells used to produce the anti-CD39 / TGFβ Trap provided herein may be cultured in a variety of media. Commercial media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM) (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) are suitable for culturing host cells. Furthermore, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S. Patents No. 4,767,704, No. 4,657,866, No. 4,927,762, No. 4,560,655, or No. 5,122,469, WO 90 / 03430, WO 87 / 00195, or U.S. Patent Re. 30,985 may be used as a culture medium for host cells. Any of these media may be supplemented as needed with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (sodium chloride, calcium, magnesium, and phosphates), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN® drugs), trace elements (usually defined as inorganic compounds present at final concentrations in the micromolar range), and glucose or equivalent energy sources. Any other necessary adjuncts known to those skilled in the art may also be included in appropriate concentrations. Temperature, pH, and other culture conditions have already been used with the host cells selected for expression and will be obvious to those skilled in the art.
[0256]
[0285] When recombinant methods are used, anti-CD39 / TGFβ traps can be produced intracellularly, in the perimembranous space, or secreted directly into the culture medium. If anti-CD39 / TGFβ traps are produced intracellularly, the first step is to remove particulate debris from host cells or lysed fragments, for example, by centrifugation or ultrafiltration. Carter et al., Bio / Technology 10:163-167 (1992) describe a procedure for isolating antibodies secreted into the perimembranous space of E. coli. Briefly, the cell paste is thawed for about 30 minutes in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonyl fluoride (PMSF). Cell debris can be removed by centrifugation. If the antibodies are secreted into the culture medium, the supernatant from such an expression system is first concentrated using a commercially available protein concentration filter, such as an Amicon or Millipore Pellicon ultrafiltration unit. To inhibit protein degradation, protease inhibitors such as PMSF may be included in any of the above steps, and antibiotics may be included to prevent the proliferation of foreign contaminants.
[0257]
[0286] Anti-CD39 / TGFβ traps prepared from cells can be purified using methods such as hydroxyapatite chromatography, gel electrophoresis, dialysis, DEAE cellulose ion exchange chromatography, ammonium sulfate precipitation, salting out, and affinity chromatography, with affinity chromatography being the preferred purification method.
[0258]
[0287] In certain embodiments, protein A immobilized on a solid phase is used for immunoaffinity purification of anti-CD39 / TGFβ traps. The suitability of protein A as an affinity ligand depends on the species and isotype of the Fc domain of any immunoglobulin present in the antibody. Protein A can be used to purify antibodies based on the heavy chains of human gamma 1, gamma 2, or gamma 4 (Lindmark et al., J.Immunol.Meth.62:1-13 (1983)). Protein G is recommended for all mouse isotypes and human gamma 3 (Guss et al., EMBO J.5:1567 1575 (1986)). The matrix to which the affinity ligand binds is most often agarose, but other matrices are also available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than those achieved with agarose. If the antibody contains a CH3 domain, Bakerbond ABX® resin (JTBaker, Phillipsburg, NJ) is useful for purification. Other protein purification methods such as fractionation on ion exchange columns, ethanol precipitation, reverse-phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE®, chromatography on anion or cation exchange resins (e.g., polyaspartate columns), chromatographic focusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered.
[0259]
[0288] Following any preliminary purification steps, the mixture containing the antibody of interest and impurities may be subjected to low-pH hydrophobic interaction chromatography using elution buffer at a pH of approximately 2.5–4.5, preferably with a low salt concentration (e.g., approximately 0–0.25 M salt).
[0260] Pharmaceutical composition
[0289] This disclosure further provides pharmaceutical compositions comprising an anti-CD39 / TGFβ trap and one or more pharmaceutically acceptable carriers.
[0261]
[0290] Pharmaceutically acceptable carriers for use in the pharmaceutical compositions disclosed herein may include, for example, pharmaceutically acceptable liquid, gel, or solid carriers, aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, anesthetics, suspensions / dispersants, sequestering or chelating agents, diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof.
[0262]
[0291] Suitable components may include, for example, antioxidants, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavoring agents, thickeners, colorants, emulsifiers, or stabilizers such as sugars and cyclodextrins. Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxyanisole, butylated hydroxytoluene, and / or propyl gallate. As disclosed herein, the inclusion of one or more antioxidants such as methionine in compositions containing anti-CD39 / TGFβ traps and conjugates provided herein reduces the oxidation of anti-CD39 / TGFβ traps. This reduction in oxidation prevents or reduces the loss of binding affinity, thereby improving antibody stability and maximizing shelf life. Accordingly, in certain embodiments, a pharmaceutical composition is provided comprising one or more anti-CD39 / TGFβ traps disclosed herein and one or more antioxidants such as methionine. Further methods are provided for preventing oxidation of the anti-CD39 / TGFβ traps provided herein, extending their shelf life, and / or improving their efficiency by mixing the anti-CD39 / TGFβ traps with one or more antioxidants such as methionine.
[0263]
[0292] To further explain, pharmaceutically acceptable carriers may include, for example, aqueous vehicles such as sodium chloride for injection, Ringer's injection, isotonic dextrose injection, sterile water for injection, or dextrose and lactated Ringer's injection; non-aqueous vehicles such as plant-derived immobilized oils, cottonseed oil, corn oil, sesame oil, or peanut oil; antimicrobial agents in bacteriostatic or fungiostatic concentrations; isotonic agents such as sodium chloride or dextrose; buffering agents such as phosphates or citrates; antioxidants such as sodium bisulfate; local anesthetics such as procaine hydrochloride; suspension dispersants such as sodium carboxymethylcellulose, hydroxypropyl methylcellulose, or polyvinylpyrrolidone; emulsifiers such as Polysorbate 80 (TWEEN®-80); sequestering or chelating agents such as EDTA (ethylenediaminetetraacetic acid) or EGTA (ethylene glycol tetraacetic acid); ethyl alcohol, polyethylene glycol, propylene glycol, sodium hydroxide, hydrochloric acid, citric acid, or lactic acid. The pharmaceutical composition in the multi-dose container may contain antimicrobial agents used as carriers, including phenols or cresols, mercury compounds, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride, and benzethonium chloride. Suitable excipients may include, for example, water, saline solution, dextrose, glycerol, or ethanol. Suitable non-toxic auxiliary substances may include, for example, wetting or emulsifying agents, pH buffers, stabilizers, dissolution accelerators, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrin.
[0264]
[0293] Pharmaceutical compositions may be liquid solutions, suspensions, emulsions, pills, capsules, tablets, sustained-release formulations, or powders. Oral formulations may contain standard carriers such as pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, polyvinylpyrrolidone, sodium saccharin, cellulose, and magnesium carbonate.
[0265]
[0294] In certain embodiments, the pharmaceutical composition is formulated into an injectable composition. The injectable pharmaceutical composition may be prepared in any conventional form, such as a liquid solution, suspension, emulsion, or solid form, suitable for producing, for example, a liquid solution, suspension, emulsion, or emulsion. Preparations for injection may include immediately injectable sterile and / or nonpyrogenic solutions, sterile dry soluble products such as lyophilized powders that can be immediately mixed with a solvent immediately before use, including subcutaneous injection tablets, sterile suspensions that are immediately injectable, sterile dry insoluble products that can be immediately mixed with a vehicle immediately before use, and sterile and / or nonpyrogenic emulsions. The solutions may be aqueous or non-aqueous.
[0266]
[0295] In certain embodiments, the unit dose preparation is packaged in an ampoule, vial, or syringe with a needle. All preparations for parenteral administration should be sterile and nonpyrogenic, as is known and practiced in the art.
[0267]
[0296] In certain embodiments, a sterile lyophilized powder is prepared by dissolving the antibody or antigen-binding fragment disclosed herein in a suitable solvent. The solvent may contain excipients that improve the stability or other pharmacological properties of the powder or the reconstituted solution prepared from the powder. Possible excipients include, but are not limited to, water, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, or other suitable agents. In one embodiment, the solvent may be at a nearly neutral pH and contain buffers such as citrate, sodium phosphate or potassium, or other buffers known to those skilled in the art. A desired formulation is provided by subsequent sterile filtration of the solution and subsequent lyophilization under standard conditions known to those skilled in the art. In one embodiment, the resulting solution is dispensed into vials for lyophilization. Each vial may contain a single dose or multiple doses of anti-CD39 / TGFβ Trap or its composition. Overfilling vials with a small amount (e.g., about 10%) more than the required dose or dose set is acceptable to facilitate accurate sample extraction and precise administration. Lyophilized powders can be stored under appropriate conditions such as approximately 4°C to room temperature.
[0268]
[0297] Formulations for parenteral administration are provided by reconstituting a lyophilized powder with water for injection. In one embodiment, sterile and / or non-pyrogenic water or other suitable liquid carrier is added to the lyophilized powder for reconstitution. The exact amount depends on the chosen therapy and can be determined experimentally.
[0269] kit
[0298] In certain embodiments, the Disclosure provides a kit comprising an anti-CD39 / TGFβ Trap provided herein, and / or a pharmaceutical composition provided herein. In certain embodiments, the Disclosure provides a kit comprising an anti-CD39 / TGFβ Trap provided herein, and a second therapeutic agent. In certain embodiments, the second therapeutic agent is selected from the group consisting of chemotherapeutic agents, anticancer drugs, radiotherapy, immunotherapy agents, anti-angiogenic agents, targeted therapies, cell therapies, gene therapies, hormone therapies, antiviral agents, antibiotics, analgesics, antioxidants, metal chelating agents, and cytokines.
[0270]
[0299] Such a kit may further include, if desired, a container containing, for example, one or more pharmaceutically acceptable carriers, an additional container, and one or more of various conventional pharmaceutical kit components, as will be readily apparent to those skilled in the art. Instructions, such as inserts or labels, indicating the amount of the component to be administered, guidelines for administration, and / or guidelines for mixing the components may also be included in the kit.
[0271] How to use
[0300] This disclosure also provides a method for treating, preventing, or mitigating CD39-related and / or TGFβ-related diseases, disorders, or conditions in a subject, comprising the step of administering a therapeutically effective amount of the anti-CD39 / TGFβ Trap and / or the pharmaceutical composition provided herein to the subject. In certain embodiments, the subject is human. The inventors unexpectedly discovered that a synergistic effect is obtained in treating, preventing, or mitigating CD39-related and / or TGFβ-related diseases, disorders, or conditions in a subject by simultaneously blocking the adenosine pathway (by inhibiting CD39) and the TGFβ signaling pathway (via TGFβ Trap).
[0272]
[0301] In some embodiments, CD39-related diseases, disorders, or conditions are characterized by the expression or overexpression of CD39. In some embodiments, TGFβ-related diseases, disorders, or conditions are characterized by the expression or overexpression of TGFβ.
[0273]
[0302] In certain embodiments, the CD39-related disease, disorder, or condition is cancer. In certain embodiments, the cancer is a CD39-expressing cancer. As used herein, "CD39-expressing" cancer means cancer characterized by the expression of the CD39 protein in cancer cells, tumor-infiltrating immune cells, or immunosuppressive cells, or by the expression of CD39 at significantly higher levels in cancer cells, tumor-infiltrating immune cells, or immunosuppressive cells than would be expected in normal cells. Various methods can be used to determine the presence and / or amount of CD39 in a test biological sample from a subject. For example, the test biological sample can be exposed to an anti-CD39 antibody or its antigen-binding fragment that binds to and detects the expressed CD39 protein. Alternatively, CD39 can be detected at the nucleic acid expression level using qPCR, reverse transcriptase PCR, microarrays, SAGE, FISH, or other methods. In some embodiments, the test sample is derived from cancer cells or tissue, or tumor-infiltrating immune cells. The reference sample may be a control sample obtained from a healthy or disease-free individual, or a healthy or disease-free sample from the same individual from which the test sample was obtained. For example, a reference sample may be a non-disease sample adjacent to or near the test sample (e.g., a tumor).
[0274]
[0303] In certain embodiments, the TGFβ-related disease, disorder, or condition is cancer. In certain embodiments, the cancer is a TGFβ-expressing cancer. As used herein, "TGFβ-expressing" cancer means cancer characterized by the expression of the TGFβ protein in cancer cells, tumor-infiltrating immune cells, or immunosuppressive cells, or by the expression of TGFβ at significantly higher levels in cancer cells, tumor-infiltrating immune cells, or immunosuppressive cells than would be expected in normal cells.
[0275]
[0304] This disclosure also provides a method for treating, preventing, or mitigating a disease associated with elevated levels and / or activity of TGFβ in a subject, comprising the step of administering a therapeutically effective amount of the anti-CD39 / TGFβ trap and / or the pharmaceutical composition provided herein to the subject.
[0276]
[0305] Various methods can be used to determine the presence and / or amount of TGFβ in a test biological sample from a subject. For example, the test biological sample can be exposed to an anti-TGFβ antibody or its antigen-binding fragment that binds to and detects the expressed TGFβ protein. Alternatively, TGFβ can be detected at the nucleic acid expression level using qPCR, reverse transcriptase PCR, microarrays, SAGE, FISH, or other methods. In some embodiments, the test sample is derived from cancer cells or tissue, or tumor-infiltrating immune cells. The reference sample may be a control sample obtained from a healthy or disease-free individual, or a healthy or disease-free sample from the same individual from which the test sample was obtained. For example, the reference sample may be a disease-free sample adjacent to or near the test sample (e.g., a tumor).
[0277]
[0306] In certain embodiments, the disease, disorder, or condition is cancer, pancreatic atrophy, or fibrosis.
[0307] In certain embodiments, cancers include anal cancer, appendiceal cancer, astrocytoma, basal cell carcinoma, gallbladder cancer, stomach cancer, lung cancer, bronchial cancer, bone cancer, hepatobiliary cancer, pancreatic cancer, breast cancer, liver cancer, ovarian cancer, testicular cancer, kidney cancer, renal pelvis and ureteral cancer, salivary gland cancer, small intestine cancer, urethral cancer, bladder cancer, head and neck cancer, spinal cancer, brain cancer, cervical cancer, uterine cancer, endometrial cancer, colon cancer, colorectal cancer, rectal cancer, anal cancer, esophageal cancer, gastrointestinal cancer, and skin cancer. The cancer is selected from the group consisting of prostate cancer, pituitary cancer, vaginal cancer, thyroid cancer, throat cancer, glioblastoma, melanoma, myelodysplastic syndrome, sarcoma, teratoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, T or B cell lymphoma, GI organ stromal tumor, soft tissue tumor, hepatocellular carcinoma, and adenocarcinoma. In certain embodiments, the cancer is leukemia, lymphoma, bladder cancer, glioma, glioblastoma, ovarian cancer, melanoma, prostate cancer, thyroid cancer, esophageal cancer, or breast cancer.
[0278]
[0308] TGF-β is a major factor promoting fibrosis in most, if not all, forms of chronic kidney disease (CKD). Inhibiting TGF-β1, an isoform of TGF-β, and its downstream signaling pathways significantly limits renal fibrosis in various disease models, while TGF-β1 overexpression induces renal fibrosis. TGF-β1 induces fibrosis through activation of both canonical (Smad-based) and non-canonical (non-Smad-based) signaling pathways, resulting in myofibroblast activation, overproduction of the extracellular matrix (ECM), and inhibition of ECM degradation. The role of Smad proteins in fibrosis regulation is complex, with competing pro-fibrotic and anti-fibrotic effects (including mesenchymal transition regulation) and intricate interactions between TGF-β / Smad and other signaling pathways. Studies have identified additional mechanisms that regulate the action of TGF-β1 / Smad signaling in fibrosis, including short and long non-coding RNA molecules, and epigenetic modifications of DNA and histone proteins. Because TGF-β1 is involved in other processes, direct targeting of TGF-β1 for anti-fibrotic therapy is unlikely to be realized. However, by deepening our understanding of the various pathways through which TGF-β1 controls fibrosis, alternative targets have been identified for developing novel therapeutics that block the most harmful processes in CKD.
[0279]
[0309] Adenosine plays a crucial role in inflammation and tissue remodeling, and its activation of the adenosine receptor (A2AR) promotes dermatofibrosis. Extracellular adenosine is produced in conjunction by the ectoenzymes CD39 and CD73, promoting fibrosis. The adenosine axis is involved in renal ischemia-reperfusion injury (IRI), and adenosine production by CD39 and CD73 is protective. However, chronic elevation of adenosine is associated with the development of renal fibrosis. Evidence has shown that CD39 and / or CD73 deletion reduces collagen content and prevents skin thickening and increased tensile strength after bleomycin loading. The reduction in dermatofibrotic features was associated with decreased expression of transforming growth factor-β1 and connective tissue growth factor, which are mediators of fibrosis, as well as a decrease in myofibroblast population in CD39 and / or CD73-deficient mice.
[0280]
[0310] We hypothesized that inhibiting CD39 and TGF-β would be promising for treating fibrosis in diseases such as scleroderma, hepatic fibrosis, and renal fibrosis.
[0311] In certain embodiments, fibrosis is selected from the group consisting of scleroderma, renal fibrosis, pulmonary fibrosis (e.g., cystic fibrosis, idiopathic pulmonary fibrosis), hepatic fibrosis (e.g., bridging fibrosis, cirrhosis), cerebral fibrosis, articular fibrosis, mediastinal fibrosis, myelofibrosis, nephrogenic systemic fibrosis, retroperitoneal fibrosis, and cardiomyopathy (e.g., interstitial fibrosis, replacement fibrosis). In some embodiments, subjects are identified, at random selection, as having cancer cells or tumor-infiltrating immune cells or immunosuppressive cells expressing CD39 and / or TGFβ at levels significantly higher than those typically seen in non-cancerous or non-immunosuppressive cells.
[0281]
[0312] In some embodiments, the immunosuppressive cells are regulatory T cells. Regulatory T cells ("Tregs") are a distinct population of T lymphocytes that predominantly suppress the proliferation of responder T cells in vitro and have the ability to inhibit autoimmune diseases in vivo. The Tregs of this disclosure are CD4 cells with inhibitory properties. + CD25 +FoxP3 + It may be a T cell. In certain embodiments, the Treg of this disclosure is a CD4 + Treg cells, particularly those overexpressing CD39, are a common CD4 gene. + It is Treg.
[0282]
[0313] In some embodiments, subjects have been identified as having overactive regulatory T cells in the tumor microenvironment compared to regulatory T cell activity typically observed in control subjects. Regulatory T cell activity in the tumor microenvironment is measured by conventional methods in the art, such as CD25 on T cells. + Foxp3 + This can be determined by upregulation, secretion of TGFβ and IL-10, inhibition of CTL cytotoxicity, etc.
[0283]
[0314] In some embodiments, the subjects are expected to benefit from the reversal of immunosuppression or the reversal of dysfunctional, exhausted T cells.
[0315] In some embodiments, the disease, disorder, or condition is an autoimmune disease or infection. In some embodiments, the autoimmune disease is immune thrombocytopenia, systemic scleroderma, sclerosis, adult respiratory distress syndrome, eczema, asthma, Sjögren's syndrome, Addison's disease, giant cell arteritis, immune complex nephritis, immune thrombocytopenic purpura, autoimmune thrombocytopenia, celiac disease, psoriasis, dermatitis, colitis, or systemic lupus erythematosus. In some embodiments, the infection is a viral or bacterial infection. In some embodiments, the infection is HIV infection, HBV infection, HCV infection, inflammatory bowel disease, or Crohn's disease.
[0284]
[0316] In another embodiment, a method is provided for treating, preventing, or alleviating a disease, disorder, or condition in a subject that would benefit from modulating the activity of CD39 and / or TGFβ, comprising the step of administering a therapeutically effective amount of the anti-CD39 / TGFβ trap and / or a pharmaceutical composition provided herein to a subject in need of treatment, prevention, or alleviation of a disease, disorder, or condition. In a particular embodiment, the disease, disorder, or condition is a CD39-related and / or TGFβ-related disease, disorder, or condition as defined above.
[0285]
[0317] The therapeutically effective dose of anti-CD39 / TGFβ Trap provided herein depends on various factors known in the art, such as body weight, age, medical history, current medications, the subject's health status and potential for cross-reactions, allergies, susceptibility, and adverse reactions, as well as the route of administration and the severity of disease onset. The dose may be proportionally reduced or increased by the parties involved (e.g., physician or veterinarian) as indicated by these and other circumstances or requests.
[0286]
[0318] In some embodiments, the anti-CD39 / TGFβ trap provided herein may be administered in therapeutically effective doses ranging from approximately 0.01 mg / kg to approximately 100 mg / kg. In certain embodiments, the dose may vary over the course of treatment. For example, in certain embodiments, the initial dose may be higher than subsequent doses. In certain embodiments, the dose may fluctuate over the course of treatment depending on the subject's response.
[0287]
[0319] The medication regimen may be adjusted to provide the optimal desired response (e.g., therapeutic response). For example, a single dose may be administered, or divided doses may be administered over time.
[0288]
[0320] The anti-CD39 / TGFβ traps provided herein may be administered by any route known in the art, such as parenteral (e.g., subcutaneous, intraperitoneal, intravenous, intramuscular, or intradermal injection, including intravenous infusion) or parenteral (e.g., oral, intranasal, intraocular, sublingual, rectal, or topical) routes.
[0289]
[0321] In some embodiments, the anti-CD39 / TGFβ traps provided herein may be administered alone or in combination with a therapeutically effective dose of a second therapeutic agent. For example, the anti-CD39 / TGFβ traps disclosed herein may be administered in combination with a second therapeutic agent, such as a chemotherapeutic agent, an anticancer drug, a radiotherapeutic agent, an immunotherapeutic agent, an anti-angiogenic agent, a targeted therapeutic agent, a cell therapeutic agent, a gene therapeutic agent, a hormone therapeutic agent, an antiviral agent, an antibiotic, analgesics, antioxidants, metal chelators, and cytokines.
[0290]
[0322] As used herein, the term "immunotherapy" refers to a type of therapy that stimulates the immune system to fight diseases such as cancer, or to strengthen the immune system in a general way. Examples of immunotherapy include, but are not limited to, checkpoint modulators, adoptive cell transplants, cytokines, oncolytic viruses, and therapeutic vaccines.
[0291]
[0323] Targeted therapy is a type of therapy that acts on specific molecules related to cancer, such as certain proteins that are present in cancer cells but not in normal cells, or are more abundant in cancer cells, or target molecules in the tumor microenvironment that contribute to the growth and survival of cancer. Targeted therapy targets the tumor with the therapeutic agent, thereby protecting normal tissue from the effects of the agent.
[0292]
[0324] In some of these embodiments, the anti-CD39 / TGFβ Trap provided herein, administered in combination with one or more additional therapeutic agents, may be administered simultaneously with the one or more additional therapeutic agents, and in some of these embodiments, the anti-CD39 / TGFβ Trap and the additional therapeutic agents may be administered as part of the same pharmaceutical composition. However, an anti-CD39 / TGFβ Trap administered "in combination" with another therapeutic agent does not have to be administered simultaneously with or in the same composition as that agent. An anti-CD39 / TGFβ Trap administered before or after another agent is considered to have been administered "in combination" with that agent, as the term is used herein, even if the anti-CD39 / TGFβ Trap and the second agent are administered via different routes. Where possible, additional therapeutic agents administered in combination with the anti-CD39 / TGFβ Trap disclosed herein shall be administered according to the schedule listed on the product information sheet for the additional therapeutic agent, or according to Physicians' Desk Reference 2003 (Physicians' Desk Reference, 57th edition; Medical Economics Company; ISBN: 1563634457; 57th edition (November 2002)) or protocols known in the art.
[0293]
[0325] This disclosure further provides a method for modulating CD39 activity in CD39-positive cells, comprising the step of exposing CD39-positive cells to an anti-CD39 / TGFβ trap provided herein. In some embodiments, the CD39-positive cells are immune cells.
[0294]
[0326] This disclosure further provides a method for modulating TGFβ activity in TGFβ-positive cells, comprising the step of exposing TGFβ-positive cells to an anti-CD39 / TGFβ trap provided herein.
[0295]
[0327] In another aspect, the Disclosure provides a method for detecting the presence or amount of CD39 and / or TGFβ in a sample, comprising the steps of contacting the sample with an anti-CD39 / TGFβ trap and / or a pharmaceutical composition provided herein, and determining the presence or amount of CD39 in the sample.
[0296]
[0328] In another aspect, the Disclosure provides a method for diagnosing a CD39-related and / or TGFβ-related disease, disorder, or condition in a subject, comprising the steps of: a) contacting a sample obtained from a subject with an anti-CD39 / TGFβ trap and / or a pharmaceutical composition provided herein; b) determining the presence or amount of CD39 and / or TGFβ in the sample; and c) correlating the presence or amount of CD39 and / or TGFβ with the presence or state of a CD39-related and / or TGFβ-related disease, disorder, or condition in the subject.
[0297]
[0329] In another aspect, the Disclosure provides a kit comprising an anti-CD39 / TGFβ Trap and / or a pharmaceutical composition provided herein, conjugated with an optional detectable portion useful for detecting CD39-related and / or TGFβ-related diseases, disorders, or conditions. The kit may further include instructions for use.
[0298]
[0330] In another aspect, the Disclosure also provides the use of anti-CD39 / TGFβ Traps and / or pharmaceutical compositions provided herein in the manufacture of pharmaceuticals for treating, preventing or mitigating CD39-related and / or TGFβ-related diseases, disorders, or conditions in a subject, and in the manufacture of diagnostic reagents for diagnosing CD39-related and / or TGFβ-related diseases, disorders, or conditions.
[0299]
[0331] In another embodiment, the Disclosure provides a method for treating, preventing, or mitigating a disease treatable by reducing the ATPase activity of CD39 in a subject, comprising the step of administering a therapeutically effective amount of anti-CD39 / TGFβ Trap and / or a pharmaceutical composition provided herein to the subject. For example, anti-CD39 / TGFβ Trap provided herein may be administered to reduce the ATPase activity of cancer cells, tumor-infiltrating immune cells, or immunosuppressive cells expressing CD39. In some embodiments, the subject is human. In some embodiments, the subject has a disease, disorder, or condition selected from the group consisting of cancer, pancreatic atrophy, fibrosis, autoimmune diseases, and infections.
[0300]
[0332] In another aspect, the present disclosure provides a method for treating, preventing, or mitigating diseases associated with adenosine-mediated inhibition of T cell, monocyte, macrophage, DC, APC, NK, and / or B cell activity in a subject, comprising the step of administering a therapeutically effective amount of anti-CD39 / TGFβ Trap and / or pharmaceutical compositions provided herein to the subject.
[0301]
[0333] The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the invention. All specific compositions, materials, and methods described below are included in the scope of the invention, either as a whole or in part. These specific compositions, materials, and methods are not intended to limit the invention, but merely illustrate specific embodiments that fall within the scope of the invention. Those skilled in the art can develop equivalent compositions, materials, and methods without exercising the inventive capacity and without departing from the scope of the invention. It will be understood that many modifications can be made within the procedures described herein while remaining within the boundaries of the invention. It is the inventors' intention that such modifications fall within the scope of the invention. [Examples]
[0302] Example 1. Material Production
[0334] 1.1. Generation of Reference Antibodies
[0335] Anti-CD39 reference antibodies were generated based on published sequences. Antibody 9-8B is disclosed in patent application WO 2016 / 073845A1, and the sequences of its heavy and light chain variable regions are included herein as SEQ ID NOs. 46 and 48, respectively. Antibody T895 is disclosed as antibody 31895 in patent application WO 2019 / 027935A1, and the sequences of its heavy and light chain variable regions are included herein as SEQ ID NOs. 55 and 57, respectively. Antibody I394 is disclosed in patent application WO 2018 / 167267A1, and the sequences of its heavy and light chain variable regions are included herein as SEQ ID NOs. 113 and 114, respectively. The heavy and light chain variable regions of antibodies 9-8B, T895, and I394 are shown in Table 10 below. The DNA encoding the reference antibodies was cloned and expressed in Expi293 cells (Invitrogen). The cell culture medium was collected and centrifuged to remove the cell pellet. The recovered supernatant was purified by protein A affinity chromatography (MabselectSure, GE Healthcare) to obtain a reference antibody preparation.
[0303] [Table 13]
[0304]
[0336] 1.2 Generation of human, cynomolgus monkey, and mouse CD39 stable expression cell lines
[0337] DNA sequences encoding full-length human CD39 (NP_001767.3), cynomolgus monkey CD39 (XP_015311944.1), and mouse CD39 (NP_033978.1) were cloned into expression vectors and subsequently transfected and expressed in HEK293 cells. Transfected cells expressing human CD39, cynomolgus monkey CD39, and mouse CD39, respectively, were cultured in selective medium. Single-cell clones stably expressing human CD39, cynomolgus monkey CD39, or mouse CD39 were isolated by limiting dilution. The cells were then screened by FACS using anti-human CD39 antibody (BD, Cat#555464), anti-cynomolgus monkey CD39 (9-8B), and anti-mouse CD39 (Biolegend, Cat#143810).
[0305]
[0338] Similarly, CHOK1 cells (Invitrogen) transfected with human CD39, cynomolgus monkey CD39, and mouse CD39 expression plasmids were cultured in selective medium. Single-cell clones stably expressing human CD39, cynomolgus monkey CD39, or mouse CD39 were isolated by limiting dilution and subsequently screened by FACS using anti-human CD39 antibody, anti-cynomolgus monkey CD39 antibody, or anti-mouse CD39 antibody.
[0306]
[0339] The stable cell lines were denoted as HEK293-hCD39, HEK293-cynoCD39, HEK293-mCD39, CHOK1-hCD39, CHOK1-cynoCD39, and CHOK1-mCD39, respectively. All of these showed high expression and ATPase activity.
[0307]
[0340] 1.3. Synthesis of Recombinant Proteins
[0341] The DNA sequence encoding the extracellular domain (ECD) of human CD39 was cloned into an expression vector and transfected into HEK293 cells to express recombinant ECD protein.
[0308] Example 2. Antibody generation
[0342] 2.1. Immunity and Hybridoma Generation and Screening
[0343] To generate antibodies against CD39, Balb / c and SJL / J mice (SLAC) were immunized with recombinant human CD39 antigen or its fragments, or full-length human CD39 encoding DNA, and / or cells expressing human CD39. Throughout the immunization protocol, the immune response was monitored using plasma or serum samples obtained by tail vein or posterior orbital blood collection. Mice with sufficient titer of anti-CD39 antibody were used for fusion. Splenocytes and / or lymph node cells from immunized mice were isolated and fused to mouse myeloma cell lines (SP2 / 0). The resulting hybridomas were screened for CD39-specific antibody production by ELISA assay using human CD39 ECD recombinant protein, or by Acumen assay (TTP Labtech) using CHOK1-hCD39 cells that stably express human CD39. hCD39-specific hybridoma clones were identified by FACS and enzyme activity blocking assays, and stable hybridoma clones were obtained by subcloning. After one or two subcloning cycles, hybridoma monoclones were grown for antibody production and frozen as stock.
[0309]
[0344] Antibody-secreting hybridomas were subcloned using the limiting dilution method. Stable subclones were cultured in vitro, and antibodies were generated in tissue culture medium for characterization. After 1-2 subcloning cycles, hybridoma monoclones were grown for antibody production.
[0310]
[0345] After approximately 14 days of culture, the hybridoma cell culture medium was collected and purified by protein A affinity chromatography (GE). The hybridoma antibody clones were denoted as mAb13, mAb14, Ab19, mAb21, mAb23, mAb34, and mAb35, respectively.
[0311] Example 3. Characterization of the antibody
[0346] 3.1. Antibodies
[0347] Hybridoma antibody clones mAb13, mAb14, Ab19, mAb21, mAb23, mAb34, and mAb35 were characterized in a series of binding and functionality assays as described below.
[0312]
[0348] 3.2 Binding affinity for human CD39, cynomolgus monkey CD39, and mouse CD39
[0349] Using FACS, we determined the binding of antibodies to cell lines that naturally express CD39 (SK-MEL-28) or recombinantly (CHOK1-hCD39, CHOK1-cynoCD39, and CHOK1-mCD39), or to cells lacking CD39 expression (CHOK1-blank) as a negative control.
[0313]
[0350] CHOK1-hCD39, CHOK1-cCD39, CHOK1-mCD39, and CHOK1-blank cells were maintained in culture medium according to the ATCC procedure. Cells were collected and the cell density was 3 × 10⁶. 6 The cells were resuspended in blocking buffer at a concentration of cells / ml. 100 μl / well (3 × 10⁶ cells). 5Cells were transferred to a 96-well FACS plate (cells / well), the plate was centrifuged, and washed twice with FACS buffer (PBS, 1% FBS, 0.05% Tween®-20). Four-fold serial dilutions of anti-CD39 antibody were prepared in FACS buffer, starting at 30 μg / ml. Reference antibody 9-8B and mouse / human control IgG were used as positive and negative controls, respectively. Cells were resuspended in 100 μL / well diluted antibody, and the plate was incubated at 4°C for 60 minutes. The plate was washed with FACS buffer, and Alexa-Fluor® 488 labeled secondary antibody (1:1000 in FACS buffer) was added to each well and incubated at 4°C for 30 minutes. The plate was washed with FACS buffer, and cells were resuspended in 100 μL / well PBS. Cells were then analyzed with FACSVerse® to determine the mean fluorescence intensity. A complete binding curve was generated for CD39-expressing cells by testing a range of antibody concentrations. The apparent affinity of each antibody was determined using Prism software.
[0314]
[0351] Similarly, human CD39-expressing cells SK-MEL-5, SK-MEL-28, or MOLP-8 were incubated with gradient-concentration anti-CD39 antibody at 4°C for 30 minutes. The cells were washed three times with FACS buffer and then incubated with a fluorescently labeled secondary antibody (goat anti-mouse IgG or goat anti-human IgG) at 4°C for 30 minutes. The cells were washed three times, resuspended in FACS buffer, and analyzed by flow cytometry using BD Celesta. Data were plotted and analyzed using GraphPad Prism 8.02.
[0315]
[0352] The binding affinities of seven purified hybridoma antibodies are summarized in Table 11, compared to the known anti-CD39 antibody 9-8B. All hybridoma antibodies bound to human and cynomolgus monkey CD39 in a dose-dependent manner, but none recognized mouse CD39 in FACS studies.
[0316] [Table 14]
[0317]
[0353] 3.3. Detection of ATPase inhibition
[0354] CD39-expressing cells, SK-MEL-5, and MOLP-8 were washed with PBS buffer and incubated with an antibody gradient at 37°C for 30 minutes. 50 mM ATP was added to each well and incubated with the cells for 16 hours. The supernatant was collected, and orthophosphate products resulting from ATP degradation were measured using the Malachite Green Phosphate Detection Kit (R&D systems, catalog #DY996) according to the manufacturer's instructions. Isotypes and / or 9-8B were used as controls. Data were plotted and analyzed using GraphPad Prism 8.02. EC 50 This represents the concentration of the antibody that reaches 50% of the signal in this assay.
[0318]
[0355] As summarized in Table 11, all seven purified hybridoma antibodies exhibited superior ATPase inhibitory activity compared to the reference antibody 9-8B.
[0356] 3.4. ATP-mediated T cell proliferation suppression assay
[0357] Human T cells labeled with CSFE and stimulated with anti-CD3 and anti-CD28 antibodies were incubated with anti-CD39 antibody or isotype control in the presence of ATP. T cell proliferation was analyzed by FACS using CSFE dilution. mIgG2a was used as the isotype control.
[0319]
[0358] The T cell proliferation activity of the selected anti-CD39 antibodies mAb21 and mAb23 is shown in Figure 1 and summarized in Table 11. 50 This represents the concentration of the antibody that reached 50% of the signal in this assay. Both antibodies dose-dependently enhanced T cell proliferation; that is, both antibodies blocked ATP-mediated inhibition of T cell proliferation.
[0320]
[0359] 3.5. Epitope Binning
[0360] Anti-CD39 antibodies were labeled using the Alex488 labeling kit, diluted to a series of concentrations, mixed with CHOK1-hCD39 cells, and bound EC was analyzed using FACS. 50 The following was tested: The blocking efficiency of unlabeled antibodies against labeled antibodies was tested. Briefly, mononuclear CHOK1-hCD39 cells were tested in 2 × 10⁶ cells. 6 Prepare the solution at 1 / ml and seed it into a 96-well plate at 50 μl / well. Mix with the antibody gradient until the final volume reaches 100 μl, and add an equal volume of Alex488-labeled antibody via EC. 80 The solution was added at twice the concentration. The 96-well plate was incubated at 4°C for 1 hour, centrifuged, and washed three times with 200 μl of FACS buffer. FACS analysis was performed using a FACScelesta machine, and the data was analyzed with Flowjo software. Blocking rates were calculated, and antibodies with a competition rate of more than 80% compared to non-competitive wells (Alex488-labeled antibody only) were assigned to one epitope group.
[0321]
[0361] The results of the competition are shown in Table 12. Based on the competition results, the four anti-CD39 hybridoma antibodies (mAb14, mAb19, mAb21, mAb23) can be classified into four different epitope groups, as shown in Table 11. Specifically, the anti-CD39 antibodies mAb19 and mAb21 competed for highly similar epitopes and are classified into epitope group I, as shown in Table 11. mAb14 did not compete with any of the other antibodies tested and is classified into epitope group IV, as shown in Table 11. mAb23 showed cross-competition with mAb19 and mAb21 and is classified into epitope group II, as shown in Table 11.
[0322] [Table 15]
[0323]
[0362] 3.6. Sequencing of Hybridomas
[0363] RNA was isolated from monoclonal hybridoma cells and reverse transcribed to cDNA using a commercially available kit. The variable regions of the heavy and light chains were then amplified using the cDNA as a template with Mouse Ig-Primer Set (Novagen) primers. PCR products of the correct size were collected, purified, and ligated with suitable plasmid vectors. The ligation products were transformed into DH5α-competent cells. Clones were selected, and the inserted fragments were analyzed by DNA sequencing.
[0324]
[0364] The variable region sequences of hybridoma antibodies are provided in Table 2 of this specification. Example 4. Generation and Characterization of Chimeric Antibodies
[0365] 4.1. Generation and production of chimeric antibodies
[0366] DNA encoding the variable regions of four selected hybridoma antibodies (mAb14, mAb19, mAb21, and mAb23) was synthesized and subcloned into expression vectors pre-containing human IgG constant genes. The vectors were transfected into mammalian cells for recombinant protein expression, and the expressed antibodies were purified using a protein A affinity column. The resulting chimeric antibodies are referred to herein as c14, c19, c21, and c23, where the prefix "c" indicates "chimera" and the number indicates the clone of the hybridoma antibody. For example, the number "14" indicates that it is derived from the hybridoma antibody mAb14.
[0325]
[0367] 4.2. Characterization of Chimeric Antibodies
[0368] The four purified chimeric antibodies were tested for their activity in blocking ATP-mediated inhibition of T cell proliferation (similar to the method described in Example 3.4). As shown in Figure 2, the anti-CD39 chimeric antibodies c14, c19, c21, and c23 showed dose-dependent activity (at concentrations ranging from 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, and 0.001 nM) in blocking CD4 + It blocked the suppression of T cell proliferation. CFSE-CD4 +T cells and hIgG4 cells were used as positive and negative controls for ATP-mediated T cell proliferation, respectively.
[0326]
[0369] Four purified chimeric antibodies were further tested for their ability to enhance ATP-induced dendritic cell (DC) activation and maturation in the presence of ATP. ATP induces DC maturation through stimulation of the P2Y11 receptor on monocyte-derived dendritic cells.
[0327]
[0370] In short, human monocytes were isolated from healthy human blood and differentiated into MoDCs (MoD cells) for 6 days in the presence of GM-CSF and IL-4. The differentiated MoDCs were then treated for a further 24 hours with four different doses of anti-CD39 chimeric antibodies in the presence of ATP. The maturation of the DCs was then evaluated by analyzing the expression of CD86, CD83, and HLA-DR using a FACS assay.
[0328]
[0371] Figure 3 shows the level of CD39 on the DC surface as measured by FACS. Figures 4A to 4C show the expression of CD86 (Figure 4A), CD83 (Figure 4B), and HLA-DR (Figure 4C), respectively, after antibody treatment. ATP-induced DC maturation was indicated by increased expression of CD86, CD83, and HLA-DR compared to vehicle treatment. All four anti-CD39 antibodies, c14, c19, c21, and c23, showed a significant effect in enhancing ATP-induced DC maturation.
[0329]
[0372] The chimeric antibody was also tested in vivo for its antitumor activity. Tumor cells (10 × 10) in 0.1 ml of PBS mixed with Matrigel (1:1) for tumor development were introduced into the right posterior ventral region of NOD-SCID mice. 6 (1) was administered subcutaneously. The average tumor size was approximately 80 mm. 3 Mice were randomly divided into groups when they reached a certain level. Treatment was initiated at 30 mg / kg on the same day as randomization and administered twice weekly. Tumor volume was measured two-dimensionally using calipers twice weekly after randomization, and the volume was expressed in mm³ using the formula: V=(L×W×W) / 2. 3The data was expressed as follows: V = tumor volume, L = tumor length (longest tumor dimension), and W = tumor width (longest tumor dimension perpendicular to L). Medication, tumor size, and body weight measurements were performed in a laminar flow cabinet. The data were analyzed using bidirectional ANOVA with Graphpad Prism.
[0330]
[0373] The tumor growth results of the chimeric anti-CD39 antibody c23 are shown in Figure 5. Both human IgG1 and IgG4 isotypes of c23 were obtained and tested. Both c23-hIgG4 and c23-hIgG1 chimeric antibodies showed antitumor efficacy compared to the vehicle group, and no significant difference was identified between c23-hIgG4 and c23-hIgG1.
[0331] Example 5. Humanization and affinity maturation of antibodies
[0374] 5.1. Humanization
[0375] Chimeric antibodies c23 and c14 were selected as clones for humanization. The antibody sequences were aligned with human germ cell sequences to identify the best-fit model. Based on homology with the original mouse antibody sequences, the best-matched human germ cell sequences were selected as templates for humanization. The CDR from the mouse antibody sequences was then grafted onto the templates along with residues to maintain the upper and central core structures of the antibodies. Optimized mutations were introduced into the framework regions to generate variants of the humanized heavy chain variable region and the humanized light chain variable region, which were then mixed and matched to provide multiple humanized antibody clones. After grafting and mutation, the humanized antibodies maintained similar binding affinity to human CD39-expressing cells. The humanized antibodies were further evaluated by CD39 ATPase inhibition assays and in vitro immune cell activation assays. In vivo studies were also performed for some of the humanized antibodies.
[0332]
[0376] A total of 31 humanized antibody clones were obtained for c23. These clones were mixed and matched with seven variants of the humanized c23 heavy chain variable region (i.e., hu23.VH_1, hu23.VH_2, hu23.VH_3, hu23.VH_4, hu23.VH_5, hu23.VH_6, and hu23.VH_7) and seven variants of the humanized c23 light chain variable region (i.e., hu23.VL_1, hu23.VL_2, hu23.VL_3, hu23.VL_4, hu23.VL_5, hu23.VL_6, and hu23.VL_7). The 31 humanized antibody clones were denoted as hu23.H1L1, hu23.H1L2, etc., as shown in Table 9 above and Tables 13, 14, and 15 below. Here, the prefix "hu" indicates "humanization," and the suffix, such as "H1L1," represents a sequential number of a c23 humanized antibody clone that has the variable regions of the hu23.VH_1 variant and the hu23.VL_1 variant.
[0333] [Table 16]
[0334] [Table 17]
[0335] [Table 18]
[0336]
[0377] Similarly, a total of 16 humanized antibodies were obtained for c14. These were mixed and matched with four variants of the humanized c14 heavy chain variable region (i.e., hu14.VH_1, hu14.VH_2, hu14.VH_3, and hu14.VH_4) and four variants of the humanized c14 light chain variable region (i.e., hu14.VL_1, hu14.VL_2, hu14.VL_3, and hu14.VL_4). The 16 humanized antibody clones were denoted using the same notation as hu14.H1L1, hu14.H1L2, etc., as shown in Table 16 below.
[0337] [Table 19]
[0338]
[0378] Several humanized antibody clones were also obtained for c23 by yeast display. Briefly, the mouse heavy and light chain sequences were aligned with our in-house database of human antibody sequences. For CDR grafting of the heavy and light chains, IGHV1-3, which has the greatest homology, was used as the template, respectively. * 01 and IGKV3-11 * 01 was selected. Revertant mutations were identified using a high-throughput method with yeast display. Specifically, positions contributing to the conformation of CDR (Vernier zone residues) were identified, and a library of revertant mutations was created by incorporating both template and mouse residues into their respective positions during DNA synthesis. The final candidate was identified by sequencing of the top binder to the human CD39 protein. Humanized antibodies against c23 obtained via yeast display are denoted as hu23.201 (having VH / VL for SEQ ID NOs. 146 / 111), hu23.203 (having VH / VL for SEQ ID NOs. 146 / 112), hu23.207 (having VH / VL for SEQ ID NOs. 147 / 111), and hu23.211 (having VH / VL for SEQ ID NOs. 39 / 63).
[0339]
[0379] Humanized antibodies from Tables 13, 14, 15, and 16 were recombinantly produced and tested for binding affinity, demonstrating their ability to maintain specific binding to human CD39. Humanized antibodies with relatively high affinity were further evaluated in functional assays, including CD39 blocking assays and in vitro immune cell activation assays.
[0340]
[0380] In particular, the humanized antibodies hu23.H5L5, hu23.201, and hu14.H1L1, as well as the reference antibodies I394 and T895, were characterized for their binding affinity to human CD39 using Biacore (GE). Briefly, the antibodies to be tested were captured on a CM5 chip (GE) using the Human Antibody Capture Kit (GE). 6×His-tagged human CD39 antigen was serially diluted for multiple doses and injected at 30 μl / min for 180 seconds. The buffer flow rate was maintained for 400 seconds for dissociation. 3M MgCl2 was used for chip regeneration. The association and dissociation curves matched the 1:1 binding model, and the Ka / Kd / K values were obtained for each antibody. D The values were calculated. The affinity data for the tested antibodies is summarized in Table 17 below.
[0341] [Table 20]
[0342]
[0381] Furthermore, using the Octet assay (Creative Biolabs) and following the manufacturer's manual, humanized antibodies hu23.H5L5 and hu14.H1L2, as well as reference antibodies I394, T895, and 9-8B, were characterized for their binding affinity to human CD39. Briefly, the antibodies were coupled to a sensor, and then the sensor was immersed in a CD39 gradient (200 nM at the start, 8 doses in total after 2-fold dilution). These binding responses were measured in real time. The results were generally in agreement. The affinity data for the tested antibodies are summarized in Table 18 below.
[0343] [Table 21]
[0344]
[0382] Furthermore, in the HCDR2 of humanized c23 antibody clones (e.g., hu23.H5L5), one NG motif (N55G56) susceptible to deamidation was identified. Various mutations were introduced into N55 or G56 to remove the deamidation site, and it was found that N55 and G56 could be mutated to various residues while retaining specific binding to human CD39. For example, replacing N55 with G, S, or Q at a single point maintained antibody binding affinity and did not adversely affect binding to human CD39. Similarly, replacing G56 with A or D resulted in the mutant antibody retaining specific binding and binding affinity to human CD39. Other mutations were expected to have similar effects.
[0345]
[0383] 5.2. Detection of Binding Specificity
[0384] The binding specificity of the purified humanized antibody hu23.H5L5 to members of the ENTPDase family was detected by ELISA assay. Briefly, ENTPD1 (i.e., CD39) and ENTPD2 / 3 / 5 / 6 proteins were coated overnight in a 96-well ELISA plate at 4°C. The following day, the ELISA plate was washed and blocked for 2 hours with blocking buffer (1% BSA and 0.05% Tween® 20 in PBS) at 200 μl / well. Then, a gradient of hu23.H5L5 was placed in two wells and stained with anti-hIgG-HRP. After washing the plate, it was stained with TMB substrate and stopped in 2N HCl. OD450 was recorded using a plate reader and plotted using Graphpad Prism. The binding specificity of hu23.H5L5 is shown in Figure 6. Figure 6A shows that the humanized antibody hu23.H5L5 specifically binds to human CD39 but does not bind to any of the ENTPD2 / 3 / 5 / 6 proteins. Figure 6B shows that the negative control hIgG4 does not bind to any of the ENTPD1 / 2 / 3 / 5 / 6 proteins.
[0346]
[0385] 5.3. Characterization of Humanized Antibodies
[0386] The binding affinity of humanized antibodies to c23 was determined by FACS using the same method as described in Example 3.2. C23 humanized antibody clones showing good binding affinity are listed in Tables 19 and 20 below, and are also shown in Figures 7A, 7B, and 8. 50 This represents the concentration of the antibody that reaches 50% of the signal in this assay.
[0347] [Table 22]
[0348] [Table 23]
[0349]
[0387] The selected humanized antibodies for c23 were tested on SK-MEL-28 cells using an ATPase inhibition assay (as described in Example 3.3). The inhibition plots of the displayed antibodies are shown in Figures 9A and 9B and summarized in Table 21. Hu23.H5L5 and Hu23.201 were selected for further validation.
[0350] [Table 24]
[0351]
[0388] The binding affinity of the humanized antibody to c14 was determined by FACS using human CD39-expressing MOLP-8 cells, in the same manner as described in Example 3.2.
[0389] Humanized antibody clones of c14 showing good binding affinity are shown in Figures 10A, 10B, and 10C. 50 This is summarized in Table 22.
[0352] [Table 25]
[0353]
[0390] 5.4. Epitope Binning
[0391] The selected humanized antibodies were tested for competitive binding (as described in Example 3.5). The results of epitope binning of humanized antibodies hu23.H5L5 and hu14.H1L1 with the reference antibody are shown in Figure 19A.
[0354]
[0392] Based on the competition results (shown in Figure 19A), the two humanized anti-CD39 antibodies, hu23.H5L5 and hu14.H1L1, could be classified into two distinct epitope groups (see Figure 19B). Specifically, the anti-CD39 antibody hu23.H5L5 competed with reference antibodies I394, T895, and 9-8B for highly similar epitopes and was classified into epitope group I. hu14.H1L1, c34, and c35 competed only partially with T895 and did not compete with any of the other antibodies tested, and were classified into epitope group II.
[0355]
[0393] 5.5. Characterization of optimized humanized antibodies
[0394] 5.5.1 Blocking of CD39 by hu23.H5L5 improved the proliferation of human T cells in the presence of extracellular ATP (eATP).
[0356]
[0395] Human PBMCs stimulated with anti-CD3 and anti-CD28 antibodies were incubated with 25 nM humanized anti-CD39 antibody hu23.H5L5 and a vehicle in the presence of ATP. Cell culture supernatants were collected for detection of IL-2 and IFN-γ secretion, respectively. CD4 + T cells and CD8 + T cell proliferation was analyzed on day 5 by FACS using Cell Trace Violet dye dilution.
[0357]
[0396] As shown in Figures 11A to 11D, hu23.H5L5 is CD4 at a concentration of 25 nM. + and CD8 +It significantly enhanced T cell proliferation and activated their production of IL-2 and IFN-γ. As shown in Figures 11A, 11B, and 11D, hu23.H5L5 showed significantly higher activity than I394 in enhancing T cell activation in PBMCs.
[0358]
[0397] Human CD8 + T cells were also isolated from PBMCs of healthy donors, labeled with cell proliferation dyes, activated with anti-CD3 and anti-CD28 antibodies, and treated with different doses of humanized anti-CD39 antibody hu23.H5L5 or reference antibody I394 for a total treatment period of 5 days. Three days after the start of CD39 blockade treatment, 200 μM ATP was added to the cells. On day 5, CD8 was analyzed by flow cytometry. + T cell proliferation %, CD25 + The percentage of cells and the percentage of live cells were analyzed.
[0359]
[0398] As shown in Figures 23A to 23C, hu23.H5L5 is human CD8 inhibited by eATP. + This significantly reversed the proliferation of T cells.
[0399] The binding affinity of humanized antibodies hu23.H5L5 and hu14.H1L1 was tested on various cells by FACS using the same method as described in Example 3.2.
[0360]
[0400] Figures 12A to 12E show the binding affinities of antibodies hu23.H5L5 and hu14.H1L1 to SK-MEL-5 (Figure 12A), SK-MEL-28 (Figure 12B), MOLP-8 (Figure 12C), CHOK1-cynoCD39 (Figure 12D), and CHOK1-mCD39 (Figure 12E), respectively. Reference antibodies T895 and I394 were tested in parallel as control antibodies. As shown in Figure 12 and summarized in Table 23, both antibodies hu23.H5L5 and hu14.H1L1 showed dose-dependent binding affinities at sub-nanomole or nanomolar levels of EC. 50These antibodies bound to human and cynomolgus monkey CD39-expressing cells with similar affinity. None of these antibodies recognized mouse CD39 in FACS studies. The differing maximum signals (mean fluorescence intensity, MFI) between cells for each antibody are thought to be due to differences in their expression levels.
[0361] [Table 26]
[0362]
[0401] Figure 13 shows that hu23.H5L5 blocked CD39 ATPase activity in SK-MEL-5 cells (Figure 13A) or MOLP-8 cells (Figure 13B), similar to the reference antibodies T895 and I394 (method described in Example 3.3). The results are summarized in Table 24.
[0363]
[0402] hu23.H5L5 is an enzyme blocking IC at 70 pM in SK-MEL-5 cells and 330 pM in MOLP-8 cells. 50 The results were similar to or slightly better than those of the reference antibodies T895 and I394. 9-8B was identified as a non-blocker in this assay.
[0364] [Table 27]
[0365]
[0403] 5.5.2 Blockade of CD39 by hu23.H5L5 enhanced ATP-mediated monocyte activation.
[0404] The humanized antibody hu23.H5L5 was also tested in an ATP-mediated monocyte activation assay. ATP-mediated pro-inflammatory activity plays a crucial role in regulating the function of various immune cell types, including monocytes. To evaluate whether CD39 blockade can enhance ATP-mediated monocyte activation, human monocytes were purified from healthy human blood and then incubated with anti-CD39 antibodies at various concentrations ranging from 0.2 nM to 100 nM in the presence of ATP. hu23.H5L5 was shown to be effective in inducing monocyte activation at 0.2 nM, the lowest concentration tested. Monocyte activation was evaluated by FACS assay, analyzing the expression of CD80 (Figure 14A), CD86 (Figure 14B), and CD40 (Figure 14C) (hu23.H5L5 concentration was 50 nM). Reference anti-CD39 antibodies I394 and T895 were used as controls, and hIgG4 was used as an isotype control.
[0366]
[0405] The results are shown in Figure 14. Stimulation with ATP alone resulted in upregulated expression of CD80 and CD86, indicating monocyte activation. The anti-CD39 humanized antibody hu23.H5L5 further enhanced ATP-mediated monocyte activation, as demonstrated by upregulation of CD80, CD86, and CD40 to levels comparable to those achieved by the reference antibody I394. The reference antibody T895 did not show a significant effect on ATP-induced activated monocytes.
[0367]
[0406] 5.5.3 Blocking of CD39 by hu23.H5L5 enhanced ATP-mediated DC activation.
[0407] The selected humanized antibody hu23.H5L5 was also tested in an ATP-mediated DC activation assay (following the same method as described in Example 4.2). Briefly, DC maturation was assessed by analyzing CD83 expression using a FACS assay. ATP induced DC maturation by showing increased CD83 expression (Figure 15A). hu23.H5L5 dose-dependently increased CD83 expression starting at a low level of 0.2 nM and significantly increased CD83 expression at an antibody level of 0.6 nM. This was more potent than both the reference antibodies T895 and I394.
[0368]
[0408] To further evaluate the consequent effect of ATP-mediated DC activation on T cell activation, ATP-activated DCs were washed and then incubated with allogeneic T cells for a mixed lymphocyte reaction (MLR). T cell proliferation (Figure 15B) and IFN-γ production from activated T cells were analyzed (Figure 15C).
[0369]
[0409] Compared to reference antibodies I394 and T895, the anti-CD39 antibody hu23.H5L5 showed a dose-dependent and significant effect on enhancing ATP-induced DC maturation. Reference antibody I394 showed similar but slightly weaker activity. On the other hand, the effect of T895 was extremely mild. Consistently, as shown in Figures 15B and 15C, ATP-mediated MoDC maturation enhanced by the anti-CD39 blocking antibody hu23.H5L5 resulted in higher T cell proliferation and IFN-γ production in MLR assays.
[0370]
[0410] 5.5.4 Blocking of CD39 by hu23.H5L5 promoted the release of IL1β by LPS-induced human macrophages.
[0411] Human CD14 from healthy human PBMC + T cells were isolated, and then enriched with CD14 + Single ball 2 x 10 6 Macrophages were seeded at a density of cells / well in a 6-well plate and cultured with 100 ng / mL human GM-CSF for 6 days to generate M1-like macrophages. In vitro differentiated macrophages were treated with increasing doses of hu23.H5L5 or reference antibody I394 for 1 hour, followed by stimulation with 10 ng / mL LPS for 3 hours, and then treated with 800 μM ATP for 2 hours. IL-1β in the cell culture supernatant was quantified by ELISA.
[0371]
[0412] The results are shown in Figure 20. Asterisks indicate significant differences between each condition. As shown in Figure 20, hu23.H5L5 significantly promoted the release of IL1β from human macrophages induced by LPS stimulation, and hu23.H5L5 showed significantly higher activity than the reference antibody I394 in promoting the release of IL1β from human macrophages induced by LPS stimulation.
[0372]
[0413] 5.6. In vivo studies
[0414] The effects of the humanized antibodies hu23.H5L5 and hu14.H1L1 were determined in MOLP-8 xenograft mice according to the method described in Example 4.2.
[0373]
[0415] The results are shown in Figure 16. All anti-CD39 antibodies inhibited tumor growth compared to the vehicle group. The efficiency observed for I394 was slightly weaker than that of the other antibodies, including hu23.H5L5 and hu14.H1L1.
[0374]
[0416] The antitumor efficiency of the humanized antibody hu23.H5L5 was also tested in vivo in a PBMC adoptive animal model (NCG mice, inoculated with MOLP-8 cells at 5M / mouse) according to the method described in Example 4.2, at a range of different doses (0.03 mg / kg, 0.3 mg / kg, 3 mg / kg, 10 mg / kg, 30 mg / kg, ip, BIW × 6 doses).
[0375]
[0417] The results are shown in Figure 21. As shown in Figure 21, the humanized antibody hu23.H5L5 potently inhibited tumor growth at all doses tested.
[0418] We also determined whether the antitumor efficiency of the anti-CD39 antibody depended on NK cells or macrophages. NK depletion treatment with anti-asialo-GM1 was initiated intraperitoneally at 20 μl / mouse on day 7 and repeated every 5 days. Macrophage depletion treatment with clodronate liposomes was also initiated intravenously at 200 μl / mouse on days 7 and 9 and repeated weekly. Blood sample analysis data demonstrated significant removal of mononuclear phagocytes or NK cells by the reagents.
[0376]
[0419] In models where NK cells (Figure 17) or macrophages (Figure 18) were depleted, the tumor growth inhibitory effect of hu23.H5L5 was abolished, suggesting that the antitumor effect of the anti-CD39 antibody is dependent on NK cells and macrophages.
[0377]
[0420] Specifically, as shown in Figure 17, anti-asialo-GM1 slightly enhanced tumor growth at a later stage compared to the vehicle. Compared to the group treated with hu23.H5L5, combining it with anti-asialo-GM1 completely eliminated the tumor growth inhibitory effect of hu23.H5L5. As shown in Figure 18, clodronate liposomes had no effect on tumor growth compared to the vehicle. However, clodronate liposome treatment completely eliminated the tumor growth inhibitory effect of hu23.H5L5.
[0378] Example 6. Epitope Mapping
[0421] To define the epitopes of anti-CD39 antibodies, CD39 variants were designed and defined by amino acid substitutions exposed on the molecular surface of human CD39. As shown in Table 25 below, the variants were cloned into expression vectors fused with the C-terminal EGFP sequence and transfected into HEK-293F cells. Targeted amino acid mutations are indicated using the numbering UniProtKB-P49961(ENTP1_HUMAN). This is the wild-type amino acid sequence of human CD39, shown herein as SEQ ID NO: 162. For example, V77G means that the valine at position 77 of SEQ ID NO: 162 is replaced by glycine.
[0379] [Table 28]
[0380]
[0422] Briefly, human CD39 mutants were generated by gene synthesis and then cloned into the expression vector pCMV3-GFPSpark. A vector containing the validated mutant sequence was prepared and transfected into HEK293F cells. Three days after transfection, cells were collected to test EGFP for transgene expression. Twenty mutants were tested with a dose-range antibody (starting at 100 nM, 3-fold dilution, 11 samples) and stained with AlexFluor647-labeled anti-hIgG by FACS. Antibody binding was described as relative binding, derived by dividing the intensity of AlexFluor647 by the intensity of GFP. The results are shown in Figure 22.
[0381]
[0423] As shown in Figure 22, the humanized antibody hu23.H5L5 lost its binding affinity to mutants KW27-6 and KW27-20, but not to the other mutants. Mutant KW27-6 contains amino acid substitutions at residues Q96, N99, E143, and R147, indicating that one, several, or all of the mutant residues are important to the core epitope of hu23.H5L5. Mutant KW27-20 contains amino acid substitutions at residues R138, M139, and E142, also indicating that one, several, or all of the mutant residues are important to the core epitope of hu23.H5L5.
[0382]
[0424] As shown in Figure 22, the chimeric antibody c34 lost its ability to bind to mutant KW27-16, but not to any of the other mutants. Mutant KW27-16 contains amino acid substitutions at residues K5, E100, and D107, indicating that one, several, or all of the mutant residues are important to the core epitope of c34.
[0383]
[0425] As shown in Figure 22, the chimeric antibody c35 lost its binding affinity to mutant KW27-2, but not to any of the other mutants. Mutant KW27-2 contains amino acid substitutions at residues V81, E82, R111, and V115, indicating that one, several, or all of the mutant residues are important to the core epitope of c35.
[0384]
[0426] As shown in Figure 22, the reference antibody T895 lost its binding affinity to mutant KW27-20, but not to any of the other mutants. Mutant KW27-20 contains amino acid substitutions at residues R138, M139, and E142, indicating that one, several, or all of the mutant residues are important to the core epitope of T895.
[0385]
[0427] As shown in Figure 22, the reference antibody I394 lost its binding affinity to mutants KW27-6 and KW27-20, but not to the other mutants. Mutant KW27-6 contains amino acid substitutions at residues Q96, N99, E143, and R147, indicating that one, several, or all of the mutant residues are important to the core epitope of I394. Mutant KW27-20 contains amino acid substitutions at residues R138, M139, and E142, indicating that one, several, or all of the mutant residues are important to the core epitope of I394.
[0386]
[0428] As shown in Figure 22, the reference antibody 9-8B lost its binding affinity to mutant KW27-6, but it did not lose its binding affinity to any of the other mutants. Mutant KW27-6 contains amino acid substitutions at residues Q96, N99, E143, and R147, indicating that one, several, or all of the mutant residues are important to the core epitope of 9-8B.
[0387] Example 7. Construction and expression of anti-CD39 / TGFβ trap.
[0429] The anti-CD39 / TGFβ Trap molecules were constructed as an anti-CD39 antibody moiety linked to a TGFβ receptor II ECD (TGFβRII ECD) at the N-terminus or C-terminus of the heavy and / or light chains of the anti-CD39 antibody moiety. A flexible (Gly4Ser)3 linker was genetically linked to the N-terminus of the TGFβRII ECD. Several anti-CD39 / TGFβ Trap molecules were constructed by changing the molar ratio of the TGFβRII ECD and the position of the anti-CD39 antibody moiety, and their schematic diagrams are shown in Figures 24A-G, respectively. Anti-CD39 / TGFβ Trap molecules containing an anti-CD39 antibody moiety linked to a TGFβ receptor I ECD (TGFβRI ECD) or a TGFβ receptor III ECD (TGFβRIII ECD) may be constructed in a similar manner, but are not shown herein.
[0388]
[0430] The anti-CD39 / TGFβ Trap molecule ES014-1 comprises one anti-CD39 antibody moiety (i.e., hu23.H5L5) and two TGFβRII ECDs (i.e., SEQ ID NO: 164), where one TGFβRII ECD is ligated to the anti-CD39 antibody moiety at the C-terminus of each heavy chain constant region (Figure 24A).
[0389]
[0431] The anti-CD39 / TGFβ Trap molecule ES014-2 comprises one anti-CD39 antibody moiety (i.e., hu23.H5L5) and four TGFβRII ECDs (i.e., SEQ ID NO: 164), where two TGFβRII ECDs are ligated to the anti-CD39 antibody moiety at the C-terminus of their respective heavy chain constant regions (Figure 24B).
[0390]
[0432] The anti-CD39 / TGFβ Trap molecule ES014-3 contains one anti-CD39 antibody moiety (i.e., hu23.H5L5) and four TGFβII ECDs (i.e., SEQ ID NO: 164), with two TGFβRII ECDs ligated to the anti-CD39 antibody moiety at the N-terminus of their respective heavy chain variable regions (Figure 24C).
[0391]
[0433] The anti-CD39 / TGFβ Trap molecule ES014-4 contains one anti-CD39 antibody moiety (i.e., hu23.H5L5) and four TGFβII ECDs (i.e., SEQ ID NO: 164), with two TGFβRII ECDs ligated to the anti-CD39 antibody moiety at the N-terminus of their respective light chain variable regions (Figure 24D).
[0392]
[0434] The anti-CD39 / TGFβ Trap molecule ES014-5 comprises one anti-CD39 antibody moiety (i.e., hu23.H5L5) and four TGFβII ECDs (i.e., SEQ ID NO: 164), wherein one TGFβII ECD is ligated to the anti-CD39 antibody moiety at the N-terminus of each heavy chain variable region, and one TGFβII ECD is ligated to the anti-CD39 antibody moiety at the N-terminus of each light chain variable region (Figure 24E).
[0393]
[0435] The anti-CD39 / TGFβ Trap molecule ES014-6 contains one anti-CD39 antibody moiety (i.e., hu23.H5L5) and four TGFβII ECDs (i.e., SEQ ID NO: 164), with two TGFβRII ECDs ligated to the anti-CD39 antibody moiety at the C-terminus of their respective light chain constant regions (Figure 24F).
[0394]
[0436] The anti-CD39 / TGFβ Trap molecule ES014-7 contains one anti-CD39 antibody moiety (i.e., hu23.H5L5) and six TGFβII ECDs (i.e., SEQ ID NO: 164), wherein one TGFβRII ECD is ligated to the anti-CD39 antibody moiety at the C-terminus of its respective heavy chain constant region, and two TGFβRII ECDs are ligated to the anti-CD39 antibody moiety at the C-terminus of their respective light chain constant regions (Figure 24G).
[0395]
[0437] For expression, CHO cells were transfected using DNA encoding the light and heavy chains in the same expression vector or separate expression vectors. The culture medium was collected, and the fusion protein was purified using a Protein A Sepharose column.
[0396] Example 8. Binding of anti-CD39 / TGFβ trap molecule to TGFβ by ELISA.
[0438] To determine the binding ability and specificity of anti-CD39 / TGFβ trap molecules, ELISA assays were performed using human TGFβ1, human TGFβ2, human TGFβ3, and mouse TGFβ1. The antigens tested were coated at a concentration of 1 μg / ml on NUNC 96-well immunosorbent plates. Binding with increasing concentration of anti-CD39 / TGFβ trap molecules was measured using an anti-human Fc antibody horseradish peroxidase conjugate diluted in PBT buffer, followed by color development with TMB substrate. Soluble TGFβ traps were used as controls. As shown in Figures 25A-25C, anti-CD39 / TGFβ trap molecules ES014-1 and ES014-2 bind to all three TGFβ homologs: human TGFβ1, TGFβ2, and TGFβ3. The results of binding assays for other tested anti-CD39 / TGFβ trap molecules (including ES014-3, ES014-4, ES014-5, ES014-6, and ES014-7) were similar and are not shown herein. EC to human TGFβ1 50 These are listed in Table 26 below. Furthermore, the anti-CD39 / TGFβ Trap molecule ES014-1 binds to mouse TGFβ1 with an affinity similar to that of human TGFβ1 (Figure 25D).
[0397] [Table 29]
[0398] Example 9. Blocking assay of TGFβ and TGFβR
[0439] For the blocking assay, TGFβ peptide (TGFβ1) was coated onto microplates. Serial dilutions of purified antibody were incubated with recombinant TGFβRII-His protein (SinoBiological) on the TGFβ1-coated plates for 1 hour. After washing, residual TGFβRII-His was detected with a secondary antibody conjugated with anti-His-HRP. To quantify TGFβRII-His binding to TGFβ1, absorbance values at 450 nm were read using a microtiter plate reader (Molecular Devices Corp). All tested anti-CD39 / TGFβ trap molecules (i.e., ES014-1, ES014-2, ES014-3, ES014-6) effectively blocked the binding of human TGFβ1 to the TGFβ receptor TGFβRII (Figure 26, soluble TGFβ trap (i.e., TGFβRII) was used as a control). IC of anti-CD39 / TGFβ trap molecules 50 The values were analyzed using GraphPad Prism. Anti-CD39 / TGFβ trap molecules with four copies of TGFβRII ECD, such as ES014-2, ES014-3, and ES014-6, are more potent than anti-CD39 / TGFβ trap molecules with two copies of TGFβRII ECD, such as ES014-1 (Table 27).
[0399] [Table 30]
[0400] Example 10. Binding of anti-CD39 / TGFβ trap molecule to CD39 by FACS.
[0440] Approximately 100,000 MOLP-8 myeloma cells overexpressing CD39 were washed with washing buffer and incubated on ice for 30 minutes with 100 μl of serially diluted anti-CD39 / TGFβ trap molecules. The cells were then washed twice with washing buffer and incubated on ice for 30 minutes with 100 μl of anti-human Fc-PE. The cells were then washed twice with washing buffer and analyzed using a FACS Canto II analyzer (BD Biosciences). As shown in Figure 27A, all of the tested anti-CD39 / TGFβ trap molecules (e.g., ES014-1, ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) bound to MOLP-8 cells in a dose-dependent manner. As shown in Figure 27B, ES014-1 bound to CHOK1 / hCD39 cells in a dose-dependent manner. The binding characteristics of other tested anti-CD39 / TGFβ trap molecules (e.g., ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) to CHOK1 / hCD39 cells were similar and were not described herein.
[0401] Example 11. Simultaneous binding of anti-CD39 / TGFβ trap molecule to CD39 and TGFβ1.
[0441] Plates coated with CD39 / His protein (Sino Biological) or CHO-K1 / hCD39 cells were incubated with serial dilutions of ES014-1, anti-CD39Ab, or TGFβ trap controls, followed by biotinylated TGFβ1. Binding was assessed using streptavidin-horseradish peroxidase or streptavidin-fluorescein isothiocyanate. Optical density (OD) was read at 450 nm. Data are mean ± SD and exhibit a nonlinear best fit (n=2 technical replicates). Results are shown in Figure 28. As shown in Figure 28, representative anti-CD39 / TGFβ trap molecules (ES014-1) were able to simultaneously bind to CD39 and TGFβ, respectively, by ELISA detection (Figure 28A) and FACS detection (Figure 28B). The results for other tested anti-CD39 / TGFβ trap molecules (e.g., ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) were similar and are not shown herein.
[0402] Example 12. Anti-CD39 / TGFβ Trap molecule inhibits TGFβ signaling.
[0442] The effect of the anti-CD39 / TGFβ Trap molecule on canonical TGFβ signaling was evaluated using the HEK-Blue® TGFβ reporter cell assay (InvivoGen). Serial dilutions of the anti-CD39 / TGFβ Trap molecule or anti-CD39 were incubated with HEK-Blue® TGFβ reporter cells for 24 hours in the presence of recombinant human TGFβ1 (5 ng / ml). The anti-CD39 / TGFβ Trap molecule showed a significant improvement in TGFβ canonical signaling [semi-maximal inhibitory concentration (IC)] in the TGFβ SMAD reporter assay in transfected HEK293 cells. 50It blocked [CD39 = 32 pM] but not anti-CD39 (Figure 29A). Furthermore, pre-incubation of the anti-CD39 / TGFβ Trap molecule with CD39 protein did not affect the TGF-β neutralizing activity of the anti-CD39 / TGFβ Trap molecule (Figure 29B). Figures 29A and 29B show the results for a representative anti-CD39 / TGFβ Trap molecule ES014-1. The results for other tested anti-CD39 / TGFβ Trap molecules (e.g., ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) were similar and are not shown herein.
[0403] Example 13. Effect of anti-CD39 / TGFβ trap molecule on CD39 activity of malignant cells
[0443] The ability of anti-CD39 / TGFβ trap molecules to inhibit the enzymatic activity of CD39 in malignant cell lines was measured using the cell-titer glo (CTG) assay. Briefly, cells were treated with anti-CD39 / TGFβ trap molecules, anti-CD39 antibody or control antibody, and 100 μM ATP for 60 minutes. The remaining ATP levels were measured using the CellTiterGlo Luminescent assay kit (Promega). MOLP-8 (human multiple myeloma cell line) or CHO / hCD39 cells were used in this assay. As shown in Figures 30A-B, treatment of MOLP-8 cells with anti-CD39 / TGFβ trap molecules or control antibodies within the indicated concentration ranges in the presence of ATP resulted in dose-dependent inhibition of CD39 activity by the tested molecules ES014-1, ES014-2, and ES014-6. The inhibition of CD39 activity was determined by the amount of residual ATP and expressed as inhibition %. ICs are listed in Table 28 below. 50 As described above, ES014-1, ES014-2, and ES014-6 are nanomolar ICs. 50Strong inhibitory activity was observed. As shown in Figure 30C, treatment of CHO / hCD39 cells in the presence of ATP with the specified concentrations of the exemplary anti-CD39 / TGFβ Trap molecule ES014-1 or the control antibody resulted in dose-dependent inhibition of CD39 activity by all tested antibodies. The results of treating CHO / hCD39 cells with the specified concentrations of other tested anti-CD39 / TGFβ Trap molecules (e.g., ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) were similar and are not shown herein.
[0404] [Table 31]
[0405] Example 14. Anti-CD39 / TGFβ Trap Binding Affinity
[0444] The representative anti-CD39 / TGFβ trap molecule ES014-1 was separately characterized for its binding affinity to human TGFβ1 or CD39 using the Octet assay (ForeBio) according to the manufacturer's manual. Briefly, the antibody was coupled to a sensor, and the sensor was then immersed in a protein gradient of TGFβ or CD39 (200 nM at the start, 8 doses in total by 2-fold dilution). These binding responses were measured in real time. The results were generally agreed. The affinity data for the tested molecule ES014-1 are summarized in Table 29 below. The affinity data for the other tested molecules (e.g., ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) were similar and are not shown herein.
[0406] [Table 32]
[0407] Example 15. Treg suppression assay
[0445] Since Tregs are the primary source of TGFβ secretion, and CD39 is expressed in both Tregs and DCs, the relative ability of anti-CD39 / TGFβ trap molecules to counteract Treg-mediated T cell suppression was investigated using a Treg suppression assay. In short, CD39 isolated from human PBMCs was used. + All T cells were isolated from PBMCs using autologous CD4 + / CD25 + In addition to allogeneic dendritic cells pulsed with IL-4 and GM-CSF in the presence of native Tregs (nTregs), they were grown in X-vivo medium in the presence of IL-2, anti-CD3 / CD28, and rapamycin in a 1:1:10 ratio.
[0408]
[0446] These mixed lymphocytes were cultured for 3 days with anti-CD39 / TGFβ trap molecules, anti-CD39 antibody, soluble TGFβ trap, or a combination of anti-CD39 antibody and TGFβ trap, followed by CD4 detection using CFSE cell tracers. + and CD8 + T cell function was evaluated by measuring T cell proliferation and IFNγ secretion induced by HTRF (Cisbo). As expected, the addition of autologous Tregs suppressed T cell activation induced by allogeneic DCs (Figure 31A). The representative anti-CD39 / TGFβ trap molecule ES014-1 was more effective than anti-CD39 antibodies, soluble TGFβ traps, or combinations thereof in counteracting Treg-mediated suppression and restoring T cell activation in the presence of autologous Tregs (Figures 31B-D). These data indicate that the anti-CD39 / TGFβ trap molecule ES014-1 is more effective than anti-CD39 antibodies, soluble TGFβ traps, or combinations thereof in restoring T cell function. Other molecules tested (e.g., ES014-2, ES014-3, ES014-4, ES014-5, ES014-6, ES014-7) showed similar effects (data not shown).
[0409] Example 16. Anti-CD39 / TGFβ Trap molecule inhibits apoptosis of human T cells without stimulation.
[0447] 2 x 10 4 Purified whole CD3 from human PBMC +T cells were cultured overnight and incubated overnight with equimolar concentrations of anti-CD39 / TGFβ trap molecules ES014-1 and ES014-2, TGFβR inactivated mutant ES014_v2, anti-CD39 inactivated mutant ES014_v1, and double-negative mutant ES014_v3. Apoptosis of human T cells was measured by flow cytometry using APC-labeled annexin V and PI, according to the manufacturer's instructions for use.
[0410]
[0448] As shown in Figures 32A and 32B, the anti-CD39 / TGFβ Trap molecules ES014-1 and ES014-2 dose-dependently inhibited apoptosis in human T cells compared to the TGFβR-inactivated mutant ES014_v2, the anti-CD39-inactivated mutant ES014_v1, and the double-negative mutant ES014_v3.
[0411] Example 17. Anti-CD39 / TGFβ Trap molecule promotes the survival and activation of stimulated human T cells.
[0449] 5 x 10 3 Purification of all CD3 + T cells were co-cultured for 4 days in the presence of anti-CD3 and anti-CD28 beads with equal molar amounts of anti-CD39 / TGFβ trap molecules ES014-1 and ES014-2, anti-CD39 antibody ES014_v2, TGF-beta trap ES014_v1, a combo (ES014_v2 and ES014_v1), and a double mutant antibody ES014_v3 as a control. T cell function was quantified by measuring T cell viability by viability staining, T cell proliferation by celltrace labeling, T cell activation by CD25 expression, and cytokine production.
[0412]
[0450] As shown in Figure 33A, anti-CD3 / CD28 stimulation resulted in predominantly dead cells in all groups except the anti-CD39 / TGFβ Trap group. Furthermore, viable cells from the anti-CD39 / TGFβ Trap group maintained higher cell proliferation and activation (Figure 33A), as well as IL-2 and IFN-γ production (Figure 33B). These data indicate that anti-CD39 / TGFβ Trap molecules are more effective than anti-CD39 antibodies, TGFβ traps, or combinations thereof in activating T cells.
[0413] Example 18. Anti-CD39 / TGFβ Trap molecule blocks TGF-beta-induced Foxp3 expression on all T cells.
[0451] 5 x 10 4 Purified T cells were pretreated for 30 minutes with equal molars of anti-CD39 / TGFβ trap molecules (ES014-1 and ES014-2), anti-CD39 antibody (ES014_v2), TGF-beta trap (ES014_v1), combo (ES014_v2+ES014_v1), and control antibody (ES014_v3) in the presence of anti-CD3 and anti-CD28 beads, followed by the addition of 10 ng / ml of TGF-beta. After treatment with TGF-beta for 4 days, Treg differentiation was measured.
[0414]
[0452] As shown in Figures 34A and 34B, treatment with anti-CD39 / TGFβ trap molecules (ES014-1 and ES014-2), TGF-beta trap (ES014_v1), and combo (ES014_v2+ES014_v1) yielded a higher CD4 count compared to treatment with culture medium, anti-CD39 (ES014_v2), and control antibody (ES014_v3). + and CD8 + We were able to block TGF-beta-induced Foxp3 expression in T cells. In particular, the blocking effect in the anti-CD39 / TGFβ trap molecule treatment group showed superior activity compared to the TGF-beta trap (ES014_v1) and combo (ES014_v2+ES014_v1) treatment groups, with the anti-CD39 / TGFβ trap molecule ES014-1 showing particularly excellent activity.
[0415] Example 19. Anti-CD39 / TGFβ Trap molecule restores ATP-induced inhibition of human T cell proliferation.
[0453] 5 x 10 4 Purified T cells were labeled with celltrace violet and pretreated overnight with anti-CD39 / TGFβ trap molecules (ES014-1 and ES014-2), anti-CD39 antibody (ES014_v2), TGF-beta trap (ES014_v1), combo (ES014_v2+ES014_v1), and control antibody (ES014_v3) in the presence of anti-CD3 and anti-CD28 beads. On day 1, 200 μM ATP was added, and after ATP treatment for 3 days, T cell proliferation was measured. As shown in Figures 35A and 35B, treatment with anti-CD39 / TGFβ Trap molecules (ES014-1 and ES014-2), anti-CD39 antibody (ES014_v2), and combo (ES014_v2+ES014_v1) yielded a higher CD4 count compared to treatment with medium, TGF beta trap (ES014_v1), and control antibody (ES014_v3). + and CD8 + We were able to reverse the ATP-induced inhibition of T cell proliferation. The restored T cell proliferation results demonstrated the effect of the anti-CD39 / TGFβ trap molecule on blocking CD39 activity, which was consistent with the results of ATPase inhibitory activity.
Claims
1. A conjugate molecule comprising a CD39 inhibitory moiety capable of interfering with the interaction between CD39 and its substrate, and a TGFβ inhibitory moiety capable of interfering with the interaction between TGFβ and its receptor.
2. The conjugate molecule of claim 1, wherein the CD39 inhibitory portion is a CD39 antagonist selected from the group consisting of a CD39 binding agent, an RNAi targeting the coding sequence of CD39, an antisense nucleotide targeting the coding sequence of CD39, and an agent that competes with CD39 to bind to its substrate; or the TGFβ inhibitory portion is a TGFβ antagonist selected from the group consisting of a TGFβ binding agent, an RNAi targeting the coding sequence of TGFβ, an antisense nucleotide targeting the coding sequence of TGFβ, and an agent that competes with TGFβ to bind to its receptor.
3. The conjugate molecule of claim 2, wherein the CD39 binding agent is selected from the group consisting of an antibody or antigen-binding fragment thereof that specifically recognizes CD39, and a small molecule compound that binds to CD39, and / or the TGFβ binding agent is selected from the group consisting of an antibody or antigen-binding fragment thereof that specifically recognizes TGFβ, and a small molecule compound that binds to TGFβ.
4. 4. The conjugate molecule of any one of claims 1 to 3, which is a fusion protein comprising a CD39 binding domain linked to a TGFβ binding domain; optionally said TGFβ binding domain binds to human TGFβ1, human TGFβ2, and / or human TGFβ3; optionally said TGFβ binding domain comprises the extracellular domain (ECD) of a TGFβ receptor; optionally said TGFβ receptor is TGFβ receptor I (TGFβRI), TGFβ receptor II (TGFβRII), or TGFβ receptor III (TGFβRIII).
5. 5. The conjugate molecule of claim 4, wherein the ECD comprises an amino acid sequence of SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, or an amino acid sequence having at least 85% sequence identity thereto and retaining binding specificity for TGFβ.
6. The conjugate molecule of claim 4 or 5, wherein the TGFβ binding domain comprises two or more ECDs of a TGFβ receptor; optionally the two or more ECDs are derived from the same TGFβ receptor or from at least two different TGFβ receptors; optionally the two or more ECDs comprise a first ECD derived from TGFβRI and a second ECD derived from TGFβRII; and optionally the two or more ECDs are operably linked in succession.
7. The conjugate molecule of claim 6, wherein the two or more ECDs are linked via a first linker; optionally, the first linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.
8. 8. The conjugate molecule of any one of claims 4 to 7, wherein the TGFβ binding domain is linked to the CD39 binding domain via a second linker; optionally said second linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.
9. The conjugated molecule according to any one of claims 4 to 8, wherein the CD39 binding domain comprises an anti-CD39 antibody portion; optionally said anti-CD39 antibody portion comprises a heavy chain variable region and a light chain variable region; optionally said anti-CD39 antibody portion further comprises a heavy chain constant domain attached to the carboxyl terminus of the heavy chain variable region; or said anti-CD39 antibody portion further comprises a light chain constant domain attached to the carboxyl terminus of the light chain variable region.
10. 10. The conjugate molecule of claim 9, wherein the TGFβ binding domain is linked to the anti-CD39 antibody portion at a position selected from the group consisting of: 1) the amino terminus of the heavy chain variable region, 2) the amino terminus of the light chain variable region, 3) the carboxyl terminus of the heavy chain variable region, 4) the carboxyl terminus of the light chain variable region, 5) the carboxyl terminus of the heavy chain constant region, and 6) the carboxyl terminus of the light chain constant region.
11. (i) the fusion protein comprises two or more TGFβ binding domains all linked to a heavy chain variable region of an anti-CD39 antibody portion; or (ii) the fusion protein comprises two or more TGFβ binding domains all linked to a light chain variable region of an anti-CD39 antibody portion; or (iii) the fusion protein comprises two or more TGFβ binding domains linked to heavy and light chain variable regions, respectively, of an anti-CD39 antibody moiety; or (iv) the fusion protein comprises two or more TGFβ binding domains all linked to a heavy chain constant region of an anti-CD39 antibody portion; or (v) the fusion protein comprises two or more TGFβ binding domains all linked to a light chain constant region of an anti-CD39 antibody portion; or (vi) the fusion protein comprises two or more TGFβ binding domains linked to heavy and light chain constant regions, respectively, of an anti-CD39 antibody portion; A conjugate molecule according to claim 9 or 10.
12. the anti-CD39 antibody portion comprises a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and / or a light chain variable region comprising LCDR1, LCDR2, and LCDR3; a) HCDR1 comprises an amino acid sequence selected from the group consisting of NYGMN (SEQ ID NO:1), KYWMN (SEQ ID NO:2), NYWMN (SEQ ID NO:3), DTFLH (SEQ ID NO:4), DYNMY (SEQ ID NO:5), and DTYVH (SEQ ID NO:6); b) HCDR2 is LINTYTGEPTYADDFKD (SEQ ID NO: 7), EIRLKSNKYGTHYAESVKG (SEQ ID NO: 8), QIRLNPDNYATHX 1 AESVKG (SEQ ID NO: 9), X 58 IDPAX 59 X 60 comprising an amino acid sequence selected from the group consisting of NIKYDPKFQG (SEQ ID NO: 151), FIDPYNGYTSYNQKFKG (SEQ ID NO: 11), and RIDPAIDNSKYDPKFQG (SEQ ID NO: 12); c) HCDR3 is KGIYYDYVWFFDV (SEQ ID NO: 13), QLDLYWFFDV (SEQ ID NO: 14), HGX 2 RGFAY (SEQ ID NO: 15), SPYYYGSGYRIFDV (SEQ ID NO: 16), IYGYDDAYYFDY (SEQ ID NO: 17), and YYCALYDGYNVYAMDY (SEQ ID NO: 18), d) LCDR1 comprises an amino acid sequence selected from the group consisting of KASQDINRYIA (SEQ ID NO:19), RASQSISDYLH (SEQ ID NO:20), KSSQSLLDSDGRTHLN (SEQ ID NO:21), SAFSSVNYMH (SEQ ID NO:22), SATSSVSYMH (SEQ ID NO:23), and RSSKNLLHSNGITYLY (SEQ ID NO:24); e) LCDR2 comprises an amino acid sequence selected from the group consisting of YTSTLLP (SEQ ID NO:25), YASQSIS (SEQ ID NO:26), LVSKLDS (SEQ ID NO:27), TTSNLAS (SEQ ID NO:28), STSNLAS (SEQ ID NO:29), and RASTLAS (SEQ ID NO:30); f) LCDR3 comprises an amino acid sequence selected from the group consisting of LQYSNLLT (SEQ ID NO:31), QNGHSLPLT (SEQ ID NO:32), WQGTLFPWT (SEQ ID NO:33), QQRSTYPFT (SEQ ID NO:34), QQRITYPFT (SEQ ID NO:35), and AQLLELPHT (SEQ ID NO:36); X 1 is Y or F, and X 2 is S or T, and X 58 is R or K, and X 59 is N, G, S, or Q; X 60 The conjugate molecule according to any one of claims 9 to 11, wherein is G, A or D.
13. a) HCDR1 comprises the amino acid sequence of SEQ ID NO:3; and / or b) HCDR2 comprises the amino acid sequence of SEQ ID NO:9; and / or c) HCDR3 comprises the amino acid sequence of SEQ ID NO: 15; and / or d) LCDR1 comprises the amino acid sequence of SEQ ID NO: 21; and / or e) LCDR2 comprises the amino acid sequence of SEQ ID NO: 27; and / or f) LCDR3 comprises the amino acid sequence of SEQ ID NO: 33; The conjugate molecule of claim 12.
14. a) HCDR1 comprises the amino acid sequence of SEQ ID NO:4; and / or b) HCDR2 comprises the amino acid sequence of SEQ ID NO: 151; and / or c) HCDR3 comprises the amino acid sequence of SEQ ID NO: 16; and / or d) LCDR1 comprises the amino acid sequence of SEQ ID NO: 22; and / or e) LCDR2 comprises the amino acid sequence of SEQ ID NO: 28; and / or f) LCDR3 comprises the amino acid sequence of SEQ ID NO: 34; The conjugate molecule of claim 12.
15. The heavy chain variable region a) an HCDR1 comprising the sequence of SEQ ID NO:1, an HCDR2 comprising the sequence of SEQ ID NO:7, and an HCDR3 comprising the sequence of SEQ ID NO:13, or b) an HCDR1 comprising the sequence of SEQ ID NO:2, an HCDR2 comprising the sequence of SEQ ID NO:8, and an HCDR3 comprising the sequence of SEQ ID NO:14, or c) an HCDR1 comprising the sequence of SEQ ID NO: 3, an HCDR2 comprising the sequence of SEQ ID NO: 37, and an HCDR3 comprising the sequence of SEQ ID NO: 40, or d) an HCDR1 comprising the sequence of SEQ ID NO:3, an HCDR2 comprising the sequence of SEQ ID NO:38, and an HCDR3 comprising the sequence of SEQ ID NO:41, or e) an HCDR1 comprising the sequence of SEQ ID NO: 4, an HCDR2 comprising the sequence of SEQ ID NO: 10, and an HCDR3 comprising the sequence of SEQ ID NO: 16, or f) an HCDR1 comprising the sequence of SEQ ID NO: 4, an HCDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 134, 135, 136, 137, 138, and 139, and an HCDR3 comprising the sequence of SEQ ID NO: 16, or g) an HCDR1 comprising the sequence of SEQ ID NO:5, an HCDR2 comprising the sequence of SEQ ID NO:11, and an HCDR3 comprising the sequence of SEQ ID NO:17, or h) HCDR1 comprising the sequence of SEQ ID NO:6, HCDR2 comprising the sequence of SEQ ID NO:12, and HCDR3 comprising the sequence of SEQ ID NO:
18. The conjugate molecule according to any one of claims 12 to 14, comprising:
16. The light chain variable region is a) an LCDR1 comprising the sequence of SEQ ID NO: 19, an LCDR2 comprising the sequence of SEQ ID NO: 25, and an LCDR3 comprising the sequence of SEQ ID NO: 31, or b) an LCDR1 comprising the sequence of SEQ ID NO: 20, an LCDR2 comprising the sequence of SEQ ID NO: 26, and an LCDR3 comprising the sequence of SEQ ID NO: 32, or c) an LCDR1 comprising the sequence of SEQ ID NO: 21, an LCDR2 comprising the sequence of SEQ ID NO: 27, and an LCDR3 comprising the sequence of SEQ ID NO: 33; or d) an LCDR1 comprising the sequence of SEQ ID NO: 22, an LCDR2 comprising the sequence of SEQ ID NO: 28, and an LCDR3 comprising the sequence of SEQ ID NO: 34, or e) an LCDR1 comprising the sequence of SEQ ID NO: 23, an LCDR2 comprising the sequence of SEQ ID NO: 29, and an LCDR3 comprising the sequence of SEQ ID NO: 35; or f) LCDR1 comprising the sequence of SEQ ID NO:24, LCDR2 comprising the sequence of SEQ ID NO:30, and LCDR3 comprising the sequence of SEQ ID NO:
36. The conjugate molecule according to any one of claims 12 to 15, comprising:
17. a) HCDR1 comprises the sequence of SEQ ID NO:1, HCDR2 comprises the sequence of SEQ ID NO:7, HCDR3 comprises the sequence of SEQ ID NO:13, LCDR1 comprises the sequence of SEQ ID NO:19, LCDR2 comprises the sequence of SEQ ID NO:25, and LCDR3 comprises the sequence of SEQ ID NO:31, or b) HCDR1 comprises the sequence of SEQ ID NO:2, HCDR2 comprises the sequence of SEQ ID NO:8, HCDR3 comprises the sequence of SEQ ID NO:14, LCDR1 comprises the sequence of SEQ ID NO:20, LCDR2 comprises the sequence of SEQ ID NO:26, and LCDR3 comprises the sequence of SEQ ID NO:32; or c) HCDR1 comprises the sequence of SEQ ID NO:3, HCDR2 comprises the sequence of SEQ ID NO:37, HCDR3 comprises the sequence of SEQ ID NO:40, LCDR1 comprises the sequence of SEQ ID NO:21, LCDR2 comprises the sequence of SEQ ID NO:27, and LCDR3 comprises the sequence of SEQ ID NO:33; or d) HCDR1 comprises the sequence of SEQ ID NO:3, HCDR2 comprises the sequence of SEQ ID NO:38, HCDR3 comprises the sequence of SEQ ID NO:41, LCDR1 comprises the sequence of SEQ ID NO:21, LCDR2 comprises the sequence of SEQ ID NO:27, and LCDR3 comprises the sequence of SEQ ID NO:33; or e) HCDR1 comprises the sequence of SEQ ID NO:4, HCDR2 comprises the sequence of SEQ ID NO:10, HCDR3 comprises the sequence of SEQ ID NO:16, LCDR1 comprises the sequence of SEQ ID NO:22, LCDR2 comprises the sequence of SEQ ID NO:28, and LCDR3 comprises the sequence of SEQ ID NO:34; or f) HCDR1 comprises the sequence of SEQ ID NO:4, HCDR2 comprises a sequence selected from the group consisting of SEQ ID NOs:134, 135, 136, 137, 138, and 139, HCDR3 comprises the sequence of SEQ ID NO:16, LCDR1 comprises the sequence of SEQ ID NO:22, LCDR2 comprises the sequence of SEQ ID NO:28, and LCDR3 comprises the sequence of SEQ ID NO:34; or g) HCDR1 comprises the sequence of SEQ ID NO:5, HCDR2 comprises the sequence of SEQ ID NO:11, HCDR3 comprises the sequence of SEQ ID NO:17, LCDR1 comprises the sequence of SEQ ID NO:23, LCDR2 comprises the sequence of SEQ ID NO:29, and LCDR3 comprises the sequence of SEQ ID NO:35; or h) The conjugate molecule according to any one of claims 12 to 16, wherein HCDR1 comprises the sequence of SEQ ID NO: 6, HCDR2 comprises the sequence of SEQ ID NO: 12, HCDR3 comprises the sequence of SEQ ID NO: 18, LCDR1 comprises the sequence of SEQ ID NO: 24, LCDR2 comprises the sequence of SEQ ID NO: 30 and LCDR3 comprises the sequence of SEQ ID NO:
36.
18. a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 60, 62, 64, 66, 68, 70, 72, 74, 140, 141, 142, 146, 147, and 39, or an amino acid sequence having at least 80% sequence identity thereto and retaining specific binding specificity for human CD39; and A light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61, 63, 65, 67, 69, 71, 73, 75, 143, 144, 145, 111, 112, and 63, or an amino acid sequence having at least 80% sequence identity thereto and retaining specific binding specificity for human CD39. The conjugate molecule according to any one of claims 12 to 17, comprising:
19. The anti-CD39 antibody portion a) a heavy chain variable region comprising the sequence of SEQ ID NO: 42, and a light chain variable region comprising the sequence of SEQ ID NO: 51, or b) a heavy chain variable region comprising the sequence of SEQ ID NO: 43, and a light chain variable region comprising the sequence of SEQ ID NO: 52, or c) a heavy chain variable region comprising the sequence of SEQ ID NO: 44, and a light chain variable region comprising the sequence of SEQ ID NO: 53, or d) a heavy chain variable region comprising the sequence of SEQ ID NO: 45, and a light chain variable region comprising the sequence of SEQ ID NO: 54; or e) a heavy chain variable region comprising the sequence of SEQ ID NO: 47, and a light chain variable region comprising the sequence of SEQ ID NO: 56; or f) a heavy chain variable region comprising the sequence of SEQ ID NO: 49, and a light chain variable region comprising the sequence of SEQ ID NO: 58; or g) a heavy chain variable region comprising the sequence of SEQ ID NO: 50, and a light chain variable region comprising the sequence of SEQ ID NO: 59, or h) a heavy chain variable region comprising the sequence of SEQ ID NO: 60, and a light chain variable region comprising the sequence of SEQ ID NO: 63, or i) a heavy chain variable region comprising the sequence of SEQ ID NO: 62, and a light chain variable region comprising the sequence of SEQ ID NO: 63, or j) a heavy chain variable region comprising the sequence of SEQ ID NO:64, and a light chain variable region comprising the sequence of SEQ ID NO:63, or k) a heavy chain variable region comprising the sequence of SEQ ID NO: 66, and a light chain variable region comprising the sequence of SEQ ID NO: 63, or l) a heavy chain variable region comprising the sequence of SEQ ID NO: 60, and a light chain variable region comprising the sequence of SEQ ID NO: 65, or m) a heavy chain variable region comprising the sequence of SEQ ID NO: 62, and a light chain variable region comprising the sequence of SEQ ID NO: 65; or n) a heavy chain variable region comprising the sequence of SEQ ID NO: 64, and a light chain variable region comprising the sequence of SEQ ID NO: 65; or o) a heavy chain variable region comprising the sequence of SEQ ID NO: 66, and a light chain variable region comprising the sequence of SEQ ID NO: 65; or p) a heavy chain variable region comprising the sequence of SEQ ID NO: 60, and a light chain variable region comprising the sequence of SEQ ID NO: 67, or q) a heavy chain variable region comprising the sequence of SEQ ID NO: 62, and a light chain variable region comprising the sequence of SEQ ID NO: 67, or r) a heavy chain variable region comprising the sequence of SEQ ID NO: 64, and a light chain variable region comprising the sequence of SEQ ID NO: 67, or s) a heavy chain variable region comprising the sequence of SEQ ID NO: 66, and a light chain variable region comprising the sequence of SEQ ID NO: 67, or t) a heavy chain variable region comprising the sequence of SEQ ID NO: 140, and a light chain variable region comprising the sequence of SEQ ID NO: 61, or u) a heavy chain variable region comprising the sequence of SEQ ID NO: 141, and a light chain variable region comprising the sequence of SEQ ID NO: 61, or v) a heavy chain variable region comprising the sequence of SEQ ID NO: 142, and a light chain variable region comprising the sequence of SEQ ID NO: 61, or w) a heavy chain variable region comprising the sequence of SEQ ID NO: 140, and a light chain variable region comprising the sequence of SEQ ID NO: 143, or x) a heavy chain variable region comprising the sequence of SEQ ID NO: 141, and a light chain variable region comprising the sequence of SEQ ID NO: 143, or y) a heavy chain variable region comprising the sequence of SEQ ID NO: 142, and a light chain variable region comprising the sequence of SEQ ID NO: 143, or z) a heavy chain variable region comprising the sequence of SEQ ID NO: 140, and a light chain variable region comprising the sequence of SEQ ID NO: 144, or aa) a heavy chain variable region comprising the sequence of SEQ ID NO: 141, and a light chain variable region comprising the sequence of SEQ ID NO: 144, or bb) a heavy chain variable region comprising the sequence of SEQ ID NO: 142 and a light chain variable region comprising the sequence of SEQ ID NO: 144; or cc) a heavy chain variable region comprising the sequence of SEQ ID NO: 140, and a light chain variable region comprising the sequence of SEQ ID NO: 145, or dd) a heavy chain variable region comprising the sequence of SEQ ID NO: 141, and a light chain variable region comprising the sequence of SEQ ID NO: 145, or ee) a heavy chain variable region comprising the sequence of SEQ ID NO: 142, and a light chain variable region comprising the sequence of SEQ ID NO: 145; or ff) a heavy chain variable region comprising the sequence of SEQ ID NO: 146 and a light chain variable region comprising the sequence of SEQ ID NO: 111, or gg) a heavy chain variable region comprising the sequence of SEQ ID NO: 146 and a light chain variable region comprising the sequence of SEQ ID NO: 112; or hh) a heavy chain variable region comprising the sequence of SEQ ID NO: 147, and a light chain variable region comprising the sequence of SEQ ID NO: 111; or ii) a heavy chain variable region comprising the sequence of SEQ ID NO: 39, and a light chain variable region comprising the sequence of SEQ ID NO: 63; or jj) a heavy chain variable region comprising the sequence of SEQ ID NO:68, and a light chain variable region comprising the sequence of SEQ ID NO:69; or kk) a heavy chain variable region comprising the sequence of SEQ ID NO: 70, and a light chain variable region comprising the sequence of SEQ ID NO: 69; or ll) a heavy chain variable region comprising the sequence of SEQ ID NO: 72 and a light chain variable region comprising the sequence of SEQ ID NO: 69; or mm) a heavy chain variable region comprising the sequence of SEQ ID NO: 74, and a light chain variable region comprising the sequence of SEQ ID NO: 69, or nn) a heavy chain variable region comprising the sequence of SEQ ID NO: 68, and a light chain variable region comprising the sequence of SEQ ID NO: 71, or oo) a heavy chain variable region comprising the sequence of SEQ ID NO: 70, and a light chain variable region comprising the sequence of SEQ ID NO: 71, or pp) a heavy chain variable region comprising the sequence of SEQ ID NO: 72 and a light chain variable region comprising the sequence of SEQ ID NO: 71; or qq) a heavy chain variable region comprising the sequence of SEQ ID NO: 74, and a light chain variable region comprising the sequence of SEQ ID NO: 71, or rr) a heavy chain variable region comprising the sequence of SEQ ID NO:68, and a light chain variable region comprising the sequence of SEQ ID NO:73, or ss) a heavy chain variable region comprising the sequence of SEQ ID NO: 70, and a light chain variable region comprising the sequence of SEQ ID NO: 73, or tt) a heavy chain variable region comprising the sequence of SEQ ID NO: 72, and a light chain variable region comprising the sequence of SEQ ID NO: 73, or uu) a heavy chain variable region comprising the sequence of SEQ ID NO: 74, and a light chain variable region comprising the sequence of SEQ ID NO: 73, or vv) a heavy chain variable region comprising the sequence of SEQ ID NO: 68 and a light chain variable region comprising the sequence of SEQ ID NO: 75; or ww) a heavy chain variable region comprising the sequence of SEQ ID NO: 70, and a light chain variable region comprising the sequence of SEQ ID NO: 75, or xx) a heavy chain variable region comprising the sequence of SEQ ID NO: 72, and a light chain variable region comprising the sequence of SEQ ID NO: 75, or yy) a heavy chain variable region comprising the sequence of SEQ ID NO: 74, and a light chain variable region comprising the sequence of SEQ ID NO:
75. The conjugate molecule according to any one of claims 12 to 18, comprising:
20. The conjugated molecule according to any one of claims 12 to 19, wherein the anti-CD39 antibody portion further comprises one or more amino acid residue substitutions or modifications and yet retains specific binding specificity for human CD39, optionally at least one of said substitutions or modifications being in one or more of the CDR sequences of the heavy or light chain variable region and / or in one or more of the non-CDR sequences.
21. The anti-CD39 antibody portion is humanized; and optionally the anti-CD39 antibody portion is a diabody, Fab, Fab', F(ab') 2 , Fd, Fv fragment, disulfide stabilized Fv fragment (dsFv), (dsFv) 2 21. The conjugated molecule of any one of claims 12 to 20, which is a bispecific dsFv (dsFv-dsFv'), a disulfide stabilized diabody (ds diabody), a single chain antibody molecule (scFv), a scFv dimer (bivalent diabody), a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody or a bivalent domain antibody.
22. A conjugate molecule according to any one of claims 1 to 21, further comprising one or more conjugate moieties.
23. A pharmaceutical composition comprising a conjugate molecule according to any one of claims 1 to 22 and one or more pharma- ceutically acceptable carriers.
24. An isolated polynucleotide encoding a conjugate molecule according to any one of claims 1 to 22.
25. A method of treating, preventing or alleviating a CD39-associated and / or TGFβ-associated disease, disorder or condition in a subject, comprising administering to the subject a therapeutically effective amount of a conjugated molecule according to any one of claims 1 to 22, and / or a pharmaceutical composition comprising said conjugated molecule and one or more pharma- ceutically acceptable carriers; a method of treating, preventing or alleviating a disease treatable by reducing the ATPase activity of CD39 in a subject; or a method of treating, preventing or alleviating a disease associated with adenosine-mediated inhibition of T, monocyte, macrophage, DC, APC, NK and / or B cell activity in a subject; or a method of treating, preventing or alleviating a disease associated with elevated levels and / or activity of TGFβ in a subject.
26. 23. A method of modulating the activity of CD39 in a CD39 positive cell, comprising exposing the CD39 positive cell to a conjugated molecule according to any one of claims 1 to 22 and / or a pharmaceutical composition comprising said conjugated molecule and one or more pharma- ceutically acceptable carriers, optionally wherein said CD39 positive cell is an immune cell.
